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Abstract 
Exhaled breath is a rich and complex matrix containing many hundreds of 
compounds. Every breath offers the potential of a non-invasive measurement of the 
biochemical processes occurring in the human body and it is this notion that has led 
to the application of breath analysis for the detection of disease. With the majority of 
research in the field being focused on the detection of biomarkers, little has been 
presented on how the seemingly homeostatic matrix of breath varies during the 
course of normal life events. The research in this thesis describes how a subject’s 
emotional state, physical state, and daily activities can alter the composition of 
exhaled breath.  
The collection of exhaled breath samples was carried out using an adaptive breath 
sampler, which monitored the subject’s breath profiles using a pressure transducer. 
The sampled breath was collected and stored using commercial thermal desorption 
tubes, containing multiple sorbents. The analysis of the exhaled breath samples was 
carried out using thermal desorption gas chromatography-mass spectrometry. The 
resultant chromatographic profiles were aligned through retention indexing which 
also provided the basis of a referencing system for the breath components. The data 
was processed through multivariate statistical analysis methods to establish potential 
markers of physical and emotional stress. 
The pilot studies presented here examine the variability associated with exhaled 
breath. Using three different cohorts of subjects, three studies were conducted into 
how emotional state, physical stress and bowel evacuation affects the matrix of 
exhaled breath.  
The homeostasis of breath was challenged by the application of a paced auditory 
serial addition task, which caused an emotional stress response in subjects and 
which was accompanied by elevated biological functions such as heart rate and 
blood pressure. Physical exercise was also investigated using an ergometer with 
breath samples being captured before and after physical exertion. These two 
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independent studies yielded a panel of potential markers associated with physical 
and emotional stress that had not been previously reported. 
The third study involved the changes observed in the exhaled breath matrix in 
subjects after bowel evacuation. This study also highlighted the lower intestinal tract 
as a major contributor and potential origin of volatile organic compounds found in 
exhaled breath. The combination of how these normal, everyday functions may 
impact on the results of breath analysis has been evaluated here. As a result, these 
potential confounding factors, which have been largely unconsidered, highlight the 
need for rigorous participant pre-sampling protocols to be incorporated into 
biomarker discovery studies. 
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Glossary of terms 
 
 
APCI-MS Atmospheric Pressure Chemical Ionization Mass Spectrometry 
atm Units of pressure 1 x Atmosphere is equivalent to 750 mm Hg 
AUC Area under the curve 
Base ion The ion fragment with the most intense signal in a mass spectrum.  
block A set of observations within a statistical matrix 
Breath matrix A table cataloguing all the VOC isolated in a study, organised by retention index and mass spectral fragments by participant. 
BTEX Collective acronym for the chemical compounds Benzene, Toluene, Ethyl benzene and the xylenes 
distal Away from the centre of the body  
EESI Extractive Electrospray ionization 
GC-MS Gas chromatography-mass spectrometry 
Gedanken experiment German term meaning “thought experiment” 
MVA Multi-variate analysis 
Negative Feedback Regulatory process in biology that causes a reaction to stimuli to maintain ideal conditions.  
OPLSDA Orthogonal partial least squares discriminant analysis 
Pareto Variance (ParN) 
A scaling method takes each variable, subtracts it from the mean 
of that variable set and divides it by the square root of the 
standard deviation for the variable set (𝒙𝒙𝒏𝒏− 𝒙𝒙𝒊𝒊)
�𝑺𝑺𝒏𝒏
 
 
PASAT Paced audio serial addition task, set to induce stress in individuals who undertake this task. 
PPE Personal protective equipment 
PSR PASAT stress response score 
PTR-MS Proton Transfer Reaction Mass Spectrometry 
RIU Retention index unit, a standardised retention scale used to compare data obtained over many analytical runs, see Appendix 2 
SIFT-MS Selective Ion Flow Tube Mass Spectrometry  
TD-GC-MS Thermal desorption gas chromatography mass spectrometry. 
TIC Total ion current. The integrated signal obtained from the ion trap mass spectrometer across the whole m/z range  
VOC Volatile organic compounds. 
Volatalome All volatile organic compounds emanating from the human body 
XIC Extracted ion chromatograms 
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  The problem of variability and the Chapter 1
potential of breath  
1.1 Proposition of the thesis 
The proposition of this thesis is that breath is more or less constant and it will only 
change if there is a perturbation, which causes metabolism to change and this 
subsequently causes the volatalome to change. It follows therefore that breath is 
susceptible to perturbation from many different sources such as disease, behavioural 
and environmental factors.  
To evaluate these phenomena effectively we will need not only rigorous and 
harmonised sampling and analysis protocols but also participant protocols. To 
examine this proposition we need to establish the extent of the variability in breath 
from emotional, environmental and physical causes. This will then enable the 
evaluation of how these factors impact on breath protocols. 
1.2  The potential of breath analysis 
If breath analysis is subject to numerous factors that cause variability the question 
must arise ‘why use it?’ 
Breath sampling and analysis has a number of advantages over other biological 
samples. Breath collection is non-invasive and carries a relative low risk of infection. 
Participants suffer no injury or pain, and are less reluctant to give breath samples 
than other invasive procedures such as biopsies for research purposes. In addition 
the collection of breath using the type of archival method described in Chapter 3 
requires non-specialist medical training to take samples. The collected samples can 
be easily stored and transported to a central laboratory for subsequent analysis.  
The analysis of VOC in breath has the potential to provide a window into the 
metabolic processes occurring in the body1. They can highlight processes from 
different compartments or organs and in addition the matrix of breath is less 
complicated than other biological matrices such as blood2.    
Although breath analysis offers many advantages there are still a number of 
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unresolved aspects that confound many applications of breath analysis.  One of the 
most pressing issues with breath analysis is that there is currently no harmonised 
method for the capture and analysis of breath samples. With numerous methods 
presented in the literature3–12 each with their own advantages and disadvantages a 
single harmonised method for collection or analysis may never be possible.  A 
potential answer to this would be a proficiency assessment scheme for breath 
analysis where many research groups could take part. Further to this the issue that 
the physiological and biological origins of many VOC’s remains elusive13 and this 
can potentially add confounding factors into the interpretation of the VOCs in breath 
profiles. This is further compounded as VOC with exogenous origins such as 
sampling equipment or environmental sources can be metabolised in the body and 
excreted through the lungs in the breath14. This is in addition to endogenous 
confounders caused through lifestyle choices or medication.  In spite of these issues 
breath analysis has found applications in the targeted analysis of breath alcohol 
levels for roadside testing15, nitric oxide analysis as a marker of inflammation16 and 
13CO2 for the determination of helicobacter pylori infections17. 
1.3 Gedanken experiment in breath complexity and biomarkers 
Firstly consider what compounds are in breath and how these compounds would 
group together. If it was possible to deconstruct a breath profile obtained using TD-
GC-MS, so that each factor contributing to the complexity of breath could be 
observed individually and it was then reconstructed one factor at a time. The 
resulting effect would be that with the addition of each factor the complexity 
observed would be compounded. This concept is attempted to be conveyed in 
Figure 1. Chromatogram (A) could be envisioned as how a breath profile might look 
if it was possible to look at a normal healthy human’s baseline metabolism. The 
second image (B) is what might be observed if environmental factors were then 
introduced from exogenous sources such as air pollution, personal care products 
etc. The third example (C) then incorporates VOC compounds resulting from lifestyle 
factors, such as diet, medication and activity levels. The final chromatogram (D) 
could then potentially include components resulting from disease. What is apparent 
is that chromatograms C and D appear very similar, this then raises the question 
how much would a VOC or panel of VOC biomarkers need to change before they 
become significant and therefore useful as a diagnostic tool?  Also, what factors can 
3 
contribute to variations in the profile that could confound this detection? 
 
 
Figure 1 Deconstructed examples of potential factors that contribute to the 
complexity of breath profiles.  (A) Hypothetical example of contributions 
from baseline metabolism in healthy human. (B) As for A, but with 
environmental factors superimposed. (C) As for B, but with lifestyle factor 
superimposed. (D) As for C but with potential biomarkers of disease 
superimposed. 
 
 
If we further consider the variation observed in a single hypothetical VOC in breath it 
is feasible that we could quantify a target VOC in the breath of a single participant 
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every six hours for a day. This would possibly yield a type of result shown in Figure 
2. A. This illustrates that this compound is stable over a short period of time. What 
would happen if the measurements were then extended not for 1 day but every six 
hours for one month? Figure 2B is what may be expected. In this example the 
emergence of diurnal cycles in the measurements starts to become apparent. If we 
also start to introduce endocrine control cycles on top of the diurnal cycles it is 
possible to establish statistical upper and lower limits on the normal concentration on 
this particular VOC in breath. Potentially responses outside these limits may 
correspond to early stage of a disease before physical symptoms have yet emerged, 
but more importantly the disease at this early stage may be curable (Figure 2C).  
If this experiment is then extended to the timeframe of one year, again continuing to 
take a measurement every six hours the possible outcome is given in Figure 2D. 
This graph illustrates how the response potentially could drift due to the development 
of disease state over the course of a sampling campaign. As the course of the 
experiment approaches one year multiple measurements reveal that depending on 
when the sample is collected due to natural variation of the biological system the 
measurement could be outside of the upper limit 50 % of the time but still not be 
detected. However this example only considers an increase in a single participant 
with an illness that has been monitored many times over the course of a year. If 
these results are then amalgamated with that of a healthy participant the type of 
outcome is illustrated in Figure 2e. There is not a clear distinction between healthy 
and disease outside of the original upper and lower limits set during the month long 
experiment but with this intensive sampling plan the small overall differences 
observed would be enough to distinguish between the two participants, in the 
absence of this potential false negatives may be observed.  The time and resources 
required to run such a sampling campaign is currently outside the scope of most 
research studies, therefore the need to understand what causes the variation in a 
normal breath profile needs to be addressed.   
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Figure 2 Hypothetical experiment 2  (A) measurement of a target VOC in human breath 
measured every 6 hours (B) continued measurements of the same target 
VOC starts to exhibit diurnal cycles. (C) Introduction of endocrine controls 
allows realistic statistical limits to be applied to the measurements. (D) 
Continued target VOC measurements for 1 year - a drift from the applied 
limits start to appear for patient as disease progresses. (E) Overlaid 
response of healthy and disease patients. 
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The concepts above illustrate how small changes can be significant and could be 
masked by the variability observed in the measurement of a particular breath VOC 
biomarker. Reducing and identifying potential sources of variability in breath is a key 
part of the analysis and the biomarker discovery process.  
As it is not experimentally possible to interrogate the different factors discussed 
earlier in the absence of all other contributors, what we are left with is potentially in 
excess of 100018 components in a complex matrix. In addition many of the co-
dependences and origins of the observed VOC in breath are not fully documented or 
completely understood14.   
How can this complexity and variation be combated when working with breath to 
ensure that the results and the changes observed are real and significant?  
Moving away from global metabolomics profiling and biomarker discovery, if the 
wider field of breath analysis is now considered and in particular reflecting on the 
lessons learnt in the development of nitric oxide in clinical diagnostics for example, 
the sampling procedure used for nitric oxide has been standardized enabling it to be 
used as a clinical tool19. Consequently the results obtained are comparable and 
reproducible across different clinical centres.  
To reduce variation, is it just a matter of harmonising sampling and analysis 
procedures?  
Undoubtedly this would enable results obtained from different research and clinical 
centres to be amalgamated more easily. This could then lead to a repository or 
database of research, which could then be independently verified or utilised. While 
this would contribute greatly to biomarker discovery in breath, it is not the only factor 
that should be considered when trying to reduce variation in breath analysis. To fully 
understand the extent of variation in breath VOC and how to deal with it, the factors 
that affect breath must first be found. 
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1.4 Research objectives 
The main aim of this research is to test the proposition that standardised participant 
protocols are needed for breath analysis. The specific experimental objectives were: 
• Examine the effect of acute psychological stress on breath analysis. 
• Investigate the impact of physiological exercise on a global metabolomics 
profiling approach of breath analysis. 
• To examine how defecation could change breath profiles. 
Before the individual experimental studies can be described, it would be helpful to 
discuss the background, fundamental principles and current literature on VOC in 
breath analysis. Chapter 2 will review these aspects and will also consider the 
methodologies current employed in the field of breath analysis.   
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  Homeostasis and VOCs in the human body Chapter 2
2.1 A brief introduction to homeostatic theory 
The term homeostasis was first coined in the 1920’s and is attributed to the 
American physiologist Walter Cannon20. Homeostasis refers to the body’s natural 
tendency to maintain a near constant internal environment in the presence of 
external stimuli. It was Cannon’s postulations on a consistent internal environment of 
the human body, which he envisaged as being in a steady state rather than an 
absolute constant that drove his research in the area. This steady state varies within 
limits while two opposing mechanisms are occurring within the internal environment. 
Cannon and his co-workers demonstrated an example of this though the opposing 
effects that insulin and adrenaline have on blood sugar20.  
 
The steady state of a biological system and the human body’s ability to maintain this 
state within limits can be explained in terms of a rudimentary concept. The human 
body maintains an internal temperature of around 37oC but it is not constant and can 
change if the body experiences an external stimulus. When exposed to heat, for 
example on a hot summer’s day, receptors in the body will attempt will send an input 
to a control centre indicating a change has occurred. This will in turn send an output 
to an effector, which generates a response to address the change. In this example 
the response causes sweating and delivery of the blood closer to the skin in order to 
aid cooling. This control mechanism within the homeostatic environment is defined 
as negative feedback21,22. The resultant responses may be measurable (a decrease 
in body temperature) or leave behind an indicator or marker; (in this case sweat), 
that this response had occurred. 
The ability to maintain the internal environment of a biological system as complex as 
a human, requires the coordination of all of the organ systems in the body23. The 
organs in turn require the cells that they are composed of to function effectively 
requiring many different biochemical reactions. The total of all of these reactions is 
termed metabolism and the chemical entities involved and produced in metabolism 
are termed metabolites23. 
 
9 
2.2 A brief history of breath analysis 
The concept of breath analysis as a diagnostic tool dates back to Ancient Greece. 
Hippocrates’s treatise on breath aroma and disease, relate how the smell of breath 
and other bodily fluids can indicate what ailments a patient may be suffering with24. 
What these early physicians were smelling during their olfactory analysis of a 
patient’s breath were scents such as rotten apples25, stale urine26, fishy-like or 
feculent scents27,which we know now to be due to diabetic ketoacidosis, renal failure 
and liver failure respectively. These rudimentary aroma tests could be considered as 
the first detection of biomarkers of disease in breath. 
The story of breath analysis is continued nearly two millennia later in 1784 when 
French chemist Lavoistier correctly identified that oxygen is a reactant consumed 
during respiration. He further demonstrated that carbon dioxide was a product of 
respiration and was exhaled in the breath of guinea pigs. Lavoistier then went on to 
confirm his findings in human volunteers28. Nearly a century after Lavoistier's 
discovery of carbon dioxide the first recorded volatile organic compounds (VOCs) 
were being discovered in the breath of humans. In 1874, British physician Anstie 
developed the first diagnostic test for the presence of ethanol in breath29. The test 
was colorimetric and involved bubbling breath through a solution of chromic acid, 
which changed colour from red/brown to green if an alcohol was present.  The 
application of the detection of ethanol in breath remains the most common and wide 
spread diagnostic breath test in use to date.  In 1897 the next VOC discovered in 
breath was one of the most abundant endogenous VOCs still often reported today. In 
Germany Nebelthau was working with diabetics and discovered that acetone was 
present in human breath30.  Shortly after Nebelthaus’ discovery, Haldane and 
Priestley described an apparatus designed for the collection of alveolar air. They 
were able to demonstrate the separation of the different phases of breathing through 
a rubber tube over a meter in length31. The concept of the collection of different 
fractions of exhaled breath developed by Haldane and Priestley in 1905, still play a 
role in modern approaches to breath collection.  
As the mid 20th century is approached, breath analysis starts to develop the basis of 
all breath tests to follow. In the early 1950’s a breathalyzer developed by Borkenstein 
for the quantification of ethanol in breath sparks the oldest and most wide spread 
application of breath analysis, this application also demonstrated the quantitative 
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relationship between blood and exhaled breath32. In the 1960’s and 1970’s clinical 
breath tests for gastroenterology start to appear which measure breath hydrogen 
and radiolabeled CO2 levels for the diagnosis of carbohydrate malabsorption33. 
Then Linus Pauling’s seminal paper entitled; Quantitative analysis of urine vapour 
and breath by gas-liquid partition chromatography published in 197134 reports over 
200 components to be present in breath. This ground breaking work used a gas 
chromatograph equipped with a stainless steel open tubular column to separate the 
breath matrix. The detection of breath components was performed using a flame 
ionization detector. Introduction of the breath sample to the chromatograph was 
accomplished by first trapping 10-15 exhaled breaths per sample onto a 5 ft. coiled 
stainless steel column, cooled using an isopropyl alcohol ice bath. The sample was 
then flash heated and transferred to the chromatography column. Pauling’s work with 
breath was to begin the era of modern breath analysis.  
Following on from Pauling’s work, throughout the 1970’s and 1980’s breath analysis 
was being explored for both clinical and environmental applications. Kaji et al. 
examined sulfur-containing VOCs in the breath of patients with liver disease35 and 
Wallace and co-workers reported a number of environmental contaminants in the 
exhaled breath of their volunteers36. Wallace’s research highlighted that our 
environment has an effect on the VOC profiles obtained from the breath matrix. In 
1985 the first report of breath analysis being used to profile VOCs in lung cancer 
patients was published37.  
The early 1990’s Phillips published his first method for the collection and analysis of 
breath using TD-GC-MS38. This sampling system used adsorbent tubes to trap 
VOCs from exhaled breath. The system incorporated a charcoal filter that supplied 
the participant with clean air. The exhaled breath was diverted through a one-way 
valve and the end phase of breath containing the alveolar fraction was drawn 
through a water trap to the adsorbent sampling tube. These tubes were then 
transferred to a GC system where they were subsequently analyzed. In the following 
20 years the field of breath analysis has expanded to include the detection of 
potential suites of biomarkers for breast cancer39, colorectal cancer40, asthma41, 
COPD42 and tuberculosis43. As the field has expanded so too has the 
instrumentation used in the analysis of breath. The analytical systems to date have 
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included but have not been limited to: GC-IMS44, GC-MS45 GCxGC-TOF-MS46, PTR-
MS47, SIFT-MS48 and sensor systems10. As the detection capabilities of these 
systems has evolved over time, so the amount of detectable breath components has 
also increased 10 fold from the initial observations made by Pauling almost 50 years 
ago34.    
 
2.3 Expired breath and metabolites 
Human breath has a distinctive chemical composition that is different from inspired 
air49. The bulk matrix of breath is composed of nitrogen, water vapour, carbon 
dioxide and oxygen1. All these components are present in percentage 
concentrations. In the small remaining fraction several hundred different volatile 
organic compounds have been observed49. Volatile organic compounds can be 
defined as any compound that has the element carbon and one or more of the 
following species; hydrogen, oxygen, nitrogen, halogens, sulfur, phosphorous or 
silicone. Moreover these compounds also have sufficient vapour pressure (>0.01 
kPa) at a temperature of 293.15 K to volatilize and enter the atmosphere50. The 
VOCs that are associated with breath are able to transverse the alveolar membrane 
of the lungs, and it is those produced through a range of different metabolic states 
that are of particular interest in this thesis. However VOCs found in breath do not all 
originate from in vivo mechanisms, other sources of VOCs in breath profiles can be 
exogenous and due to the inspiratory air, food and drink, and the uptake of 
chemicals through inhalation or dermal absorption38. 
2.3.1 ORIGINS OF VOCS IN BREATH  
Exhaled breath is a mixture of both “dead space” and alveolar air. Alveolar air is that 
fraction of breath that has been in contact with blood via the alveoli. “Dead space”1 
breath is made up of the air that has been in contact with the trachea, bronchi and 
the upper respiratory tract51. The mixture of gases that we exhale is complicated and 
its value as a sample can be largely dependent on where, or rather what phase of, 
the expired breath is taken1. The majority of VOCs reported to have been found in 
breath are hydrocarbons but also incorporate acids, esters, aldehydes, ketones, 
furans, ethers, and sulfur-, nitrogen-, and halogen- containing compounds52  
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A single expired breath maybe broken into four parts and is best illustrated by the 
schematic drawing of a single expired breath shown in Figure 3. 
 
Figure 3 Diagram of a normal single expired breath illustrating the four phases of a single 
breath. The response in volts is representative of the pressure 
response from a pressure transducer from a sampler using pressure 
to control breath collection. 
From Figure 3, phase 1 represents the start of the expired breath and gas sampled at 
this point would not contain alveoli breath but would comprise dead space air. Phase 
2 shows the steep increase in pressure compared to the baseline, samples taken 
from this region show a mixture of both dead space air and alveolar air. Phase 3 on 
the diagram shows a plateau in the pressure and is attributed to alveolar evacuation. 
Inspiration is the terminal phase of the exhaled breath1  
 
 
2.3.2 GAS EXCHANGE IN THE LUNGS 
The exchange of oxygen and carbon dioxide is required for life. The way in which the 
lungs achieve this can be described by the following concepts. 
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The concept of diffusion is illustrated in Figure 4 and can be thought of as the 
movement of molecules from a region of high concentration to a region of low 
concentration, and maybe described as a concentration of molecules ([M]) that move 
through an area (A) with a parallel z-axis (z) per unit time (t). This concept was 
described by Adolf Fick53 is known as flux (J) and is driven by a decrease in the 
Gibb’s free energy54 [M]A. t = J =  −D. δNδz  
Equation 1 
Where:  J = Flux (mol/m2/sec) 
  D = Diffusion coefficient (m2/sec) 
  δ𝑁𝑁 = Change in number density of particles or concentration (mol/m3) 
  δ𝑧𝑧 = distanced travelled (m) 
 
Figure 4 Graphical representation of the diffusion of gas molecules (green 
circles) from a region of high concentration to a region of low concentration 
through a membrane (blue squares).   
This is Fick’s first law and can be used to describe the diffusion of gases across the 
alveoli membranes53. However when dealing with gases and biological fluids the use 
of concentration is insufficient. Concentration of a particular gas would incorporate all 
of that gas that is available for diffusion (free) and that which is bound to other 
chemical entities such as haemoglobin and is not freely available to take part in the 
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diffusion process.  In this case the use of partial pressures is employed. The partial 
pressure of a gas can be thought of as the pressure exerted by that gas alone on the 
external walls of a container. As the partial pressure of gas is proportional to its 
concentration it can therefore be substituted for the concentration term in Equation 2. 
𝐽𝐽 ∝ 𝐴𝐴
𝑇𝑇
 𝐷𝐷 Δ𝑃𝑃 
Equation 2 
The above equation states that the number of molecules per unit time per unit 
membrane surface area or flux (𝐽𝐽) is inversely proportional to the thickness (𝑇𝑇) of the 
alveoli membrane and proportional to the membrane surface area(𝐴𝐴), the diffusion 
constant (𝐷𝐷) for a particular compound and the change in partial pressure(Δ𝑃𝑃). 
If we further consider the diffusion constant (𝐷𝐷) we find that it is proportional to the 
solubility of the compound (𝑆𝑆𝑆𝑆𝑆𝑆) and is inversely proportional to the square root of 
the compound’s molecular weight (𝑀𝑀𝑀𝑀). 
𝐷𝐷 ∝ 𝑆𝑆𝑆𝑆𝑆𝑆
√𝑀𝑀𝑀𝑀
 
Equation 3 
The difference in the rates of diffusion of carbon dioxide and oxygen through the 
alveoli membrane can be explained using this equation53. Carbon dioxide diffuses 
much more rapidly (approximately 20 times) than oxygen, which is due to its greater 
solubility even though the molecular weights are not vastly different. 
The solubility of gases in liquids is described by Henry’s law, which states that the 
solubility of a gas in a liquid is dependent on the temperature, the chemical 
properties of the gas and the liquid, and the partial pressure over the liquid.  The 
relationship of these factors may be summarised in the following equation23  
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𝐶𝐶 = 𝑘𝑘𝑃𝑃 
Equation 4 
Where: 
C = The molar concentration of the gas 
P = The partial pressure of the gas 
k = Henry’s law constant at a given temperature 
 
Therefore at a constant temperature the concentration of gas in a liquid is 
proportional to its partial pressure23. 
In the alveoli the gas pressure differs from that of atmospheric pressure because of 
the exchange of gases occurring continuously between alveolar air and capillary 
blood. In addition the air in the alveoli is saturated with water vapour and as the lung 
is inflated drawing atmospheric air in, mixing occurs between the fresh atmospheric 
air and the carbon dioxide rich, oxygen deficient alveolar air. As blood enters the 
pulmonary capillaries, gases in the blood and lungs then diffuse along their 
respective partial pressure gradients53,23.  
Using oxygen and carbon dioxide as examples, 𝑃𝑃𝑂𝑂2  alveolar = 100 mm Hg and 
𝑃𝑃𝑂𝑂2  blood = 40 mm Hg allowing the oxygen to diffuse into the blood whilst 𝑃𝑃𝐶𝐶𝑂𝑂2   
alveolar = 40 mm Hg and 𝑃𝑃𝐶𝐶𝑂𝑂2  blood = 46 mm Hg allowing for the diffusion of carbon 
dioxide out of the blood23. 
The examples of oxygen and carbon dioxide are the most common, but the 
principles illustrate how both endogenous and exogenous VOCs can find routes of 
excretion through the lungs. 
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2.3.3 METABOLIC FUNCTIONS OF THE LUNGS 
The lungs contain a large number of the total vascular endothelial cells found in the 
human body and are the only other organs apart from the heart that receives all of 
the blood from the body23. It is this attribute that makes the lungs an appropriate site 
for the modification of blood borne substances53. In addition to gas exchange the 
lungs perform metabolic functions. In particular a number of vasoactive substances 
are metabolised in the lung. Peptides, amines and arachidonic acid metabolites can 
undergo deactivation and activation mechanisms in the lung, and peptides such as 
Angiotensin I and bradykinin are metabolised. Angiotensin I is the only known 
example of biological activation by passage through the pulmonary system. It is 
converted by Angiotensin Converting Enzyme (ACE) to the potent vasoconstrictor 
Angiotensin II which is up to 50 times more active than its precursor and is 
subsequently unaffected by passage through the lungs. In the case of serotonin 
(amine) the lungs are the main site of inactivation by means of uptake and storage53. 
 
2.4 Variability of VOCs in human breath 
From the established definition of homoeostasis, it could be assumed that the matrix 
of exhaled breath is in a constant steady state with little variation occurring in the 
observed concentration of VOCs. As there is a constant exchange of gases 
occurring between the blood in the pulmonary capillaries and the alveoli of the lungs, 
the detection of VOCs in breath must therefore reflect the levels of VOCs in the 
blood and by extension reflect the metabolic processes occurring in the body. It 
therefore stands to reason that if these metabolic processes were disrupted, that this 
would also impact on the concentrations of VOCs in the expired breath. In fact we 
know this to be true: the most well-known example of exhaled breath analysis is that 
of the breathalyzer used by police forces in the UK on a daily basis. This breath test 
indicates the level of ethanol in expired breath and as a result reflects the 
concentration of ethanol in the blood. Here we have a demonstration of a deviation in 
homoeostasis occurring through the consumption of alcoholic drinks and as a result 
the body’s normal metabolic pathways becoming saturated and the concentration of 
ethanol observed in expired breath increasing. The concept described above 
illustrates how external stimulus disrupts the normal levels of VOCs in expired 
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breath. As an extension to this concept it is therefore not unreasonable to assume 
that disease may also cause variations in VOCs in human breath. To date the bulk of 
the research involving VOC breath analysis has been concentrated in the field of 
disease diagnostics.  
2.4.1 EXOGENOUS SOURCES OF VOCS 
There are two main sources of VOC variability that contribute to differences within 
the profiles observed in humans: exogenous and endogenous. Exogenous sources 
of VOC exposure can be further classified into personal and social contributions to 
VOCs, and housing and demographic exposure.  
Personal and social contributions to VOCs include factors such as occupational 
exposure through working with chemicals and proximity to vehicular exhaust 
systems. Cleaning products used in the home and the use of scented body sprays 
and perfumes can also add variability55,56 to an individual’s profile. Social activities, 
for example smoking and consumption of alcohol, also contribute to VOCs found in 
breath.     
Demographic factors can affect the variability within breath profiles. The location of 
residential housing relative to petrol stations, airports, industrial sites, landfill and 
incinerators can contribute to the uptake of numerous VOCs and environmental 
contaminants, which can present themselves in breath profiles as either the parent 
compound from the initial exposure or its corresponding metabolites55,56,57  
The types of compounds associated with these two categories of exogenous factors 
include but are not limited to; Benzene, toluene, ethylbenzene and xylene (BTEX) 
which are ubiquitous exogenous VOCs associated with gasoline, paints, adhesives 
and vehicular exhaust emissions. Methyl tert-butylether (MTBE) is another VOC that 
is connected with exposure to gasoline products as it is used as an additive in fuels. 
Chloroform is a by-product created when water is treated with chlorine: swimming 
pools and showers are both sources of chloroform found in breath profiles. The use 
of products such as deodorizers, disinfectants and air fresheners in confined areas 
contribute to the uptake of 1,4-dichlorobenzene. The six compounds mentioned 
above are just a few examples of the exogenous VOCs that people are commonly 
exposed to when carrying out routine daily tasks, for example housekeeping and 
commuting by car55,56.  
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2.4.2 ENDOGENOUS SOURCES OF VOCS 
The second source of variability associated with inter-individual VOC breath profiles 
are endogenous origins. Numerous factors such as diet, age, hormonal state, sex 
and disease effect endogenous sources of VOCs.  The presence of acetone in 
breath profiles is common and is formed via the decarboxylation of acetoacetate, in 
addition in vivo studies have indicated possible routes by the dehydrogenation of 
isopropanol58. The concentration of acetone in breath has been seen to be elevated 
in individuals who have been fasting. In contrast elevated concentrations are also 
associated with uncontrolled diabetes mellitus1,59. 
The unsaturated hydrocarbon isoprene is a common constituent of human breath 
and is formed along the mevalonic pathway during cholesterol synthesis1. The 
parallel decrease of isoprene in exhaled breath when sterol synthesis is impeded 
through the administration of lovastatin has been documented by Stone et al60 and 
provides evidence for isoprene production through this biological mechanism. In 
addition further evidence suggests that oxidative damage to the body and fluid lining 
of the lungs can contribute to isoprene concentrations in breath61. Although 
persistent in human breath the concentration of isoprene does vary with a circadian 
rhythm which shows a maximum at 6 am and a minimum at 6 pm1. Therefore there 
may be significant variation in isoprene levels between an individual’s breath profile 
taken on a particular day at a particular time, and a further breath sample taken a 
few hours or days later.  Age is also a factor that contributes to the concentration of 
isoprene in breath with relatively low concentrations being identified in children’s 
breath61. 
Lipid peroxidation of polyunsaturated fatty acids is a biological mechanism by which 
saturated hydrocarbons can be formed. Ethane and pentane are known to form in a 
ratio of 1:4 through this type of chain reaction. However, as pentane is more readily 
metabolised than ethane by cytochrome P450 enzymes, variations from this ratio 
can be due to changes in hepatic function in different individuals. Other factors such 
as increased mental and physical stress contribute to increases in levels of pentane 
and ethane62. Methylated hydrocarbons have also been reported in breath but their 
metabolic pathways have not been elucidated sufficiently for their diagnostic 
potential to be realised1. 
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Anaerobic fermentation, which occurs through the action of bacteria in the gut gives 
rise to alcohols from methanol to heptanol63. These VOCs can transverse the 
intestinal barrier between the gut and the blood stream and although hepatic 
clearance is the primary mechanism alcohols can also find excretion routes through 
the lungs. 
For a biomarker to have a physiological significance and diagnostic impact the 
biological pathways by which the substance is produced need to be identified. Sulfur-
containing compounds can occur when methionine is not completely metabolised 
during transamination reactions and have been found to be significantly higher in 
patients with diminished hepatic function62. Kidney disorders and stomach ulcers can 
have an effect on the urea balance of the human body: If ammonia is not converted 
to urea and excreted in urine then it will be evacuated through the lungs. Patients 
with kidney failure have been known to have a distinctive breath malodour which can 
be attributed to increased concentrations of dimethylamine and triethylamine1. 
VOCs are generated in many parts of the body and depending on their origins they 
could potentially find an excretion route by the lungs. The extensive types and the 
geography of VOCs in healthy humans have been reviewed by de Lacy Costello et 
al52. This collection of VOCs reported from different biological samples (faeces, 
urine, breath, skin, milk, blood and saliva) show very little cross commonality of 
VOCs between the samples types (Figure 5).  Out of the 872 individual VOCs found 
in breath it was reported that only 12 were present in all other six sample types52. 
This surprisingly low cross-compartmental correlation between the sample types in 
this review highlights the human body’s ability to effectively and efficiently deal with 
VOC metabolites and eliminate them from the body.  It must be considered that while 
this is a comprehensive view of what has been identified and reported in the 
literature the methods of collection and analysis of each of the compartmental 
samples will have been different. In such cases the overall extraction and suitability 
for multi-VOC metabolomic profiling methods may need to be brought into question 
in terms of the specific analyte’s recovery or extractability form each matrix / 
sampling technique.      
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#Figure 5 A plot of the relative number of compounds in each class that have 
been detected in various biological samples. Figure taken without modification 
from52  
 
 
 
 
 
 
 
 
 
                                                 
 
# De Lacy Costello, B.; Amann, A.; Al-Kateb, H.; Flynn, C.; Filipiak, W.; Khalid, T.; Osborne, 
D.; Ratcliffe, N. M. J. Breath Res. 2014, 8, 014001 P4. 
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2.5 Disease diagnostics 
The following section on disease diagnostics is taken from the publication: Thomas, 
P.; Turner, M. In Global Metabolic Profiling: Clinical Applications64 and highlight two 
main areas of disease diagnostics where breath analysis has been applied over the 
last decade. 
2.5.1 LUNG CANCER 
Lung cancer can affect all areas of the respiratory system from the trachea down 
through to the alveoli and the surrounding lung tissue. Current clinical diagnostic 
methods for lung cancer use a combination of: 
• Chest X-rays  
• Computed Tomography  
• Sputum Cytology  
• Tissue Biopsy           
The lesions have to be large enough to be discernible with these imaging/surgical 
approaches and the larger the lesion the more advanced the disease and the less 
likely a cure or extended period of remission. There is a need and demand for more 
sensitive and enhanced methods for the early detection of lung cancers. 
One of the most influential and arguably the lead group in this area are the 
Menssana group (New Jersey, USA), led by Michael Philips, have published multiple 
studies on lung cancer. The first set of 22 VOCs that differentiated 60 participants 
with primary stage lung cancer from 50 healthy controls was published in 1999, with 
100% sensitivity and 83% specificity65. The next study was larger with a panel of 280 
participants with 4 disease classifications (healthy volunteers, participants with no 
histological evidence of cancer, participants with stage I disease, and participants 
with metastatic cancer) during which a total of 9 potential biomarkers were identified. 
This time the detection of disease through breath profiling had a sensitivity of 89 % 
and 83 % specificity 66. These two studies employed the collection of exhaled breath 
on to sorbent tubes and subsequent analysis by thermal desorption gas 
chromatography mass spectrometry. Multi-variate data modelling based in forward 
stepwise discriminant analysis was used in both studies and random data selection 
approaches were used to test the data models. No individual compound was 
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identified as a discriminator of the disease, methylated hydrocarbons as a class of 
VOCs were however identified; and these are acknowledged markers of oxidative 
stress.  
2.5.2 TUBERCULOSIS 
Tuberculosis (TB) is the second leading cause of death from infectious disease 
worldwide. WHO reported 1.4 million tuberculosis deaths in 201167. The statistics of 
infection are challenging: 40 million new infections each year; ca. 10 million new 
cases of the active disease each year;  more than half a million new TB infections 
each year are resistant to Isoniazid and Rifampin; and strains resistant to practically 
all anti-TB drugs have been isolated in 55 countries. As a result of inadequate 
treatment and subsequent transmission there is an estimated global burden of 2 
billion people infected with TB worldwide. Current diagnosis is based on the following 
panel of tests: 
• chest x-ray 
• sputum culture 
• sputum smear 
• nucleic acid amplification tests (NAAT) 
While culture and microscopy remain the gold standard for detection it is unlikely that 
the clinical infrastructure will ever develop sufficiently to address the enormous need 
painted in stark colours by the statistics above. These approaches require aseptic 
microbiologic facilities and highly skilled technical staff and take days to complete. 
Such approaches have limited value in many in-community screening settings 
across the world where TB disease reservoirs have become well-established within 
the affected populations 68. 
This case study also draws on the metabolic approach of the Menssana Research 
team. In 2007 a preliminary study was presented with 42 suspected cases of TB, 19 
of whom would go on to provide positive sputum cultures, and 59 healthy controls43. 
A battery of multi-variate analysis tools were used on the data produced from 
controlled sampling of end-tidal breath onto adsorbent traps with thermal desorption 
GC-MS. The study was supported with in-vitro VOC samples obtained from M. 
tuberculosis cultures. The conclusion was a panel of 7 markers that coded for 
patients with suspected TB.  The next study by the same team, published in 201069 
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was larger with 226 participants sampled at four clinical centres: 38 at the University 
of California San Diego, California; 100 from The University of Santo Tomas, Manila, 
Philippines, and 66 from, De La Salle University Hospital also in the Philippines; 
finally 22 from The East London Tuberculosis Service, UK. The data processing 
approach had developed to use 900 8 s data bins with 4 s overlaps and the 
differences in VOC concentrations in the expired air and concordant environmental 
samples, termed alveolar gradients, in each of the data bins were ranked in terms of 
the resultant ROC curve. Monte Carlo simulations were employed to test the 
outcomes of the data modelling against randomly assigned diagnostic states of the 
participants. The participants were assessed by sputum culture, sputum smear, and 
chest x-ray. The combination of these tests was found to have area under the ROC 
curve of 0.65 vs. a value of 0.85 for the breath tests. In this study the candidate 
panel of markers was revised once again. Inflammatory oxidative stress was cited as 
one of the sources of these markers, as well as the infectious organism. The 
difficulty in establishing consistent marker identities in these studies may be 
attributed to several reasons. Different co-eluting contamination profiles introducing 
artefacts into the mass spectra, and the continued enhancement in the fidelity of the 
analytical systems are two prominent reasons. Consequently the use of library 
matches from mass spectrometry databases for compound identification without 
confirmatory standards is highlighted as a potentially important gap in assigning 
identities to candidate biomarkers. Nevertheless a double blind metabolic approach 
was found to diagnose TB faster and as reliably, if not more so, than the current 
accepted clinical protocols.  
One of the most recent developments in this study was the translation from thermal 
desorption GC-MS to a point-of-care device; a thermal desorption GC-surface 
acoustic sensor based system that provided a diagnostic test in 6 min. This was 
achieved through the continued use of rigorous Monte Carlo based tests of the 
validity of the data drawn from multi-national and multi-centre studies with 251 
participants (130 with active TB)70.  
These three papers addressing a global health challenge have probably not 
definitively described the VOCs associated with TB, however they have defined a 
bench-mark work-flow and process associated with a metabolic profiling approach to 
therapeutic marker discovery, and its translation to point of care diagnostics. The 
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author list in these publications confirms the statements by Risby of the importance 
of substantial multi-disciplinary teams and critical mass in breath research.71 
 
2.6 Sampling exhaled breath 
2.6.1 SINGLE END TIDAL BREATH SAMPLING 
End tidal breath sampling is based on the principle that an adult expires 
approximately 4 litres of breath when exhaling deeply. The first fraction of the 
expired breath is made up of the dead space air, which has not been involved in gas 
exchange in the lungs. The middle fraction of breath is a mixture of both dead space 
and alveolar air. The final component of the single breath is the undiluted alveolar 
faction, which constitutes the last 1 to 2 litres of the breath72. To sample this portion 
of a single breath a syringe-based sampler is the most simple and convenient 
method. An advantage of this approach is that it requires little in the way of services 
such as compressed air, pumps or computer assisted sampling valves. Markes 
International produce a commercially available end tidal breath sampler called the 
Bio VOC™. This particular sampler has found applications in workplace VOC 
monitoring of benzene, xylenes and toluene (BTEX)72 and has been found to 
effective for capture and analysis of over 20 VOCs metabolites73. 
The syringe style sampler incorporates a one way valve mechanism on the 
plunger73. The participant providing the sample exhales through a disposable 
cardboard mouthpiece into the barrel of the syringe until they can continue to exhale 
no further. Utilising this method the undiluted end fraction of alveolar breath passes 
through the syringe barrel. The disposable mouthpiece can then be removed and a 
plunger is connected to the syringe. Breath samples can then be transferred to an 
appropriate storage media or taken for direct analysis. 
The disadvantage of single breath sampling is that only a small amount of alveolar 
breath is collected for analysis and thus applications are limited to measuring major 
constituents of breath or targeted analyte methods. An alternative approach would 
be to employ more sensitive detection systems however this incurs greater cost and 
makes analysis less viable if one day breath analysis is to be used in a routine 
clinical environment.          
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2.6.2 CO2 AND PRESSURE CONTROLLED BREATH SAMPLERS 
CO2 and pressure controlled breath samplers employ a CO2 sensor or pressure 
transducer which are used to monitor the breath profile obtained as a subject 
expires. The samplers use microprocessor controlled valves or pumps to collect a 
subject’s breath at appropriate points during exhalation11,14 The advantage of 
visualising a breath profile is that it allows the whole breath or an isolated particular 
phase of expiration to be collected (see Figure 3). The schematics of these systems 
vary from instrument to instrument but the overall principle of operation remains the 
same.  
The main differences between systems occur in the techniques used for VOC 
capture and the inlet mechanism for the subject’s breath.  Miekisch et al described a 
CO2 controlled system that employed a syringe to sample the alveolar faction of 
breath74 This system is also able to incorporate a Tedlar ® bag for breath capture at 
the same sampling point. Other systems like those described by Basanta11 and 
Phillips75 employ thermal desorption tubes at the sampling point for pre-
concentration of breath samples. 
The second main difference between breath sampling apparatuses is the inlet 
system.  Depending on the application the user has the option of supplying 
participants with filtered clean air or allowing them to breathe air from the immediate 
environment74. The use of a purified air supply minimises contributions from 
exogenous VOCs and provides a consistent field blank11. A further adaptation is the 
incorporation of a mask that is fitted over a subjects face and nose; this replaces the 
conventional mouthpiece and nose clip74. The mask provides an alternative for those 
studies that investigate lung diseases whose volunteers would be expected to have 
diminished lung function and may find it difficult or uncomfortable to breathe through 
a mouthpiece into a tube11. Whichever inlet system is used in the breath sampler 
apparatus, it has to be changed between volunteers. The tube inlet would require 
removal, disposal and replacement of a single use mouthpiece. When masks are 
employed they have to be cleaned, sterilized and purged of any VOCs from the 
cleaning process. The number of masks therefore becomes a rate-limiting step in the 
number of volunteers that can be sampled at any one time. A disadvantage to using 
this type of sampler is the service requirements, (compressed air supply, computers 
26 
for controlling the sampler and power supply) which make them more complex and 
less portable than other sampler systems.                                
2.6.3 WHOLE BREATH COLLECTION 
Whole breath collection is the simplest and most straightforward approach to breath 
sampling. This technique involves the collection of breath into pre-cleaned, nitrogen 
purged Tedlar® style sample bags. There is very little required in the way of 
hardware, a simple breathing tube is all that is needed to fill the Tedlar®  bag with 
expired air. Exhaled breath is collected directly with no distinction between the 
phases of breath and both dead space and alveolar air are collected 
simultaneously76.    
After collection the sample can be processed for analysis either through a gas 
injector system34,77 or subjected to pre-concentration techniques such as solid phase 
micro extraction (SPME)78,79 or cold trapping34,77,38. While this sampling mechanism 
requires no services, e.g. compressed air, there can be issues with condensation 
build up in the bags, and between samples the bags have to be purged and cleaned 
of any residual VOCs76. The drawback to sampling in this manner is the dilution 
effects occurring with the dead space air in respect to the alveolar air. As a result the 
responses obtained for endogenous VOCs in breath profiles when using this method 
of sampling have been reported to be two to three times less intense when 
compared to those samples taken from the alveolar fraction of breath alone1. 
Moreover, dead space air also has the largest concentration of contamination from 
exogenous sources of VOCs and therefore real care is required to ensure that a 
definite distinction is made between background contaminants and endogenous 
VOCs1.       
2.7 Methods of capture and analysis 
There are two main approaches for the capture of exhaled breath for analysis, these 
maybe termed direct and archival. Within each of these two approaches there are a 
number of different techniques used to solve the challenge of producing robust 
reproducible measurements of exhaled breath. 
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2.7.1 DIRECT APPROACH 
This approach is the simpler of the two sampling systems, where samples of exhaled 
breath are introduced directly into the instrumentation performing the analytical 
measurement. This has been achieved by incorporating a transfer-line, which 
participants blow through and the exhaled breath is transferred to the instrument 
where it undergoes analysis.  This approach is generally used in applications where 
breath-by-breath and real-time analysis is performed. Applications of direct analysis 
of breath have been used in real-time, in-vivo monitoring and pharmacokinetics of 
valproic acid80 and the real-time monitoring of fatty acids in breath59,81–84. The 
analytical systems have included extractive electrospray ionization-mass 
spectrometry (EESI-MS), atmospheric pressure chemical ionization-mass 
spectrometry (APCI-MS), Proton transfer reaction- mass spectrometry (PTR-MS) 
and metal oxide sensors, this is by no means an exhaustive list of the analytical 
instrumentation used in the direct analysis of breath and is just an example of the 
variety of techniques that have been used. 
The direct approach has the advantage that real time data can be collected and 
monitored. Breath by breath analysis gives researchers the opportunity to examine 
changes in breath that can occur rapidly, such as isoprene concentrations during 
exercise85, whereas collection methods would only offer the average over the 
multiple breaths collected. However there are two factors that affect the analysis of 
breath VOCs by the direct approach which are evident from the literature. The first is 
that sensitive instruments are needed because numerous analytes are present in the 
breath in low concentrations, whereas collection methods offer considerable 
enrichment of the exhaled breath samples. The second affliction is the requirement 
for the analytes to undergo protonization in order to be detected and identified. The 
direct detection methods are based around soft ionization mass spectrometric 
methods or sensors.  PTR-MS, EESI-MS and APCI-MS all rely on breath analytes 
being able to undergo protonization. In PTR-MS for example as the proton transfer 
reaction requires the analyte in question to have a higher proton affinity than water to 
be successfully ionized and thus detected. In addition these ionization mechanisms 
can suffer from competitive ionization and ion suppression. These confounding 
factors should be considered as breath potentially contains upwards of 1000 
individual components86 that have broad concentration ranges (ppmv to pptv) with 
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little to no separation prior to the matrix of breath entering the ionization source, so 
there is a potential for matrix suppression. This particular confounding factor has yet 
to be addressed in the literature as it pertains to breath analysis and remains a 
known unknown. However all these detection systems have the advantage of 
incorporating a mass analyser which provides details on the mass to charge ratio 
(m/z) and the potential structure of an analyte. With the advent of time of flight 
systems the ability to discriminate analytes using accurate mass can also provide 
information on an analyte’s elemental composition. In contrast the sensor systems 
are less discriminating, they can be tuned to specific analytes or functional groups87 
but for global profiling where changes may be seen between control and test groups, 
identification of analytes can be problematical. The sensor systems do have an 
advantage in their ability to be portable and more cost effective when compared to 
the mass spectrometer based instrumentation.   
2.7.2 ARCHIVAL METHODS 
Collection of exhaled breath has yielded a number of different approaches and the 
archival methods can be further subdivided into gas and adsorbent collection 
methods. 
Gas collection methods 
The two main gas collection methods used for breath are Tedlar® bags88 and 
canisters89.  
Canisters are stainless steel cylinders. They require evacuation before sampling and 
draw in the sampled air or breath through a valve system. The inside surfaces of the 
canisters can be treated or passivated to provide a reasonably inert surface to 
minimize the interactions between the sampled VOCs and the inner walls of the 
canister. There can still remain some loss of particular classes of volatiles, for 
instance aldehydes and terpenes, after collection.  The canister method is not a 
concentration method and may still require subsequent concentration of the collected 
sample before analysis to achieve sufficient limits of detection to study trace VOCs in 
the captured sample. The main advantage of canister sampling is that it allows for 
multiple replicate analyses of single collected samples. The down side of this 
technique is that it is costly and bulky making transport more problematic than 
sorbent based sampling.   
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Tedlar® bags are one of the simplest approaches to the collection of VOCs from 
breath. They have been applied in the capture of breath in a number of studies. The 
bags are constructed from sheets of a polyvinylfluoride polymer that are heat sealed. 
They are re-useable and are available in a variety of different sizes they are less 
expensive than the canisters but are very fragile in comparison and are at risk of 
punctures or tears. This method is also a non-concentration approach to collection of 
breath that can then be analysed directly or concentrated prior to analysis. Tedlar® 
bags require extensive conditioning prior to use as carry over can be an issue with 
this technique. Post sampling the bags suffer from losses through permeation and 
absorption/adsorption. One main drawback is that they are not suitable for use with 
humid sample matrices as recovery of VOCs have been shown to decline in such 
samples.  
 
2.7.3 ADSORBENT BASED COLLECTION METHODS 
Solid phase micro extraction (SPME) is a technique that was originally used for 
headspace analysis and liquid sample extractions. The SPME fibre is bonded to a 
stainless steel plunger and is a simple adsorption/desorption sampling technique. 
The fibre can be coated with a range of sorbent materials that are often either non-
polar or highly polar. Typical sorbents used in SPME are polydimethylsiloxane 
(PDMS), polyacrylate or Carbowax. A divinylbenzene polymer may also be 
incorporated with the sorbent material, increasing the surface area of the sorbent to 
aid extraction efficiency. The fibres are usually 1 cm long and are very delicate. They 
are housed in a hollow needle, into which they are retracted when not being exposed 
to sample matrix. They have been used in the collection of breath directly from 
participants and as a pre-concentration technique for Tedlar® bag samples79. The 
sampling procedure requires the fibre to be exposed to the sample, usually for a 
fixed length of time until the fibre’s sorbent reaches equilibrium with the analytes in 
the sample matrix. The fibre can then be transferred to a standard GC injection port 
and be thermally desorbed directly without the need for any additional 
instrumentation. While the fibres have been demonstrated to be applicable to breath 
analysis the analyte capture range is still limited due to limited number of sorbents 
bonded to the fibres that are commercially available and the small amount of sorbent 
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present on the fibre. Although re-useable, SPME fibres are relatively expensive 
compared to other sorbent capture methods like adsorbent tubes. Also, commercial 
fibres are designed for analysis directly after capture making them unsuitable for 
storage and transport of breath samples. 
Adsorbent tubes and needle traps are different variants of the same methodology. 
The needle traps use a standard 22 gauge needle packed with sorbent material90. 
The adsorbent traps are much larger in comparison to the needle trap and can be 
constructed out of stainless steel or borosilicate glass. A standard adsorbent trap 
used in commercial thermal desorption systems are approximately 89mm in length 
with an internal diameter of 5 mm and have gastight sealing caps used for storage 
pre and post sampling.  The combination of multiple sorbents within in the same tube 
enhances the range of analytes that can be captured for analysis.  As with the SPME 
fibres the efficacy of the sorbent to capture VOCs is dependent on the analytes of 
interest and their intermolecular interactions with the sorbents in the tube or needle 
trap. The advantage of using this type of capture mechanism is that samples can be 
captured away from the laboratory environment and be transported with relative 
ease compared to the canisters and Tedlar® bags. Tubes and needle traps are 
robust11,90 and providing they are sealed appropriately the chance of contamination 
or damage during transport is minimal. Adsorbent tubes have an additional 
advantage over the needle traps as the sorbent bed can be packed with much larger 
amounts of sorbents making sample breakthrough less likely and increases the 
amount of sample enrichment that can be achieved. While both sampling systems 
are re-useable the adsorbent tubes do require additional instrumentation for 
desorption of the sample analytes into the analytical system where as the needle 
traps utilize a standard GC injection port in combination with an autosampler add on 
for the desorption of the captured VOCs. 
2.8 Ambient air correction in breath analysis  
The composition and concentrations of VOCs in ambient air is a potential issue that 
requires consideration in the field of breath analysis. There have been numerous 
approaches, which have sought to deal with the potential confounding VOCs that are 
introduced from ambient air. One of the most common methods used is that of 
ambient air subtraction. Philips et al, described one such method which utilizes the 
technique of alveolar gradients14. In this approach those VOC responses (peak 
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areas of chromatographic responses) recorded from components detected in 
ambient air are subtracted directly from VOC responses detected in exhaled breath. 
The result is that the VOCs detected have either a positive or a negative alveolar 
gradient. Those VOCs that have a negative gradient are considered to be of 
exogenous origin while those with positive gradients are thought to be from 
endogenous origins. While this method is simple and logical, it has been shown that 
is does not reliably account for uptake of background VOCs in the air that the 
participant breathes at concentrations higher than 5 % of that found in breath74,91.  
 
An alternative to attempting to compensate ambient air is to provide clean purified air 
to the participants. The purified air supplied to participants can be monitored and 
controlled to give a higher degree of consistency in the composition and 
concentrations of VOCs between participants11. Studies reported in the literature 
have suggested that participants require as little as 4 minutes for a lung washout 
using purified air92. This approach may reduce the overall intensity of exogenous 
VOCs found in a breath sample but a total body washout out of exogenous VOCs 
may take hours or days to achieve92,93.  While not an ideal solution to the problem of 
inhaled exogenous VOCs, it does offer potential for the reduction of inhaled VOCs 
and therefore where exogenous VOCs are reduced to less than 5% of those found in 
breath it should follow that subtracting VOCs from purified air after a lung washout 
could give more reliable results. 
An additional factor that further complicates and confounds both these methods is 
the potential of a pre-exposure to VOCs that are ubiquitous in a participant’s 
everyday environment. One such example may be found in the compound limonene. 
Limonene is a compound that has many potential sources which participants could 
be exposed to, for example limonene is found in household cleaning products and air 
fresheners, and therefore exposure from indoor air is one possible route. A second 
possible route of exposure is that limonene is used in both toothpastes and skincare 
/ beauty products which expose the mouth directly and provide exposure through 
trans-dermal uptake respectively. Finally limonene is a natural occurring compound 
that is found in citrus fruits, herbs and spices, and fruit juices, so there is a high 
likelihood of exposure through ingestion57. As such subtraction of limonene from 
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background air measurements is likely to be insufficient to identify this VOC as being 
exogenous in origin based on the alveolar gradient method.     
What is apparent from the literature is that there is this is a known problem with 
breath analysis and the subsequent identification of potential biomarkers. As there is 
currently no consensus for a standard method that deals with the elimination of 
confounding factors from ambient air, and in the absence of reliable toxicokinetic 
models for the uptake and washout of VOCs in ambient air, the subtraction of VOCs 
from breath must be treated with caution92.  
2.9 Methods of analysis 
The detection systems used in the analysis of breath can be broken down into those 
instruments capable of direct analysis and those which offer off-line analysis. There 
are numerous systems that offer direct analysis of breath. These systems include 
PTR- MS94–97, SIFT- MS9,48,98, sensor-based87,99 systems, EESI100,84,101 and APCI-
MS100,102. In addition to being able to be used for direct analysis many of these 
systems may also be used in conjunction with archival sampling systems and pre-
concentration techniques for off-line analysis. While suitable for direct analysis of 
breath many of these systems, especially mass spectrometer based systems, are 
movable but far from portable. In addition these systems are expensive and are far 
from the stage where non-specialists may be able to use and maintain them 
effectively. Those instruments such as sensor-based systems that can be 
considered portable lack in their ability to detect the multitude of analytes found in 
breath, being limited to one (Breathalyzer) or only a few analytes or functional 
groups, compared to the mass spectrometer systems.  
One of the most widely used and long established techniques for off-line analysis of 
VOCs in breath is the use of archival capture methods coupled with gas 
chromatography as a separation technique. This system of analysis was first 
demonstrated for breath analysis by Pauling in 197134, where a flame ionization 
detector was used and 250 breath components were observed. With modern GC 
instruments, mass spectrometers are commonly used for the detection of breath 
VOCs. While not portable or inexpensive this approach provides separation and 
detection of the largest range of VOCs in breath. Philips et al 86 used a GCxGC-MS 
system to analyse exhaled breath of 34 normal healthy participants resulting in the 
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identification of approximately 2000 individual VOC analytes and thus highlighting 
the technique as ideal platform for metabolomics style analysis of VOCs in breath. 
2.9.1 THERMAL DESORPTION  
The technique of thermal desorption for the introduction of VOCs to an analytical 
system such as a gas chromatograph utilizes archival methods of collection 
(previously described.) A description of the instrumentation and the thermal 
desorption process that pertains to the instrument platform used in this research are 
described in Chapter 3.5. 
For thermal desorption to be used successfully as an introduction system there are 
two physical processes that need to occur.  
• Adsorption  
• Desorption 
 
Adsorption 
Adsorption is the process of adhesion of molecules onto the surface of an adsorbent. 
In the case of breath analysis we are concerned with the adsorption of molecules in 
the gas phase depositing onto the surface of a solid adsorbent54.  
The processes that are involved with molecules attaching themselves to the surface 
are physisorption and chemisorption. Physisorption describes the adsorption of 
molecules by Van der Waals interactions such as dipolar interactions. These types of 
interaction are weak but are long ranging.  Chemisorption in contrast refers to 
molecules that adhere to the surface by forming chemical bonds such as covalent 
bonds. The distance between the surface and the molecule is much shorter when 
chemisorption is involved than when physisorption processes are involved54.  
The extent of adsorption of molecules on a sorbent is known as surface coverage (𝜃𝜃) and is often expressed as a fraction of the number of adsorption site occupied (𝑋𝑋𝑂𝑂) over the number of adsorption sites available(𝑋𝑋𝐴𝐴). 
𝜃𝜃 =  𝑋𝑋𝑂𝑂
𝑋𝑋𝐴𝐴
 
Equation 5 
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The rate of adsorption is the rate of surface coverage per unit time. The variation of 
𝜃𝜃 with pressure at a given temperature is termed the adsorption isotherm.  
If we consider the simplest isotherm where adsorption of a molecule on the surface 
would not proceed past a monolayer and that all adsorption sites were equivalent, 
and finally if we assume that the ability of a molecule to adsorb at a given site is 
independent of the occupation of any neighbouring sites then at a dynamic 
equilibrium: - 
 
𝜃𝜃 =  𝐾𝐾𝐾𝐾1 + 𝐾𝐾𝐾𝐾 
Equation 6 
This is the Langmuir isotherm. Where p is the partial pressure of the gas phase 
molecule and K is the rate of adsorption divided by the rate of desorption. Figure 6 
illustrates the shapes of the Langmuir Isotherms at different rates of adsorption. The 
different shapes of the curves illustrate the different rates, K, observed at different 
temperatures, pressures or concentration of adsorbate. In Figure 6 the surface 
coverage increases with increasing concentration of adsorbate and only at very 
higher concentrations does the coverage approach 1, where almost all available 
sites for a molecule to adsorb on to the surface have been occupied.  
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Figure 6 Example of the resultant Langmuir isotherms at different rates of 
adsorption(K)  
Desorption is the process of departure of a molecule from the surface of an 
adsorbent where it was previously adsorbed. This process always has to be 
activated and is temperature dependant. The liberation of an adsorbate molecule 
from the surface of an adsorbent adopts a first order rate which can be described 
through an inversion of the Arrhenius equation. 
𝑘𝑘𝑑𝑑 = 𝐴𝐴𝐴𝐴−𝐸𝐸𝑑𝑑 𝑅𝑅𝑅𝑅�  
Equation 7 
Where: kd is the rate constant of desorption 
A is the pre-exponential factor 
Ed is the activation energy 
R is the gas constant 
T is absolute temperature in degrees Kelvin 
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Therefore the mean lifetime (𝜏𝜏̅ ) of an adsorbed species may be expressed as 
follows: 
𝜏𝜏̅ ≈  𝜏𝜏0𝐴𝐴 �𝐸𝐸𝑑𝑑𝑅𝑅𝑇𝑇� 
at STP 𝜏𝜏̅ ≈ 10−8𝑠𝑠 
𝜏𝜏0 =  𝐴𝐴−1 
𝜏𝜏̅ = 𝑘𝑘𝑑𝑑−1 
 
Equation 8 
Where: kd is the rate constant of desorption 
A is the pre-exponential factor 
Ed is the activation energy 
R is the gas constant 
T is absolute temperature in degrees Kelvin 
𝜏𝜏0 is the period of vibration of a bond between the adsorbed molecule 
and adsorbent 
𝜏𝜏̅ is the mean lifetime of an adsorbed species 
 
On an adsorbent where many adsorbates or VOC molecules are present there will 
be a number of Ed that need to overcome to successfully recover the all of the 
adsorbed molecules present on the surface. The choice of sorbent in thermal 
desorption traps and tubes should be considered carefully to achieve the highest 
recoveries possible. In addition the storage conditions and length of storage should 
also be taken into account as the resonance time of a molecule on the surface of a 
sorbent is dependent on temperature. 
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2.9.2 BASICS OF GAS CHROMATOGRAPHY 
The following section intends to give a basic overview of gas chromatography and is 
not intended as a fully comprehensive guide to the technique as it is already a long 
established analytical technique.  
Chromatography is a physical separation process wherein a mixture of components 
is distributed between two phases. One phase is the stationary phase, which 
remains immobilised and the second is the mobile phase that moves in a definite 
direction. In the technique of gas chromatography the stationary phase can be a 
solid or a liquid, while the mobile phase is a gas (usually helium, nitrogen or 
hydrogen). GC is also an elution chromatography technique and as such the mobile 
phase is continually being passed along the chromatographic bed. Most modern gas 
chromatographs employ capillary columns which are made from fused silica and are 
open tubes, where a liquid stationary phase is coated on the inside walls of the 
column. These types of column vary in size and length (0.1mm - 0.53 mm ID and 
15m to 100m) and have an array of stationary phase coatings that can be applied to 
the internal walls of the column at different thicknesses. The column is housed in the 
chromatograph inside a temperature-controlled oven, where the temperature can be 
kept constant (isothermal) or be varied throughout the method cycle (programmed 
temperature). The latter can be very useful when dealing with a mixture of 
compounds that have different boiling ranges103,104.  
The rate at which an analyte traverses the chromatography column is dependent on 
the thermodynamic equilibrium constant called the distribution coefficient Kc. For a 
given analyte (X), Kc is the ratio of the concentration of the analyte in the mobile 
phase verses that in the stationary phase Equation 9. From Equation 9 it can be 
seen that the higher the value of Kc the greater the concentration of analyte in the 
stationary phase. This leads to a longer the retention time of the analyte on the 
column. This interaction with the stationary phase and thus the retention time is 
dependent on three factors: the analyte, the stationary phase and temperature of the 
column.  
𝐾𝐾𝑐𝑐 =  [𝑋𝑋]𝑆𝑆[𝑋𝑋]𝑚𝑚 
Equation 9 
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As the column temperature increases the distribution coefficients decrease and thus 
the retention time of an analyte is reduced, this dependency is expressed in terms of 
the Clausius-Clapeyron equation103,104. 
log𝑃𝑃0 =  −  ∆𝐻𝐻2.3 𝑅𝑅𝑇𝑇 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 
Equation 10 
Where delta H is the enthalpy of vaporization at absolute temperature T. R is the gas 
constant and Po is the compound’s vapour pressure at T.   
Although the term equilibrium constant is used there is in fact no static equilibrium 
and the movement of the analyte through the column may be thought of as a number 
of equilibrium steps or plates that occur through the length of the column. The 
number of these plates describes the efficiency of the column and may be calculated 
from the Equation 11. 
𝑁𝑁 =  �𝑐𝑐𝑅𝑅
𝜎𝜎
�
2 = 16 � 𝑐𝑐𝑅𝑅
𝑀𝑀𝑏𝑏
�
2 = 5.54 � 𝑐𝑐𝑅𝑅
𝑀𝑀ℎ
�
2
 
Equation 11 
Where:N is the column efficiency or plate number  
tR is the retention of the analyte peak.  
σ is the is the width associated with the Gaussian chromatographic peak at 
either σ 2.354 (Wh) or σ 4 (Wb) 
Wb is the width at the base of the chromatographic peak 
Wh is the width at half height of the chromatographic peak. 
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As an analyte moves through these equilibration steps a phenomenon known as 
band broadening occurs. The causes of band broadening that are inherent to 
chromatographic systems are explained by three effects (A) eddy diffusion, (B) 
longitudinal molecular diffusion and (Cs) mass transfer in the stationary phase. When 
band broadening is expressed in terms of plate height (H) as a function of the linear 
velocity of the mobile phase (?̅?𝜇) this is the van Deemter equation.  
 
𝐻𝐻 = 𝐴𝐴 + 𝐵𝐵
?̅?𝜇
+ 𝐶𝐶𝑠𝑠?̅?𝜇 
Equation 12 
However the van Deemter equation was originally envisaged for the band 
broadening effects in packed columns and as such when dealing with open tubular 
columns the A term of the original equation becomes redundant. Golay proposed a 
modified version of van Deemter equation in which the mass transfer term is further 
modified and expanded to account for the gas phase process in capillary columns. 
An additional mass transfer term was added to account for the mass transfer in the 
mobile phase (Cm).    
𝐻𝐻 = 𝐵𝐵
?̅?𝜇
+ (𝐶𝐶𝑠𝑠 + 𝐶𝐶𝑚𝑚)?̅?𝜇 
Equation 13 
As a result when utilizing capillary columns in gas chromatography to achieve the 
maximum column, and in turn the highest resolution between analytes, one must 
seek to minimise the B and C terms. However this ideal is often not practical as it 
can lead to very long columns with lengthy run times and so in practice there often 
remains a degree of less than ideal resolution between analytes in highly complex 
mixtures such as breath. One way of tackling this problem is to introduce a mass 
spectrometric detector system103,104. 
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2.9.3 AN INTRODUCTION TO QUADRUPOLE ION TRAP MASS 
SPECTROMETERS 
The following section is designed to give an overview of the mode of operation and 
principles involved in quadrupole ion trap theory, it is not intended as a 
comprehensive guide to the mathematical theory of ion motion in an ion trap as this 
is considered to be outside the scope of this section.  
Gas phase analytes that are eluted from the gas chromatograph enter the ion trap 
directly where they undergo electron ionisation. The analyte molecules interact with 
electrons that are produced from a heated rhenium filament and accelerated across 
the source at 70 eV. This process leads to the formation of an analyte radical cation. 
The technique is a “hard” ionization method and the resultant analyte radical cation 
undergoes extensive fragmentation, so that there is often little to none of the original 
cation observed. The ionization time in an ion trap is sufficient so that a 
predetermined number of ions are produced in a process known as automatic gain 
control. The resultant ions produced in the electron ionization process are gated into 
the ion trap105.  
The quadrupole ion trap consists of three shaped electrodes two of which are 
virtually identical. These two electrodes are known as the end cap electrodes and 
have a hyperboloidal geometry.  The third electrode is hyperboloidal in shape and is 
called the ring electrode (Figure 7). The ring electrode is situated symmetrically 
between the two, end cap electrodes and is isolated from each end cap electrode by 
means of a quarts spacer106–108.  
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Figure 7 Cross section of a typical quadrupole ion trap mass analyser  
illustrating the geometry. F is the filament of the ion source and D is the 
electron multiplier detector. EC are the end-cap electrode and RE is the centre 
ring - electrode 
As the ions are gated in to the analyser they immediately come under the influence 
of the trapping potential in the ion trap, this is achieved by the ring electrode having 
an applied initial RF voltage. This causes ions of a particular m/z to come under the 
influence of the imposed quadrupole field thus trapping them. The motion of the ions 
within the quadrupole field can be described mathematically by the Mathieu 
equation105. 
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𝑑𝑑2𝑢𝑢
𝑑𝑑2𝜉𝜉
+ (𝑐𝑐𝑢𝑢 − 2𝑞𝑞𝑢𝑢𝑐𝑐𝑐𝑐𝑠𝑠2𝜉𝜉)𝑢𝑢 = 0 
Equation 14 
 
Where: u represents the coordinates of x, y and z. a and q are the trapping 
parameters and are dimensionless. 𝜉𝜉 is defined as follows:- 
  
𝜉𝜉 = 𝜔𝜔𝑐𝑐2 =  2𝜋𝜋𝜋𝜋𝑐𝑐2  
Equation 15 
Where   
f is the fundamental RF frequency of the ion trap (ca. 1MHz) 
𝜔𝜔 is angular frequency applied to the RE electrode 
t is time  
In a conventional quadrupole mass analyser the ion motion that results from the 
applied potentials to the 4 rods of the quadrupole occurs in two directions (x and y) 
with the motion on the z axis accruing from the acceleration of the ions from the ion 
source, optics as they enter the quadrupole. With the ion trap however the motion of 
the ions in the quadrupole field occur in three dimensions x, y and z. When the 
geometry of the ion trap is taken in to account the resulting cylindrical symmetry 
results in X2+Y2 = r2 and so the motion of ions in an ion trap may be expressed in 
terms of r and z coordinates106. 
In terms of the Mathieu equation if u can be either r or z then as a result the 
coefficients a and q may be summarised using Equations 16 and 17 
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𝑐𝑐𝑢𝑢 = −2𝑐𝑐𝑟𝑟 =  −16z𝐴𝐴𝑒𝑒𝑚𝑚(𝑟𝑟02 + 2𝑧𝑧02)𝜔𝜔2 
Equation 16 
𝑞𝑞𝑢𝑢 = −2𝑞𝑞𝑟𝑟 =  8z𝐴𝐴𝑒𝑒𝑚𝑚(𝑟𝑟02 + 2𝑧𝑧02)𝜔𝜔2 
Equation 17 
Where m = mass of an ion  
 e = electronic charge 
 z = number of charges on the ion 
 V = is the RF frequency or AC voltage 
 U = the DC potential and is proportional to au and is equal to zero 
For an ion to have a stable trajectory within the mass analyser, the ions must have 
simultaneous stability in both the r and z axes. By plotting qu against au it is possible 
to illustrate where the regions of stability residue. This type of plot is known as a 
Mathieu stability diagram (Figure 8). Those regions which overlap closest to the 
origin provide the stable trajectory necessary for an ion to remain caged in the 
quadrupole field. The stability of the ion trajectory is dependent on the stability 
parameters βr and βz which are in turn dependent on a and q. The limits of this first 
stability region are defined by 0< βr ,βz <1  
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Figure 8 Mathieu stability diagram, the shaded indicates the regions of a/q 
space that overlap and provide stable trajectories for an ion to remain 
in the quadrupole field. 
As U=0 (i.e. no DC voltage is applied) the ion trap will operate along the qu axis. At a 
given U/V ratio ions of varying m/z can be found to reside in a line that crosses the 
stability region. Ions with the highest m/z are located closer to the origin than those 
with lower m/z ratios. The regions of stability found in a/q space can then be plotted 
as envelopes that have a characteristic shape. If V is increased qz is also increased 
for each ion. At the point where qz = 0.908 (az = 0), β = 1 and the ion has reached its 
stability limit. If V increases past this point the ion’s trajectory becomes unstable and 
the ion is then ejected from the ion trap in the z axis. This mode of operation is 
known as mass-selective instability mode and as the RF or V is continually increased 
ions of increasing m/z are ejected from the mass analyser and detected resulting in a 
full scan mode spectrum106 
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Figure 9 Example of ion ejection at the stability limit. 
 
2.10 Data processing  
2.10.1 MULTIVARIATE ANALYSIS 
The multitude of data that can be generated in “-omic” style mass spectrometry 
approaches is overwhelming. The interpretation of such complex data sets is 
challenging as they typically contain hundreds of variables and many observations. 
Simple uni-variate or bi-variate statistical approaches are simply not up to dealing 
with such extensive data sets. Two approaches used to tackle such vast data sets 
are principal component analysis (PCA) and partial least squared discriminate 
analysis (PLS-DA)109. 
PCA is an unsupervised multivariate analysis method and does not involve the 
identification of particular groups within the data sets by the analyst. 
The PCA process aims to reduce the dimensions of observational space in which a 
given set of observations reside. To accomplish this the PCA model creates new 
linear combinations of variables that characterize the observations studied, these 
new variables are termed principal components. 
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The first step in the PCA process is to subtract the mean observed value of each of 
the variables; then a covariance matrix can be constructed110,111. The number of 
different covariance values for a data set with n- variables can be summarized by 
Equation 18  
𝑐𝑐(𝑐𝑐 − 2)𝑥𝑥2  
Equation 18 
The covariance matrix for n-variables may be defined using Equation 19. 
𝐶𝐶𝑛𝑛×𝑛𝑛 = (𝐶𝐶𝑖𝑖,𝑗𝑗,𝐶𝐶𝑖𝑖,𝑗𝑗 = 𝑐𝑐𝑐𝑐𝑐𝑐�𝐷𝐷𝐷𝐷𝑚𝑚𝑖𝑖,𝐷𝐷𝐷𝐷𝑚𝑚𝑗𝑗�) 
 
Equation 19 
where 𝐶𝐶𝑛𝑛×𝑛𝑛 is the matrix with n- variables and n- observations and 𝐷𝐷𝐷𝐷𝑚𝑚𝑥𝑥 is the xth 
variable. Therefore if the data set has n-variables then the covariance matrix will 
have n-rows and n-columns, with each matrix entry being the calculated covariance 
between two variables. Using the covariance matrix, eigenvectors and eigenvalues 
can be calculated.  As the covariance matrix contains n x n rows and columns it is 
possible to calculate n- eigenvectors each that are all perpendicular to each 
other110,111.  
Once the eigenvectors are found the next step is to order them in descending 
eigenvalue.  The eigenvectors with the highest values have the most significance. 
These eigenvectors can then be combined and transposed into a matrix, which is 
then combined with the original matrix to produce the principal components109. This 
can be summarized in Equation 20.  
 
𝑃𝑃𝐶𝐶1 = (𝑐𝑐11𝑋𝑋1 + 𝑐𝑐12𝑋𝑋2 + …𝑐𝑐1𝑛𝑛𝑋𝑋𝑛𝑛 ) 
𝑃𝑃𝐶𝐶2 = (𝑐𝑐21𝑋𝑋1 + 𝑐𝑐22𝑋𝑋2 +  … 𝑐𝑐2𝑛𝑛𝑋𝑋𝑛𝑛 ) 
etc. 
Equation 20 
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These new principle components can then be represented graphically in terms of a 
score plot. The score plot shows how the observations trend or cluster compared to 
each other and acts like map of the observations. The projection of a score plot from 
two principal components to a 2D surface is shown in Figure 10. Typically to 
highlight any potential outliers in the data set a 95 % tolerance is applied and is 
represented by an ellipse drawn on the score plot. This ellipse is based on 
Hotelling’s T2 distribution110,111.  The variables responsible for any separation or 
clustering apparent in the score plot can be elucidated by means of interrogation of a 
loading plot. A loading plot is the plot of all the variables measured plotted on the 
same axis diagram as the principal components. As a result any variables that are 
subsequently overlaid in the corresponding quadrant to the apparent clusters from 
the score plot can be isolated and elucidated.  
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Figure 10 Projection of a score plot from calculated principle components. 
The second approach to multivariate analysis that has been used in “omic” style 
studies is partial least squares discriminate analysis. The aim of partial least squares 
discriminate analysis, like that of PCA, is to reduce the dimensions in the data sets 
and to highlight those variables that contribute significantly to any separation 
observed in the dataset. The approach of PLS-DA differs from PCA, in that this 
multivariate analysis procedure is a supervised method where the analyst will 
indicate to the model the class membership of the observations in the data set. 
These classifications may be two groups, for example healthy vs. disease 
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participants. The model uses this information to build a learning or training set of 
data which generates a set of rules to enable the fit of new unknown observations to 
the correct groups or classes. The application of these rules to unknown 
observations enables the assessment of the predictive ability of the model. The 
results then provide the maximum amount of discrimination available between the 
two classifications of observations.    
The partial least squares model attempts to do this by using linear combinations of 
the original X variables in order to obtain a linear discriminant function. An example 
of this is given in Equation 21. 
𝑌𝑌1 =  𝑐𝑐1𝑋𝑋1 + 𝑐𝑐2𝑋𝑋2 + ⋯𝑐𝑐𝑛𝑛𝑋𝑋𝑛𝑛 
Equation 21 
As in the PCA model the coefficients a1, a2…etc. are assigned so that the Y exhibits 
the maximum variation between the classifications of the observations. This method 
of multivariate analysis has been used extensively in metabolomic studies, where the 
number of variables vastly out weights the number of observations.  
The vast discrepancy between the number of variables and the amount of 
observations in this type of data means that only part of the data contains any useful 
information. Beyond a certain point the useful information starts to diminish and the 
principal components will then only be modelling noise. As a result cross validation 
of the model needs to be undertaken to ensure that spurious relationships in the data 
are avoided. A widely used approach of cross validation is the “leave one out” 
method. This approach works by keeping a fraction of the observations of the data 
out of the model; these observations are then predicted by the model and compared 
with the actual values obtained. This process is repeated until all observations have 
been kept out once and only once112.  
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2.10.2 POTENTIAL PITFALLS OF MULTIVARIATE ANALYSIS METHODS WHEN USED IN 
CONJUNCTION WITH METABOLOMIC DATA SETS. 
The application of multivariate statistics enables researchers to interrogate the 
multitude of data acquired using modern chromatography based separation methods 
coupled with mass spectrometric detection. These large datasets containing many 
variables make multivariate analysis susceptible to both confounding variables and 
voodoo correlations. 
 Confounding variables are variables that have real statistical correlation with a 
particular class or group of observations113. As a result they can be highlighted using 
multivariate approaches as potential principal components. It is worth noting that 
these variables are not fictitious eigenvectors generated through the mathematical 
modelling process, they are in fact real artefacts present within the samples that 
have undergone analysis. These artefacts may be introduced through improper 
sampling, poor storage or be produced from the analytical system itself. Other 
sources of confounding variables may arise through participants’ interactions with 
their environments and in the case of clinical studies potential confounding factors 
may arise from the medication the study volunteers are taking to manage their 
medical condition. The identification and elimination of confounding variables from 
data sets should be standard practice, as inclusion of these components increases 
the number of variables, which further contributes to the potential rise of voodoo 
correlations. 
Voodoo correlation was a term that was first introduced in the field of social 
science113–115. These correlations are seemingly real correlations between variables 
and observations. However they appear coincidently in sets of data where there are 
a disproportionately high number of variables compared to the number of 
observations.  This scenario then must apply to the types of data sets examined in “-
omic” style studies for biomarker correlations with disease. Miekisch et al 
demonstrated an example of voodoo correlations by using 128 coin tosses to 
generate random numbers for a population size of n = 8 (four controls subjects and 
four test subjects). Miekish reported that on average they only needed 16 coins 
before finding one that was able to correctly predict 7 out of 8 subjects correctly113.  
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Instruments such as GCxGC–TOF–MS used for the analysis of exhaled breath yield 
upto 3000 VOC components in an individual’s breath86. The profiles obtained from 
such systems have highlighted the complexity of breath and show how many 
variables are on offer to the analytical or clinical scientist when it comes to finding 
potential voodoo correlations within the resultant data sets. 
The question must then arise: how can these confounding factors and correlations 
be eliminated from data sets used in the interpretation of breath studies? The first 
and most obvious way is to ensure that there are a sufficient number of independent 
observations being produced in studies. However this solution poses a problem as 
Miekish et al recommends that 5 to 10 times more observations should be used than 
there are variables113. As 3000 VOC components have thus far been shown to be 
present in breath86, this would mean that for any study to statistically acceptable it 
would require somewhere between 15000 to 30000 observations to be made. The 
author has yet to discover a published study that even comes close to this number of 
observations within the breath analysis community. In many cases this first approach 
is practically unfeasible and as a result there are a number of precautions that can 
be used to ensure the validity of the results obtained from “-omic” style studies. 
These include but are not limited to:- 
• Standardisation of sampling and analysis procedures 
• Rigorous quality control procedures for the instrumentation used 
• Acquisition of blank samples from air supplies or room air 
• Removal of contributing VOCs found to be present in blanks to aid in reducing 
the number of measured variables 
• Relevantly matched participant control cohorts  
• Cross validation of statistical models 
• Voodoo testing of statistical software by generation of random data sets with 
equivalent numbers of variables and observation as the data set under 
analysis. 
• The use of metadata, such as body mass index, age, sex, medication, alcohol 
intake etc. 
• Investigation of the proposed biomarkers origins in the human body. 
• Biomarker validation and conformation through independent studies at 
different clinical centres and different participant cohorts. 
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These suggested precautions should be considered throughout the study design, 
participant selection, sample collection and analysis and statistical analysis. At each 
stage there is the possibility to introduce a multitude of confounding factors that can 
lead to erroneous results when data mining for potential biomarkers113,116. 
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 Method and systems Chapter 3
3.1 Overview 
Figure 11 is a summary of the processes for the collection and analysis of exhaled 
breath used in this research. Further, the data modelling and statistical approaches 
used in this work are also described.  
The collection of expired breath has been approached through the application of the 
adaptive breath sampler described11. This procedure uses an instrumented non-
vented RESMED Mirage Series 2, full-face mask (RESMED (UK) Ltd, Oxfordshire, 
and UK.) to collect distal breath, which includes the alveolar fraction, onto a mixed-
bed thermal-desorption tube. The masses of analyte associated with these 
procedures are typically in the pg to ng region and the potential for contamination, 
artefacts and interference is always present. The procedures, described below, for 
conditioning and preparing the materials and systems required for the collection of 
breath samples needs to be followed carefully to ensure that samples and analytical 
results are valid. 
3.2 Ethics 
This research was undertaken in accordance with the ethical principles of Good 
Clinical Practice and the Declaration of Helsinki. The breath samples were collected 
using a protocol approved by the Local Ethics Advisory Committee (Ref: 
Loughborough University G09-P5) from volunteer participants who gave informed 
consent.  
Each participant was given an overview of the study and what their part in the study 
would involve. This document was known as the participant information sheet and an 
example of the participant information sheets can be found in. This information was 
provided to each participant prior to any visit to give a breath sample and on arrival 
participants were given the opportunity to ask any questions pertaining to the study. 
Following this the participants were given a demonstration of the sampler and shown 
what would happen when a breath sample was taken. If the participant then wished 
to continue with the study they were presented with two further documents, firstly an 
informed consent document and a health screen questionnaire.  Following this all 
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participants were then given a study specific identifier and the consent forms were 
sealed, this process pseudo-anonymised the participants.     
  
Figure 11 An overview of the breath analysis work-flow adopted for this research 
showing the three main stages of the process. Taken from 117. 
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3.3 Sampler preparation 
3.3.1 ASSEMBLING AND DISASSEMBLING OF FULL-FACE MASKS 
The RESMED full face masks comprise 5 main parts that are completely detachable, 
a diagram of a participant wearing the full-face mask can be found in Figure 12. To 
disassemble the mask, firstly remove the forehead support and forehead pad located 
at the top of the mask. Once separated the forehead pad may be removed from the 
support.  The mask is now ready to have the mask cushion removed from the mask 
support, this is achieved by removing the cushion clip from the mask support and 
then gently lifting the cushion pad from the locating rim of the mask support. 
Spreading and lifting the locating clip on the interior of the mask support will allow 
the removal the elbow fitting. To reassemble the mask this procedure should be 
performed in reverse order.      
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Figure 12 Illustration of a participant wearing a full face mask (A) forehead support 
and pad, (B) face mask, (C) adaptive sampler sampling capillary, (D) 
Thermal desorption tube (E) elbow fitting, (F) silicon tube connecting the 
mask to adaptive sampler pressure transducer (G) T-piece and air inlet and 
(H) one way disposable valve.  
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3.3.2 STERILIZATION AND CLEANING OF THE FULL-FACE MASKS 
To reduce cross-contamination of samples and eliminate transmission of 
communicable disease masks must only be used once with an individual participant 
and then cleaned and sterilized before reuse.  
A sufficient amount of the disinfectant Cidex® OPA (Johnson & Johnson UK) 
solution was transferred to a plastic container such that the component parts of the 
facemask could be fully submerged. The Cidex® OPA solution contains 0.55 % 
ortho-phthalaldehyde as the active ingredient and therefore all operations involving 
the solution were carried out in a fume cupboard and appropriate PPE was worn at 
all times. The facemask was disassembled, see above, and all parts of the mask 
were submerged in the Cidex ® OPA solution before a bottlebrush was used to 
ensure that all areas of the mask were cleaned. Once clean the components of the 
mask were left completely submerged in the solution for a further 10 min before 
removal and immediate and rapid transfer into a bucket containing approximately 5 
dm3 of potable water, where they were rinsed for a minimum of 1 min. Each mask 
component was then transferred to a second bucket containing a further 5 dm3 of 
potable water and rinsed thoroughly. The mask-components were rinsed a third time 
to ensure that all the disinfectant was removed before they were placed to air-dry on 
clean paper towelling. Once dry the components were inspected and any solid 
residue from the water was removed by polishing with a paper towel before all 
component parts were placed in a vacuum oven (set at 50oC and -1 atm) for a 
minimum of 8 hr to vacuum polish the components to ensure that potential VOC 
contaminants from the cleaning procedure were supressed. After this process the 
masks were reassembled and placed into sealed clean air-tight containers ready for 
use. Note that the air-tight containers were cleaned sterilized and prepared using the 
same procedure. 
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3.3.3 CONDITIONING AND EVALUATION OF MIXED BED THERMAL 
DESORPTION TUBES 
The thermal desorption sampling tubes used to trap VOCs from exhaled breath were 
industry standard 89 mm long 6.4 mm id stainless steel tubes. Each tube was 
packed with Tenax™ /Carbograph TD1 (Part No C2-AAXX-5032, from Markes 
International, Llantrisant, UK). Figure 13 is an engineering drawing of the adsorbent 
sampling-tubes used in this research. 
 
Figure 13 An image of a thermal desorption tube showing the sampling and 
conditioning flow directions flow  (green and red arrows respectively)  
The adsorbent media in the sampling-tubes was conditioned before use and in-
between reuse of the sampling tube, to remove VOC contamination, using a 
conditioning manifold (Figure 14) placed inside a conventional GC oven, designed to 
condition eight sampling tubes simultaneously. Purified nitrogen was supplied at a 
minimum flow of 100 cm3.min-1 to all eight thermal desorption tubes. The thermal 
desorption tubes were connected with 1/4” Swagelok fittings (PTFE ferrules) such 
that the direction of the gas flow was in the conditioning flow direction to back-flush 
sampled materials out of the adsorbent bed (see Figure 13). The manifold system 
was tested for the absence of gas leaks and the nitrogen-flow was measured at each 
tube to ensure that the minimum 100 cm3.min-1 was flowing through each tube.  The 
tubes were then purged with nitrogen for a minimum of 5 mins, to remove residual 
oxygen and prevent oxidative damage of the adsorbent, before they were heated to 
310oC for a minimum of 30 min using the GC oven. After heating the tubes were 
allowed to cool to ambient temperature and then removed from the manifold and 
sealed with a long-term storage cap. The conditioned adsorbent tubes were then 
analysed by TD-GC-MS to verify they were free from any potential VOC 
contaminants.  
Conditioned tubes were evaluated by TD-GC-MS desorbed with a rapid (10 min) 
high temperature (310oC) isothermal GC method. The resultant chromatogram and 
spectrum of the desorption profiles was inspected, and any response over 1M counts 
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in the TIC trace above baseline indicated potential contamination or degradation of 
the adsorbent in the tube. When such a situation arose the tube was desorbed again 
and if the elevated response persisted the tube was removed from service. After 
blanking the adsorbent tubes were recapped using the long-term storage caps and 
placed in a laboratory refrigerator at 4oC until required or 1 week whichever the 
sooner. 
 
Figure 14 The adsorbent tube conditioning manifold was installed into a GC oven 
where up to eight adsorbent sample tubes were processed at the same 
time.  
3.4 Sampling exhaled breath 
3.4.1 EXHALED BREATH COLLECTION  
A conditioned full-face mask was equipped with a PTFE t-piece fitted with a 
disposable one-way non-rebreathing cardboard valve. The t-piece was then 
connected to a filtered air supply. A flow rate of > 20 dm3.min-1 of air was supplied to 
the mask through a triple filter system (Parker 2000 Balson series with 100-12-BX, 
100-12-DX and CI100-12-000 2002-series grade filters).  The mask was then fitted to 
the participant’s face using the head straps supplied by the manufacture and 
adjusted so that a seal was formed between the mask cushion and the participant’s 
face. The participant was then asked to breath normally for a minimum of 5 mins so 
that a normal breathing rhythm could be established at which point the adaptive 
breath sampler was connected to the mask. 
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3.4.2 ADAPTIVE BREATH SAMPLER 
The adaptive breath sampler used to collect VOC breath samples has previously 
been described in detail11 (Figure 15) therefore only a brief overview will be given 
here. The sampler unit was controlled by a laptop computer (DELL Inspiron 1100 
with Windows XP operating system) equipped with a 6024E PCMI data acquisition 
card (National Instruments) running Labview™ Virtual Instrument (VI) software. A 
25-pin RS232 plug connects the sampler unit to the laptop computer. The sampler 
employs a pressure transducer with a programmable gain amplified circuit to monitor 
the breathing profile of the participants via the Labview VI software. During the 
exhalation of the distal breath the VI software automatically switches the sampler’s 
two electro fluidic micro-switch valves from the vent to the sampling position. An 
Escort Elf® Sampling Pump (Part No 497701, MSA, UK) was used to accurately 
sample 0.8 dm3 min-1 through the valves when in the sampling and vent positions. 
A silicon tube was connected from the sampler unit’s pressure transducer to the first 
luer fitting on the full-face mask and acted as the pressure measurement line for the 
sampler.  
The second luer fitting housed the VOC sampling manifold and comprised a PTFE 
mask connector with male luer fitting which housed a 1/4’’ to 1/16” reducing union 
that was fitted with a 5 cm length of 0.53 mm id MXT passivated stainless steel 
column  
 
 
Figure 16. The column protruded into the mask through the luer fitting and seated 
above the participants upper lip. Held in position by a nut and graphite/vespel ferrule 
connected to the 1/16” end of the reducing union the column acted as the sampling 
outlet of the mask. A conditioned and blanked thermal desorption tube was 
connected to the 1/4’’ side of the reducing union using the brass nut and PTFE 
ferrule of the brass sealing cap supplied with the adsorbent tube from the 
manufacturer. Silicone tubing connected the outlet of the adsorbent tube to the 
sampler unit’s electro fluidic micro-switch valves and sampling pump. Figure 17 is an 
example of the pressure transducer’s output with the switching signal superimposed 
on top of the breath profile.  
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Figure 15 Schematic diagram of the adaptive breath sampler11  A)Purified air supply; 
B) pressure regulator; C) pressure relief valve; D) Resmed full face mask; 
E) air supply assembly; F) adsorbent sampler assembly (exploded diagram 
see Figure 16); G) micro-control valves; H) pressure transducer; I) 
electronics interface; J) precision air sampling pump; J) Laptop with DAC 
card and Labview software. 
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Figure 16 Adsorbent sampler assembly. The adsorbent trap (A) was connected to the 
sampling line through a 1/4” push fit connector sealed with a PTFE ferrule, 
(B). The other end of the trap was fastened into a 1/4” to 1/16” reducing 
union, (C), also with a PTFE ferrule (B). A shaped 5cm MXT passivated 
stainless steel column (D) was passed through the mask connector and 
reducing union so it was inserted into the top of the adsorbent trap. A 
1/16” nut with a 0.53mm vespel ferrule sealed the capillary in place (E). The 
mask connector (F) was machined from PTFE with a male Luer fitting. The 
reducing union was held firmly in place while the capillary was threaded 
and positioned carefully inside the mask, before the Leur fitting secured 
the whole assembly (Figure reproduced from Theo Koimtzis original 
artwork)11.  
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Figure 17 Example of a typical breath profile obtained from the adaptive breath 
sampler. Black line illustrates the inhalation and exhalation of the profile of 
the participant over 26 seconds. Blue line highlights the switching of the 
sampling values on (high blue plateau) and off (low blue plateau) indicating 
the fraction of the expired breath collected on to the thermal desorption 
tube  
3.5 Breath sample analysis by thermal desorption gas 
chromatography mass spectrometry (TD-GC-MS) 
3.5.1 THERMAL DESORPTION SAMPLER 
Sample introduction to the GC-MS is performed using a Series 1 Unity thermal 
desorption platform (Markes International, UK). The Unity system employs a two-
stage thermal desorption process which comprises a glass refocusing cold-trap that 
has an internal diameter of 2 mm and is packed with identical adsorbent to that of 
the sample tube used for the breath sample collection described in Section 3.3.3. 
The cold-trap is commercially available from Marks International and is a general-
purpose hydrophobic cold-trap. The cold-trap refocusing system is electrically cooled 
by a Peltier system that is capable of generating temperatures down to -10°C.  
Figure 18 illustrates the thermal desorption inlet process. When a sample is placed 
into the sample oven the Unity system performs a leak-test to ensure that there will 
be no loss of sample during the desorption process. On successful completion of the 
leak-test the system purges the sample tube with the carrier gas (helium) before any 
heat is applied to the tube, this process removes any air in the sample tube that may 
cause damage to the sorbents through oxidation from residual oxygen when the tube 
is heated to high temperatures. The primary desorption flow through the sample tube 
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(45 cm3 min-1) is higher than the flow of the GC capillary column (2 cm3 min-1). The 
sample tube is then heated rapidly to a high-temperature (300°C) for 5 mins. The 
primary desorption-flow is directed through the cold-trap (-10°C) where the VOC 
analytes freeze and concentrate into a small volume in the cold-trap adsorbent. The 
gas-flow to the cold-trap is then reversed and directed into the capillary column of 
the GC-MS system at a rate of 2 cm3min-1. The cold-trap is then heated rapidly to 
300°C causing desorption of the concentrated VOCs onto the head of the analytical 
capillary column. The operating parameters for the thermal desorption process used 
in this work are summarised in Table 1. 
Table 1 Thermal desorption parameters for the Series 1 Unity Thermal 
Desorption  
 
Parameter Setting 
Tube desorption 300 oC for 5 minutes 
Desorption flow 45 ml min-1 Splitless 
Cold trap General purpose hydrophobic 
Trapping Temperature  -10 oC 
Trap desorption 300 oC for 5 minutes  
Trap desorption flow 2.0 ml min-1 Splitless 
Split ratio splitless 
Flow path temperature 180 oC 
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Figure 18 Overview of the thermal desorption process in the Unity thermal desorption 
platform. (A) Sample pre purge, He flows through the sample tubes at 
ambient temperature to purge the sample tube of any oxygen. (B) Sample 
cold trapping, the sample tube is heated desorbing the analytes off the 
surface of the adsorbent in the tube in to the Helium flow and is refocused 
on to the cold trap. (C) Sample introduction, the helium flow supplied to the 
cold-trap is reversed and diverted to the analytical column. The cold-trap is 
then heated rapidly desorbing the sample analytes.   
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3.5.2 GAS CHROMATOGRAPHY MASS SPECTROMETRY  
 
Figure 19 Schematic diagram of TD-GC-MS, (A) thermal desorption sampler, (B) 
Heated transfer line, (C) capillary column, (D) Gas Chromatograph, (E) 
Mass spectrometer heated transfer line and (F) Ion trap mass 
spectrometer.   
Chromatographic separation of VOC analytes from exhaled breath samples was 
performed with a Varian 3800 GC equipped a 60 m x 0.25mm x 0.25µm capillary 
column with a 5% phenyl 95% dimethyl arylene siloxane stationary phase (DB5-MS, 
Agilent technologies). The analytical column was connected directly to the outlet 
transfer-line of the thermal desorber and was supplied with a constant flow (2 cm3 
min-1) of helium carrier gas through the instrument’s pneumatic flow controller.  The 
oven’s initial temperature was 40 oC with no hold-time, the oven temperature was 
then increased at a rate of 5 oC min-1 to 300oC. The final hold-time was 8 min 
bringing the total run-time to 60 min. 
Detection of VOC analytes was performed with a Varian 4000 ion-trap mass 
spectrometer. The spectrometer uses a 3-D ion-trap mass analyzer with an electron 
ionization (EI) source. The system was configured in internal ionization mode, which 
allows both EI and positive chemical ionization (PCI) to be performed in separate 
time segment in the same analytical run. The column effluent-flow enters the 
ionization source though a heated transfer line set to 300oC, located between the 
spectrometer and GC oven.  In addition to the column effluent flow the spectrometer 
also employs a helium buffer gas flow at 4 cm3 min-1, which is directed into the trap 
and causes the ions to adopt a more compact orbit. This buffering produces higher 
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resolution when the ions are ejected from the mass analyzer. After ejection, the ions 
strike a conversion dynode, which begins the signal multiplication process performed 
by an electron multiplier. A comprehensive list of instrumental conditions is given in 
Table 2.  
Table 2 Gas chromatography conditions (Varian 3800) 
Parameter Setting 
Column DB 5 MS 60 m x 0.25 mm id x 0.25 μm 
Initial oven temperature 40 oC   Hold for 0 min 
Oven temperature ramp 300 oC at 5 oC min-1 Hold for 8 min 
Total analysis time 60 min 
Carrier gas Helium 
Carrier gas flow 2.0 ml min-1 
  
Mass spectrometer conditions (Varian 4000) 
Parameter Setting 
Trap temperature 150 oC 
Manifold temperature 50 oC 
Transfer line temperature 300 oC 
EI scan mode EI Auto 
EI scan frequency  2 Hz 
EI scan range m/z 40 – 45  
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3.6 Method development. 
At the outset of this research the GC-MS methodology used a 30 M analytical 
column with a DB5-MS stationary phase and a flow rate of 4 ml min-1. The GC 
temperature program incorporated ramps at different rates and temperature holds. 
The Varian 4000 mass spectrometer’s ion trap analyzer was factory standard. Due to 
the nature of the volatiles contained in breath and the high water content of both the 
breath samples and contributions from the Unity thermal desorption platform this 
initial methodology was improved and re-optimized specifically for the analysis of the 
breath samples that were collected in the studies presented in this research. The 
conditions of analysis were optimized to those presented in Table 2.   
Gas chromatography method development 
In order to ensure that chromatographic data was aligned over the course of the 
studies presented in this thesis a chromatographic method was required that could 
be used in conjunction with retention indexing. Previous methods presented in the 
literature11,118 that have used the adaptive breath sampler have employed GC 
methods that incorporated multiple temperature gradients and hold steps throughout 
the oven program. While retention indexing can be performed on these types of 
methods successfully, the application of retention indexing for data alignment is less 
reliable than that of linear temperature programing over long periods of time due to 
changes in the column performance. Changes in the column performance may be 
brought about through general maintenance or through stationary phase degradation 
due to age and use.  Calculations of component retention indices when using 
temperature programing must be carried out under constant flow and a constant 
linear temperature program119 in order to establish alignment of chromatographic 
data over a longitudinal time frame. It was found that a temperature gradient of 
5oC/min from and initial oven temperature of 40oC to a final oven temperature of 
300oC afforded adequate separation of the VOCs with lower boiling points. The final 
temperature of 300oC ensured that all potential analytes captured using the Tenax / 
Carbotrap thermal desorption tubes were eluted from the analytical column, 
eliminating any potential carryover effects. In addition to the oven program the inlet 
temperature (Unity thermal desorption platform transfer line) was increased from 
140oC to 200oC. This improved the transfer of higher molecular weight components 
such as eicosane (part of the retention index standard) from the thermal desorber to 
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the analytical column. Finally a 60M x 0.25mm x 0.25u DB5 MS capillary column 
replaced the original 30 M x 0.25mm x 0.25u column and the constant flow rate was 
reduced to 2ml / min which provided increased resolution enabling improved de-
convolution of the chromatographic data.           
 
Instrumentation development  
The Varian 4000 mass spectrometer is equipped as standard with 3 analyzer 
electrodes (Figure 7) that have been silica-coated120. This protective layer is around 
1 μm thick is strongly bonded but is susceptible to damage when exposed to acids 
and bases or abrasive cleaning chemicals such as aluminium oxide. As such the 
manufacturer’s recommended cleaning methods for the parts that are silica-coated 
are limited to sonication with solvents such as methanol or dichloromethane and 
non-abrasive cleaners such as mild detergent (pH 6 to 7.5) and water.   
The high water content of the breath samples and the inherent water associated with 
the Markes Unity thermal desorption platform causes a high degree of column bleed 
in this combination of instrument hardware for the analysis of VOCs in exhaled 
breath samples. As a result the mass analyser becomes dirty and the ionization time 
falls below the manufacturer’s specification of 20,000 to 25,000 us in full scan mode. 
The reduction in the ionization time occurs extremely rapidly (over 6 sample 
injections) reducing the ionization time below 8,000 us and making it inconsistent 
between samples. This reduction in ionization time occurs due to the automatic gain 
control (AGC) attempting to maintain a total ion count of 20,000 cps in the ion trap in 
order to reduce the potential of space charging effects.  The resulting high proportion 
of background ions to analyte ions in this dirty system means that the majority of 
molecules being ionized are background ions. This intern results in less analytes 
molecules becoming ionized and therefore negatively impacts on the mass 
spectrometers sensitivity, overall performance and sample-to -sample consistency. 
The combination of high system bleed and limitations on the cleaning protocols leads 
to incomplete cleaning of the analyzer electrodes resulting in a permanent loss of 
sensitivity and performance. To address this issue the manufacturer (Varian. UK) 
was approached for the production of non-standard stainless steel DC and RF 
electrodes that would enable abrasive cleaning methods to be adopted this 
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adaptation over the standard electrodes supplied allowed completed cleaning of the 
electrodes, this resulted in mass spectrometer was able to meet the minimum 
manufacture specification for the ionization time consistently between runs ensuring 
system performance was maintained for longer periods of between maintenance 
intervals.  
 
3.6.1  QUALITY CONTROL PROCEDURES  
The management of day-to-day system compliance was performed by a series of 
checks and standards. To ensure the TD-GC-MS instrument was performing 
consistently the mass spectrometer operation was evaluated through a number of 
checks 
• Air and Water check. 
• Background and Ionisation time check. 
• Calibration and ionisation response check  
• Auto tune  
This series of checks are recommended by the manufacturer and were evaluated 
before performing any analysis to ensure that the mass spectrometer was working 
correctly and was free from any interferences. Results of these checks were 
recorded in a daily log and the following specifications were applied to each test. 
Air and water 
The results and testing procedure for the air water check was performed by the 
Varian Saturn software and returned a result of OK, High or Massive.  The system 
evaluated the air by comparing the ratio of m/z 28 to m/z 32 ions. The water content 
of the system was evaluated on comparison of the response of m/z 19 to m/ z 18 
ions. Due to the nature of the thermal desorption platform the evaluation of the air 
and water was deemed to be acceptable if the air result was OK and the water result 
was High. 
Background and ionization time check. 
This check was performed under a system file provided by the instrument 
manufacturer (Varian). The system was turned on and a range of m/z 50 to 750 was 
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evaluated. This check highlighted any background-ions present in the system and 
provided a read back on the ionization time achieved by the spectrometer for a 
specified number of ions entering the detector. The specification was a maximum 
ionization time of 25 ms or a total of 20000 ions whichever was the fastest. The 
specification for this check, set by the manufacturer, was an ionization time of 
greater than 20 ms before the target ions were reached. 
Calibration and ionization response check. 
To evaluate the mass spectrometer sensitivity and mass tune, an ionization 
response check was performed on a daily basis. This involved the introduction of a 
perfluorotributylamine (PFTBA) standard into the mass spectrometer through the 
actuation of a solenoid valve connected to the Vacuum system of the mass 
spectrometer. The characteristic ions monitored by this calibration standard were 
m/z 69, 131, 264, 416 and 502.  The specification for this system test was all ions 
had to be present and m/z 69 was the most abundant producing a response of 
38000 to 43000 counts per second. The ion m/z 502 should also be present at an 
abundance of at least 1.5 % of that of the response of the ion m/z 69. Calibration of 
all ions should not exceed m/z + 0.2 of the masses indicated above.  
Auto tune 
If the calibration and response check did not meet the specification described above 
then the system underwent the manufacturer’s auto tune. If the system did not meet 
specification after an auto tune was performed then maintenance/repair was 
performed to restore the system to an acceptable standard. 
Retention index standard 
In addition to the daily checks performed on the mass spectrometer, a retention 
index standard was also analysed to evaluate the total system performance. The 
retention index standard was prepared in-house and was mix of n-alkane 
hydrocarbons. The standard mixture contained 50 µg cm-3 of each of octane, 
nonane, decane, undecane, dodecane, tetradecane, heptadecane and eicosane in 
methanol. A volume of 0.2 µl of this solution was injected onto a conditioned and 
blanked thermal desorption tube and analysed under the conditions specified in 
Table 2 with the addition of a 1 in 10 split applied on the trap desorption. This yielded 
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an on-column mass of 1 ng for each alkane. The response and retention times of the 
standards were monitored to ensure that the chromatography and thermal 
desorption systems were performing satisfactorily. 
3.7 Data processing 
3.7.1 THE NEED FOR DATA PROCESSING 
The data obtained from the analysis of breath samples by TD–GC–MS provides an 
analyte rich environment containing upwards of 300 individual chromatographic 
entities.  The majority of these components are from exhaled breath and the filtered 
air being supplied to the mask. A small contribution comes from the facial skin of the 
participant and artefacts from the analytical system. Many of the sampled VOCs co-
elute in the analysed breath samples. As a result a single chromatographic 
separation alone is not sufficient to distinguish all potential analytes in the sample 
chromatograms. This complexity in the data was addressed by the following data 
processing steps: 
• deconvolution of the a mass spectral data,  
• registration of the deconvoluted analytes by retention indexing  
• Integration of potential analyte peaks areas.  
This sequence of procedures produced a catalogue of analytes in the breath 
samples and the formation of a breath matrix, which may then be applied to further 
statistical analysis.  
3.7.2 DECONVOLUTION OF MASS SPECTRAL DATA 
Spectrum deconvolution of the chromatographic peaks was performed using 
Analyser Pro (Spectral Works, Cheshire, UK) and the list of the settings elucidated 
for the de-convolution of the exhaled breath sample data with Analyser Pro is given 
in Table 3 . On average Analyser Pro isolated 325 individual components within a 
typical breath sample chromatogram. Resultant data was exported in the form of a 
table and provided the chromatographic peak start retention time, retention time and 
m/z of the ions of a particular compound. An illustration of this process may be seen 
in Figure 20. 
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Table 3 Deconvolution parameters 
Detection parameter Settings  
Area threshold 500  
Signal to noise 3  
Width threshold 0.06  min 
Resolution low  
Minimum ions for a component 2  
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Figure 20. The deconvolution process. [1] shows the TIC TD-GC-MS spectrum with a 
co-eluting peak at A identified. Following peak deconvolution in [2] three 
peaks A and minor peaks B and C were isolated and the selected ion 
chromatographic peak is shown in [2]. Integration of these peaks against 
their retention index [3] results in the retention index registered histogram 
[4] required for the multi-variate analysis117.  
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3.7.3 ALIGNMENT OF DATA BY RETENTION INDEXING 
To compensate for variability in the analytical method over extended operations, 
especially variation associated with gradual column degradation, retention indexing 
was employed (see Appendix 2). With each batch of samples analysed, a retention 
index standard was also run. The standard provided a primary retention index ladder 
based on the n-alkanes within the mixture. In each case the theoretical retention 
index was plotted against the observed retention time of each alkane. From this 
primary retention index ladder, a secondary retention index ladder was constructed. 
The secondary retention index ladder used five ubiquitous siloxane components 
present in the chromatograms of all the exhaled breath samples1. The secondary 
retention index ladder enabled the timescale of the chromatogram to be converted 
from time to retention index units, using the equation of the graph produced from the 
retention time obtained from the sample of the ubiquitous siloxanes versus their 
calculated retention index. 
3.7.4 INITIAL COMPONENT CATALOGUING 
The combined application of retention index registration and de-convoluted mass 
spectra for each individual analyte yielded a unique identifier that was assigned to 
each isolated breath component which resulted in the creation of a catalogue of 
breath VOCs. This unique identifier uses a numeric method for describing the 
component and comprises retention index and then the five most abundant ions in 
the deconvoluted spectrum. To indicate that each component had originated from an 
exhaled breath sample the prefix BRI was added to the identifier code for example 
BRI-1701-57-43-85-112. 
3.7.5 COMPONENT INTEGRATION AND BREATH-MATRIX FORMATION 
Extracted Ion chromatograms (XIC) were used for the integration of the individual 
components identified through spectral deconvolution. Integration of each 
component was performed using Varian Saturn workstation software.  
                                                 
 
1 The siloxane artefacts are produced through the interaction between the moisture in the breath 
sample which causes hydrolysis of the sorbents of the thermal desorption tubes and cold trap, and 
the GC columns’ stationary phase. 
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The construction of a matrix was performed by listing all samples from a particular 
study (observations) against the total catalogue of identifier entries (variables) from 
that study. The resultant grid was then filled in with the integrated peak areas of each 
component from each sample. Where a component was not present in a sample the 
value of zero was used. This matrix could then be represented as a heat map of 
observations against variables and could be directly inserted into statistical analysis 
software. An example of a heat map obtained from one of these matrices is given in 
Chapter 5. 
3.8 Statistical treatment of data 
Multivariate analysis was performed on all studies using a matrix constructed as 
described in Section 3.7.1 and the software program SIMCA-P+ (V12.0, Umetrics 
UK). The theoretical aspects of the statistical methods employed using the SIMCA-
P+ software have already been discussed in Section 2.10.1. The data matrix can be 
imported directly into the SIMCA-P+ Software from a standard Microsoft Excel 
spreadsheet. An example of the matrix format is given in Figure 21 
  
Figure 21 The breath matrix summarising the observations recovered from a breath 
study.  
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SIMCA-P+ software uses the original data from the matrix to form a work-set that is 
used to define which observation to include or exclude from the MVA. The 
observations may also be grouped into classes, for example pre- and post- an 
intervention. In each of the three studies presented in Chapter 4,Chapter 5 and 
Chapter 6 all observations were included, initially, in the work-sets and were 
classified according to the sample type for each particular study. 
The variables in the work-set may also be included or excluded from the model at 
this stage. The SIMCA-P+ software has an automated evaluation tool that will 
include or exclude variables based on the number of responses in each variable set. 
The value is inputted as a percentage and has a default setting of 50%. To evaluate 
the data sets used in these studies the variables were considered by the software 
and included in the data analysis if the variable had values for responses above zero 
for more than or equal to 25% of the total number of observations for that particular 
variable.  
The responses for each of the variables may then be scaled to one of four scaling 
types (None, Unit variance, (UV), Pareto (par) or control (Ctrl)). The final option to 
address in the work-set was to select the required model, in the research presented 
in Chapter 4,Chapter 5, and Chapter 6 partial least squared discriminant analysis 
PLS-DA and principal component analysis (PCA) models only, were used to classify 
the data obtained in each study.  
The complete work-set could now have the model applied and generate component 
variables using the Autofit function in the SIMCA-P+ software. This function 
generates component variables until the maximum number of permissible variables 
for a particular module had been generated or until the predictive ability (Q2) of the 
model begins to degrade and the resulting Q2 value becomes lower than that of the 
previous component variable. In addition to the Q2 value for each component 
variable the SIMCA-P+ software also generates a Fit value (R2) for each variable.  
Cross validation of the models generated in the SIMCA-P+ software is performed 
automatically and is accomplished using the “leave one out” method. The default 
conditions for the validation require the data to be divided into to 7 groups. A model 
is then generated for the data, which is devoid of one of these several groups and is 
repeated until all groups and therefore all variables have been left out. In each 
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instance a predictive residual sum of squares (PRESS) value is generated and if a 
new component has an elevated PRESS value compared with the previous 
component then the new component is retained.   
Transformation of the model in to a visual format is achieved by generating a Score-
plot where potential trends in the separation of the observation types can be 
assessed by hierarchical clustering. The separation of the different clusters of 
observations in the score-plots can then be attributed to the differences in the 
variable responses through loading plots or contribution plots. 
When the Initial approach did not yield any separation of the observation types using 
the PCA approach the model type was modified to a supervised PLS-DA model. The 
model was refitted using the Autofit function and score plots for PLS-DA model were 
then generated and assessed. In addition to the score and loading plots the PLS-DA 
model also allows the generation of an S-Plot for each component variable. The S-
plot enables the identification of the most reliable and most intense variables in the 
data and is a useful tool to identifying putative markers within groups of 
observations. The identified variables from the S-plot could then be extracted and re-
modelled using the unsupervised PCA approach described above to both confirm 
and enhance the separation of the observations.  
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  It’s all in the mind and sometimes in the Chapter 4
breath 
4.1 An introduction to psychological stress 
Psychological stress (stress) is experienced by everyone and it is a healthy response 
to a challenging or threatening environment, evoking what is known as the general 
adaptation syndrome (the fight or flight response). It is conceivable that participants 
providing breath samples for diagnostic research during a visit to a clinical facility 
might be experiencing differing degrees of stress. The UK Health and Safety 
Executive (HSE) reported over 400,000 cases of psychological stress related 
complaints in the UK from 2009 to 2010121. Psychological stress disorders such as 
anxiety and depression have also been shown to have a higher prevalence in 
patients suffering from COPD122 and lung cancer compared to healthy volunteers123 
Stress and anxiety may be a common concurrent factor in many breath samples. 
Stress causes a cascade of hormonal releases. The most well known is the 
secretion of cortisol, but this is only one aspect of the body’s response. 
Gluconeogenesis, glucogenolysis and lipolysis are also stimulated and increased 
and levels of renin and angeotensin II enzyme are produced causing elevation in 
blood-pressure (BP) and heart-rate (HR)23. Research into the exposure to stress 
prior to influenza vaccination has led to claimed increases in the level of antibody 
response in women124 Long-term exposure to psychological stress has been 
reported to cause headaches125, back pain126 and reduced cognitive function127  
Such observations lead to the research questions: 
• Does stress change breath VOC profiles? 
• and, if so, are putative markers of stress potential confounding factors 
for the diagnosis of disease by breath analysis.  
At the outset of this study the observation and description of the effect of 
psychological stress on breath VOCs was unreported. This study, therefore, sought 
to engender a stress response in human breath using a Paced Auditory Serial 
Addition Task (PASAT) intervention128,129.  
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An adjunct to this study was a tentative examination of the potential of objective 
stress monitoring through exhaled VOC markers. 
4.2 Study objectives 
• Evaluate the effect of a PASAT on the VOC composition of exhaled 
breath. 
• Identify any VOCs in the breath samples that indicate a change in 
homeostasis after a stressful event. 
• Develop an understanding of the potential origins of those VOCs 
present in which changes are observed and how this may potentially 
confound future studies into breath research. 
4.3 Overview of the study 
4.3.1 VOLUNTEER PARTICIPANTS 
The ethical framework of this study has been reviewed in Section 3.2, and the 
protocols were reviewed and granted a favourable opinion the Local Ethics Advisory 
Committee (Ref: Loughborough University; G08-P7 and G09-P5). All participants 
taking part in the study gave written informed consent. 
Male (n=10) and female (n=13) volunteers aged between 19 and 26 years 
participated in the study, and 22 complete sets of breath samples were obtained. 
The study used a randomised cross-over design with the participants attending two 
sampling sessions. In one session they were asked to sit comfortably and listen to 
relaxing music (neutral intervention), in the other they were asked to undertake 
cognitive and mental arithmetic tests (PASAT intervention). The mental arithmetic 
test (PASAT) was augmented with enhanced audio/visual alarms to intensify their 
perception of errors, and to mislead the participants with false-positive error alarms.  
The sampling/test sessions ran in the morning. Before the sampling/test sessions the 
participants had fasted for a minimum of 9 hr and had drunk only water during this 
time. Further, the participants had refrained from washing or using oral hygiene 
products on the morning of their visit. In each session, two VOC breath samples 
were collected. The first breath sample was taken prior to beginning the 
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experimental interventions (neutral /PASAT intervention) and the second directly 
after completion of the intervention.  
4.3.2 HEART-RATE AND BLOOD-PRESSURE MEASUREMENTS 
Heart-rate and blood-pressure measurements were recorded using a Datex Ohmeda 
S/5 patient monitoring system. A finger clip was attached to the index finger of the 
participant’s left hand in order to monitor the heart rate.  A Critikon 23 -33 cm Dura-
Cuf® blood-pressure cuff was applied to the participant’s upper left arm. Three 
baseline blood-pressure and heart--rate readings were taken at 2 minute intervals. A 
further 12 readings were taken over the course of the experimental session at 12, 
16, 19, 23, 30, 42, 45, 48, 49, 57, 60, 65 and 71 minutes. Heart rate, systolic blood-
pressure, diastolic blood-pressure and the mean arterial pressure were recorded at 
each time point.  
4.3.3 COGNITIVE FUNCTION TESTS 
During each of the two visits the participants also undertook three cognitive function 
tests before and after the intervention period. The tests were a Stroop test, a Flanker 
test, and a Rapid Visual Information Processing test (RVIP). Each test lasted 
approximately 5 minutes and they were always given in the same order. In brief, the 
Stroop test, involved presenting the participants with words for a colour e.g. blue, 
red, green etc. The text colour for these words was different to the written colour 
presented. The aim was to discern the written word and not the colour it was 
presented in. The Flanker task required the participant to view an image of three 
arrows in a line, each pointing randomly left or right. The aim was identify correctly 
the direction of the centre arrow while ignoring the flanking arrows. Finally, the RVIP 
test presented the participants with a series of random numbers from 1 to 9 and 
required the participant to indicate when they observed three consecutive odd 
numbers. These tests were developed at the School of Sport, Exercise and Health 
Science at Loughborough University. 
4.3.4 PACED AUDITORY SERIAL ADDITION TASK (PASAT)  
The PASAT, originally developed to assess neurological injury129, was used to 
induce stress in a reproducible manner in the participants128. The PASAT requires 
participants to perform mental arithmetic in which they listened to a recording of a 
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series of random single digit numbers (1 to 9) where each number was followed by a 
pause.  Participants were instructed to take the first number they heard and add it to 
the second number. They were then required to state their result. If they were 
incorrect, a loud buzzer sounded to indicate a wrong answer while the next number 
in the series was presented for the participant to add to the last number they had 
been given and for them to once more state the result. The task ran for ten minutes 
with the frequency at which the numbers were presented increasing. At pre-defined 
points over the task, regardless of the accuracy of an answer the error-buzzer 
sounded; causing frustration, disorientation and feelings of self-doubt.  
The control for the PASAT intervention session required participants to listen to ten 
minutes of calm classical music comprising four instrumental pieces; Truman Sleeps 
composed by Burkhard Dallwitz, Guitar Flute & String composed by Moby, Gabriel's 
Oboe composed by Ennio Morricone and Suite Bergamasque: Clair De Lune 
performed by Dame Moura Lympany.  
The collected samples were then analysed by GC-MS under the conditions in Table 
2. 
4.4 Results and discussion  
4.4.1 BLOOD PRESSURE AND HEART RATE  
Individual heart rates, systolic blood pressures and diastolic blood pressures were 
collated and the average observations show the physiological responses to the 
PASAT and neutral interventions (Figure 22). The period of PASAT intervention (23 
to 60 minutes) elicited a significant increase in these physiological responses, 
compared to the relaxed intervention where no discernible changes were observed. 
The baseline and cognitive function test portions of the two experimental sessions 
also showed no significant difference prior to the experimental intervention (0 to 23 
minutes).  
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Figure 22 Heart rate and blood pressure responses in PASAT and neutral sessions. 
Left  Averaged responses of 22 participants for systolic blood pressure 
(top), and heart rate (bottom) over the 70 minute PASAT (solid line) and 
relaxing music (dashed line) interventions. 0-23 minutes 1st cognitive 
function session, 24-48 minutes experimental intervention and 49-70 
minutes 2nd cognitive function session. The error bars designate the 95 % 
confidence limit on the mean. Right Box-whisker summaries of the 
physiological stress response (PSR) scores classified by male stress (MS), 
male neutral (MN), Female stress (FS), Female neutral (FN) and Total stress 
(TS) and Total neutral (TN). 
4.4.2 PASAT RESPONSE SCORE 
In order to evaluate the extent at which a participant had been effected by the two 
interventions a PASAT Stress response score (PSR) was constructed. The 
participants’ individual physiological responses to the PASAT and neutral 
interventions were scored on the basis of observed changes in their systolic blood 
pressure and heart rate. The average of the 3 initial baseline observations were used 
to give blood pressure and heart rate start values (PSstartand HRstart). The maximum 
observed value of the four readings taken during the intervention periods ( and HRmax) were assigned the points of maximum “stress”. Equation 22 defines a PASAT 
stress response score (PSR) derived in-house for the PASAT (PSRS) and neutral 
interventions (PSRN).  
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Equation 22 
The PSR sought to emphasise the change in systolic blood pressure that occurred 
during the intervention ( ∆𝑃𝑃𝑆𝑆)  and relate this back to the baseline 
observations(𝑃𝑃𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑟𝑟𝑆𝑆). Heart rate was also included in the same manner providing a 
ratio between the overall change (∆𝐻𝐻𝑅𝑅) and the baseline values. The PSR score in 
Equation 22 was designed to give higher score for those individuals showing the 
largest physiological responses under the interventions. The PSR scores for the 
participants are summarised in Table 4 and Figure 22. Of the 22 participants 21 
showed significant physiological responses to the PASAT intervention consistent 
with a stress response and this is reflected in their PSR score. The median PSR 
score during the neutral intervention was 3.5 compared to 428 for the PASAT 
intervention. Male and female responses were not statistically different with 
male/female participants’ median PSR scores for neutral and PASAT interventions 
being 2.9/3.6 and 28.9/58.6 respectively. Female PSR scores showed a greater 
range of responses during the PASAT intervention (PSR = 12 to 233), while it was 
the male participants who had the greatest variability (PSR = 0.1 to 18.6) in the 
neutral state. Overall, the physiological responses as summarised by the PSR score 
indicated a significant acute response to the PASAT intervention that was consistent 
with the individuals experiencing psychological stress over the intervention period. 
4.4.3 CHROMATOGRAPHIC DATA    
The gas chromatographic-mass spectrometric (GC-MS) data were processed 
following a work-flow that has been described previously in Chapter 3. Retention 
times were correlated to a retention index scale constructed from a primary retention 
ladder generated from a quality assurance standard for the analysis, and a 
secondary retention index scale based on the retention times of five ubiquitous 
siloxane components present in all breath samples as a result of hydrolysis of the 
active phases within the analytical system. Figure 23 illustrates a typical example of 
the total ion current (TIC) chromatograms with both retention time and retention 
index values (RIU) obtained from the filter air blanks and breath samples collected 
under the two experimental sessions.  
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The GC-MS data were deconvolved and a typical breath sample would yield 
between 300 and 400 individual components. A breath matrix was constructed that 
contained 154 breath VOCs that were unique to breath and not found in any 
background sample. Each component was assigned a unique reference number. 
Saturn MS workstation software (Varian Inc, UK) was used to integrate peak areas 
for each breath component’s extracted ion chromatograms (XIC) and both the ID 
assignments and the peak areas made up the breath matrix as described previously 
in Chapter 3.  
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Table 4 PASAT response scores of participants during the neutral (PSRN) and PASAT intervention sessions (PSRS).  
Note: The suffix * indicates that the participants were subjected to the PASAT session on their first visit.  
Ref 1* 2 3* 4 5* 6 7* 8 9* 10 11* 12 13* 14 15* 16 17* 18 19* 20 21* 22 
M/F M F M M M F F M F M M F F F M M F F F F F M 
 PASAT intervention                  
HRmax 90 119 70 92 80 77 105 91 90 90 96 100 82 134 95 84 146 66 97 95 105 85 
HRstart 78 94 54 90 69 68 81 76 66 73 59 66 72 84 75 76 88 42 82 61 65 54 
𝑃𝑃𝑆𝑆
start 141 121 112 136 121 113 105 120 129 141 113 119 102 117 107 138 112 112 116 126 110 144 
𝑃𝑃𝑆𝑆
max 152 148 122 142 144 124 125 136 155 168 129 138 117 146 121 153 152 120 133 154 132 162 
PSRS 11.6 60.6 27.5 0.9 30.3 12.9 56.7 26.1 74.2 44.8 87.6 84.5 19.7 149 34 11.1 233 40.8 27.5 125 125 72.6 
 Neutral intervention                 
HRmax 81 102 65 72 74 83 98 85 69 101 71 89 101 73 82 95 113 54 79 94 71 70 
HRstart 75 90 58 65 68 79 85 82 61 81 60 72 84 56 73 78 81 49 60 79 68 56 
𝑃𝑃𝑆𝑆
start 126 120 125 118 120 107 102 125 120 135 113 113 111 116 107 133 118 108 120 119 103 147 
𝑃𝑃𝑆𝑆
max 127 121 125 124 122 122 101 118 123 138 122 111 109 123 114 131 117 107 122 116 105 148 
PSRN 1.0 0.8 0.1 5.3 1.6 7.4 1.9 2.0 3.2 4.7 15.5 5.0 4.2 18.6 7.7 3.9 2.7 1.2 4.5 4.5 1.0 1.4 
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Figure 23 Examples of total ion current (TIC) chromatograms of five participants [Top] 
relaxed session and [Bottom] stressed session breath samples. Lower x- 
axis shows retention index units (RIU) and upper x-axis illustrates the 
equivalent retention time (tR), overlaid chromatograms are offset by 2% 
4.4.4 MULTI-VARIATE ANALYSIS (MVA) 
The breath data matrix was subject to MVA using SIMCA-P+ software package. 
Those compounds that were present in less than 30% of the breath samples 
collected were excluded from the data modelling, this value ensured that potential 
present / absence compounds would not be excluded. This inclusion criterion yielded 
a resultant data set of 50 breath components that were used in the subsequent multi-
variate analysis (MVA).  
The breath data matrix consisted of the peak areas of the 50 VOC breath 
components (variables) against the participants (observations). MVA was conducted 
using SIMCA-P+ software (Version 12, Umetrics, UK). Partial least squared 
discriminate analysis (PLS-DA) was initially performed on the post-intervention 
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samples from both PASAT and neutral experimental sessions. All variables were 
assigned to a single block and a weighting of 1/√𝐵𝐵𝐵𝐵𝑐𝑐𝑐𝑐𝑘𝑘 was applied making the total 
variance of all variables equal to 1. In addition Pareto Variance (ParN) was selected 
for base scaling of the data set; this scaling method takes each variable, subtracts it 
from the mean of that variable set and divides it by the square root of the standard 
deviation for the variable set130. The S-plot generated from this statistical model 
(Figure 24) indicated six possible VOC variables (α1 to α6) that changed in response 
to interventions experienced by the participants.  
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Figure 24 S-Plot of variables used for discrimination of stressed and neutral states S-
plot generated from the modelled covariance (P(corr)[1]) and modelled 
correlation (w[1)] of the partial least square discriminate analysis (PLS-DA) 
from  the intensities (peak areas) of 50 breath components (variables) from 
44 breath samples (observations). The six variables highlighted (black 
dots) were found to provide the highest magnitude (intensity) of the 
variables in the data set and greatest reliability (P(corr)[1] axis) of the 
variables in the data set; indicating potential putative markers sensitive to 
PASAT intervention  
Principle component analysis (PCA) of these six VOC variables enabled the 
separation between the PASAT and neutral observations to be evaluated. The score 
plots generated from these data are given in Figure 25. In each plot responses from 
the PASAT and neutral interventions are seen to cluster and a distinction between 
breath profiles obtained under the two experimental sessions can be observed. The 
principle components identified exhibited 44.1% [PC1] and 15.7% [PC2] of the total 
explained variance of the data set for male participants yielding a 100% sensitivity 
(% of correctly assigned true positive observations) for the male PASAT 
observations and 90% selectivity (% of correctly assigned true negative observation) 
for the neutral observations. In contrast to this the female observations produced a 
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weaker model and yielded a sensitivity of 83.3% and a selectivity of 91.6%. The total 
variance modelled by each component was 34.5% and 28.4% for [PC1] and [PC2] 
respectively.  Further when the multivariate results were cross-correlated to the PSR 
scores the outliers were found to have anomalous PSR scores. Participants 4 and 6 
had low PSR scores during the PASAT intervention and Participants 11 and 14  
scored  higher PSR score in the neutral intervention than any of the other 
participants  (Table 4) finally participant 17 had the largest PSR score during the 
PASAT intervention and was classed as an outliner by the multivariate analysis. 
4.4.5 PRELIMINARY IDENTIFICATION OF PASAT SENSITIVE BREATH 
COMPONENTS 
Elucidation of the VOC components α1 to α6 was based on three tests. The first was 
a satisfactory match of the de-convoluted spectrum generated from Analyzer Pro to 
the respective entry in the NIST MS library (NIST05). Satisfactory is defined in this 
instance as forward (direct matching of spectrum peaks to library reference 
spectrum) and reverse (matching by omitting spectrum peak not present in the 
library spectrum) match factor with a value greater than, or equal to, 650131, see 
Table 5. 
The second test was a satisfactory match between the observed retention index 
value (IU) and the estimated retention index value obtained from NIST05 MS library. 
Satisfactory is defined as a difference not greater than ±50 IU. The recorded 
retention index value for α2, see Table 5, of 1063 IU for BRI1063-105-77-52-106-51 
(indicated by mass spectrometric library matching to be 2-hydroxy-1-
phenylethanone) did not match the estimated NIST retention index value of 1272 IU. 
No record of an experimental retention index for this compound for a DB5 (5% 
phenyl 95 % methyl) stationary phase appears to be currently available. 
The third and final test was based on matching the preliminary assignments in Table 
5 to standards analysed under the same conditions (chapter 3). An adsorbent 
sampling tube was spiked with 0.1 µl of a 50 µg ml-1 methanol solution of: indole 
(α1), 2-hydroxy-1-phenylethanone (α2), 1,4-cyclohexadiene, 1-methyl-4-(1-
methylethyl) (α4), benzaldehyde (α5), 2-ethylhexan-1-ol (α6); all reagents were 
purchased from Aldrich. The on-column mass of each of the components was 500 
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pg. 2-methylpentadecane (α3) was not available commercially and was not included 
in this test.  
These three tests confirmed the assignments of indole, 2-hydroxy-1-phenylethanone, 
benzaldehyde, and 2-ethylhexan-1-ol.  α4 was not confirmed as 1,4-cyclohexadiene, 
1-methyl-4-(1-methylethyl) however, the mass spectrum indicates that α4 was likely 
to be a terpene. 2-methylpentadecane (α3) remains putatively annotated  and Table 
5 summarises the PASAT sensitive components. 
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Figure 25 Unsupervised principle component analysis (PCA) of six stress sensitive 
breath components identified from PLS-DA  (Figure 24) model on [A] 12 
observations from the stressed (black dots) experimental session and 12 
observations from relaxed (grey squares) experimental session from 
female participants. [B] 10 observations from the stressed experimental 
session and 10 observations from the relaxed experimental session from 
male participants.  100 % sensitivity was obtained for the male stressed 
observations and 90% selectivity was obtained for the relaxed 
observations. In contrast to this the female observations yielded a 
sensitivity of 83.3% and a selectivity of 91.6% was observed. Outliers are 
annotated with participant references given in Table 4 
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Table 5  Identification of PASAT sensitive breath components C1 to C6 with reverse and forward spectral match and de-
convoluted spectrum lists.    
Ref Name and library entry Deconvolved mass spectra MS F/R RI O/E CAS 
α1 
Indole 
BRI-1286-117-90-89-63-73 
117 (999); 90 (411); 89 (310); 63 (151); 73 (130) 850/889 1286/1276 120-72-9 
α2 
2-hydroxy-1-phenylethanone 
BRI-1063-105-77-52-106-51 
105 (999); 77 (311); 52 (172); 106 (73); 51 (66) 889/885 1063/1272 118-93-4 
#α3 
2-methylpentadecane 
BRI-1527-41-57-43-85 
41 (999); 57 (786); 71 (776); 43 (619); 85 (412) 
 
650/658 1527/1548 1560-93-6 
*α4 
unknown terpene compound 
BRI-951-93-91-92-79-121 
93 999); 91 (435); 92 (430); 79(264);121 (217) 
 
-  951/   -      -     
α5 
Benzaldehyde 
BRI-976-105-77-52-106-95 
105 (999); 77 (239); 52 (222); 106 (103); 95 (72 ) 
 
813/813 976/982 100-52-7 
α6 
2-ethylhexan-1-ol 
BRI-1019-41-57-70-85-55 
41 (999); 57 (756); 70   (620); 85 (543); 55 (389) 
 
732/830 1019/995 106-76-7 
Note: MS F/R Forward (F) and reverse (R) mass spectral match of deconvolved mass spectrum to NIST05 library search.                
RI O/E Observed (O) and estimated (E) retention index value for deconvolved peak.        
# Putatively annotated by spectral match with NIST05 Library only as reference standard is not commercially available.  
  
* BRI-1527-41-57-43-85 NIST match indicates 1,4-Cyclohexadiene, 1-methyl-4-(1-methylethyl), this was not confirmed with a reference 
standard. 
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The origins of these VOCs in breath are not well defined and may be 
generated through a combination of independent mechanisms. Benzaldehyde 
is a common food component and occurs naturally in fruits like apples and 
honey132,133 likewise terpenes occur naturally in foodstuffs134. These 
components may be due to dietary intake and may not have an endogenous 
origin. Indole is associated with the production of the essential amino acid 
tryptophan, which in turn is part of the pathway that produces serotonin; 
previously reported to be involved in cardiovascular and psychological 
response to acute stress135 Indole may also be generated from tryptophan 
metabolism by indole positive bacteria in the gastro intestinal system. 2-
Ethylhexan-1-ol has been associated with polyvinylchloride (PVC)136 and also 
as a potential VOC marker of lung cancer137 In addition 2-ethylhexan-1-ol has 
also been observed in the headspace of in-vitro cultures of lung carcinoma 
A549 cells138. Methylated hydrocarbons have been reported as the 
endogenous products of oxidative stress and numerous VOCs in this class 
have been identified as potential biomarkers of various cancers40,138  
Example responses from Participant 14, for these six compounds are 
presented in Figure 26. Indole and 2-methylpentadecane exhibit an increased 
or up-regulated response during the PASAT intervention. Indole signals 
increased from +140% to +360% in response to the PASAT intervention, 
compared to the Neutral intervention samples. 2-methylpentadecane 
increased to a lesser extent, between +30% to +80% increases compared to 
the Neutral intervention. The remaining four components show a reduced or 
down-regulated response compared to the neutral Intervention.  
The collective scores for the six VOC markers were combined by taking their 
Euclidian distance, based on the peak intensities (𝐼𝐼𝑅𝑅) to generate a marker 
score (CMS), and the box whisker plots in Figure 27. The median CMS for the 
neutral intervention was 5.42x104 compared to 4.62x104 for the PASAT 
intervention. Female participants exhibited the greatest range and variability 
during the PASAT intervention. In contrast male participants showed the 
widest range and variability during the neutral intervention. In comparison to 
the PSR the CMS results show equivalent trends in the female participants 
with an increase in range and variability in breath samples collected under 
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PASAT intervention when compared to the results from the neutral 
intervention. This correlation was not reflected in the male participants, one 
reason for this may be due to the lower intensities observed for the down 
regulated breath components indicating a higher rate of clearance.             
𝐶𝐶𝑀𝑀𝑆𝑆 = �� 𝐼𝐼𝑅𝑅2      6
𝛼𝛼=1
 
Equation 23 
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Figure 26 Overlaid extracted ion chromatogram (XIC) responses for stressed 
experimental session (dashed line) and relaxed experimental 
session (solid line) for stress sensitive breath components, Indole 
(α1), 2-hydroxy-1-phenylethanone (α2), 2-methylpentadecane (α3), 
unknown terpene (α4), benzaldehyde (α5)  and 2-ethylhexan-1-ol 
(α6) from a single male participant.  The intensities (IR) displayed 
have been normalised with respect to the relaxed experimental 
session to indicate those components that have been up-regulated 
and down-regulated as a result of undertaking the PASAT.  
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4.5 Study summary 
Changes in the exhaled breath VOC profiles of healthy volunteers were 
observed in participants who underwent a PASAT intervention. Four of the 
VOCs have been identified through mass spectral, retention index and 
chemical standard matches. A combination of all six components enabled the 
population to be classified as PASAT Responsive or Neutral with a sensitivity 
of 90.9% and a selectivity of 90.9%. These data correlated with their 
physiological scoring; the PSR score, and the individuals who were not 
correctly classified exhibited possible stress, induced by the unfamiliar 
surroundings of the test rooms and laboratory environments, or who had low 
PSR scores; indicative of not experiencing stress during the PASAT 
intervention. 
The biological origin and role of these VOCs in breath has yet to be 
completely described. The four down-regulated VOCs may have been 
depleted through enhanced ventilation from elevated heart-rate, and 
respiratory rate. In contrast 6-methyl-pentadecane and indole, which were up–
regulated, may be indicative of biochemical response to the PASAT 
intervention. 
The PASAT intervention has been developed specifically to induce signs and 
symptoms associated with stress in the participants. These preliminary 
findings are indicative of the existence of a stress-related response in the 
VOC profiles of humans. The concentrations involved may be estimated at 
this stage to range from 20 ng m-3 for indole to 4.8 µg m-3 for benzaldehyde 
and targeted studies with labelled standards would be a logical follow-up to 
this study. 
Demonstrations of the utility of breath analysis in providing next generation in-
community diagnostic capability through monitoring biochemical changes in 
the human body continue to be reported70. This study indicates that the 
human VOC profile may also be sensitive to non-physical stimuli. Physical 
disease may not be the only contributing factor in breath profiling and the 
acquisition of samples and data from people undergoing traumatic and 
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emotionally challenging diagnoses associated with serious diseases may 
need to consider this factor.   
 
 
Figure 27 Box-whisker summaries of the combined marker scores (CMS) for 
stressed and neutral participants, classified by male stressed and 
neutral interventions (MS and MN), female stressed and neutral (FS 
and FN) and the total group stressed and neutral (TS and TN) 
results.  
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 Changes in VOC profiles of exhaled Chapter 5
breath before and after induced physiological 
stress 
5.1 Introduction to VOCs and exercise 
During the onset of exercise the human body responds by increasing gas-
exchange in the lungs and the independent regulation of organ blood flow. As 
a result of this new internal environment the biochemical reactions in the body 
change to accommodate the increased workload and to keep the human body 
functioning.  At rest the average cardiac output is approximately 5 dm3min-1, 
and this increases rapidly during moderate exercise to somewhere in the 
region of 25 dm3 min-1 Figure 28 highlights this23.  
 
Figure 28 Bar Chart illustrating the approximate proportion blood of the total 
cardiac output at rest (5 dm3 min-1) and during exercise (25 dm3 
min-1) to organs of the body (graph drawn from data presented in 
Stanfield, C. L. Principles of Human Physiology; 4th ed.; Pearson, 
2009) 
At rest skeletal muscle receives approximately 20% of the total cardiac output 
and this increases to approximately 80% when the body is engaged in 
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exercise. It is helpful to note that both the skin and heart show an increase in 
blood flow during exercise. Blood-flow in the gastro intestinal (GI) tract and 
kidneys, decreases as the metabolic demands in these areas is low during 
exercise23. 
Gas exchange in the lungs increases under physical exercise with the intake 
of O2 and output of CO2 increasing to over 10 times the resting-rate. This is 
characterised by the respiratory exchange ratio (RER); the ratio of the volume 
of CO2 expired per unit time (VCO2) to the volume of O2 inspired per unit time 
(VO2) inspired (equation 22). At rest the RER ≈ 0.8, and during exercise when 
there is a greater reliance on carbohydrates for energy production the RER ≈ 
1.0139.  
During exercise the O2 uptake or VO2 increases linearly with the workload until 
the VO2 becomes constant; known as the VO2max. Workloads above the VO2max 
require the body to use anaerobic glycolysis for the production of energy. 
𝑅𝑅𝐸𝐸𝑅𝑅 = 𝑒𝑒𝐶𝐶𝑂𝑂2
𝑒𝑒𝑂𝑂2
 
Equation 24 
 
Monitoring of breath VOCs during exercise has been approached by a 
number of different analytical techniques and include PTR-MS82,140, 
sensors141 API- MS142 and SPME-GC-MS143. The most common technique 
used to monitor VOCs in breath during exercise has been PTR-MS as 
continual monitoring during the exercise regime can be achieved.  
The exercise protocols presented in the literature used to induce physical 
stress though exercise have incorporated both resting and active exercise 
phases. The workloads on the exercise phases of the protocols ranged 
between 50 W and 100 W over time periods between 5 to 15 min. The resting 
phases, which are dispersed throughout the exercise protocol, lasted between 
3 to 12 min. Further studies presented in the literature have negated any 
resting phases and precede the exercise phase by a warm up period. Other 
exercise phases used have included a stepped workload. In these scenarios 
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the literature reports the workload was increased in steps of 20 W every 3 min 
over a period of 24 mins144. Conversely the exercise protocols have also been 
tailored to the individual participants with a study using a 20 W.min-1 
incremental workload up to a sub maximum of 80 % of the participants’ 
maximum workload142 
The cohorts reported in the literature for studies involving breath VOCs during 
exercise have been on small pilot study scale with many cohort sizes in single 
figures or low teens82,142,144. Participant panels have included populations of 
both sexes and have incorporated both smokers and non-smokers. The age 
range reported has also been broad, ranging from early 20’s to mid 50’s142 
The changes in acetone and isoprene profiles under different exercise 
protocols using an ergometer have been reported82,142,144. An increase in both 
acetone and isoprene during the exercise phases has been shown, however 
they did not follow similar profiles. Acetone increases in response rapidly until 
it reaches a plateau, the plateau then continued until exercise stopped and 
then reduces rapidly82. This trend with acetone appears to happen 
consistently throughout each exercise phase with responses of similar 
concentration in each subsequent exercise phase when rest periods are 
incorporated in the protocol. The isoprene response differs markedly to that of 
acetone: in isoprene there is an abrupt increase in the response that is 
followed by a rapid decline. This response profile is repeated over each phase 
when rest periods are included however in each subsequent exercise phase 
the initial response observed is lower than the previous phase. The isoprene 
and acetone profiles have been confirmed across different research groups, 
however differences in the profiles of acetone were observed when the 
exercise protocol was based on continuous exercise. In contrast to the 
protocols using rest periods the acetone also follows initially the same raise 
and plateau, however when an extended exercise protocol was used, acetone 
exhibits a reduction in response after approximately 20 min of continual 
exercise. King et al concluded the observed profiles could be ascribed to 
different exhalation patterns during exercise in the case of acetone, while 
changes observed for isoprene were due mainly to changes in pulmonary gas 
exchange82. 
102 
 
In addition to PTR-MS, VOCs have been monitored simultaneously using 
SPME-GC-MS for four VOCs in expired breath144. Acetone, isoprene, 
acetaldehyde and hexanal have been monitored as they are produced 
through different metabolic pathways: lipolysis, cholesterol biosynthesis, a 
metabolic product of ethanol, and oxidative stress, respectively. Only the 
PTR-MS data was reported from this comparison study, however it was 
reported that the data from PTR-MS and SPME-GC-MS follow similar trends 
with the exception of the initial warm up phase where it is commented that the 
two data sets diverge.  
One of the few approaches to the analysis of VOCs in breath during exercise 
that does not utilize PTR-MS is the use of APCI-MS for real time analysis of 
VOCs. The expired breath is passed in to an APCI source set in negative 
ionization mode. This study reported numerous responses of VOCs that show 
variation during exercise, however no VOC identities were elucidated and only 
the m/z ratios were reported.  
At the outset of this study there was little research into the VOCs in breath 
associated with exercise and recovery using a global metabolic approach with 
TD-GC-MS.   
5.2 Study objectives 
 Evaluate the effect of moderate exercise on the VOC composition of 
exhaled breath. 
 Identify possible VOC markers of recovery to homeostasis following 
exercise. 
 Develop an understanding of the potential origins of those VOCs in 
which changes are observed and how this may potentially confound 
future studies into breath research. 
5.3 Study overview 
The study panel consisted of 10 male participants aged between 18 and 35. 
All participants were healthy non-smokers and gave informed consent prior to 
taking part. This study used a combined sampling approach to collect breath, 
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skin VOCs, saliva, urine and blood. The local ethical committee at 
Loughborough University (G09-P5) approved the sampling protocols used in 
the study.  
The experimental design comprised four Phases; Phases A to D. Each phase 
lasted approximately 30 min. Phases A, C and D were resting phases where 
the participants were required to sit upright in a chair. Phase B was the 
exercise fraction of the study and during this phase participants were 
relocated onto an ergometer and required to peddle for 30 min at a resistance 
based on the participant’s body weight. The resistance was set at 2 W.Kg-1. A 
comprehensive timeline for the experiment if given in Figure 29 
 
Figure 29 Experimental timeline of samples in each phase of the experiment 
Participants undertaking the study were asked to arrive without exerting 
themselves (i.e. Cycling or running) at the sampling station in one of two slots 
(7:30 am or 10:30 am), having not brushed their teeth or washed. The 
participants were further briefed and shown the exercise facilities, they then 
had the chance to ask any questions and be shown how to adjust and use the 
ergometer. Each participant’s weight and height was recorded (Table 6) and 
they were fitted with a heart rate monitor. The participant’s heart rate was 
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recorded every 10 min throughout Phase A, Phase C and Phase D and every 
5 min of Phase B of the experiment. These data are summarized in Table 7. 
 
Table 6 Summary of participant height, weight and calculated body mass 
index (BMI). 
 
The participants provided three breath samples, see chapter 3. The first 
sample was collected at the start of Phase A. The second sample was 
collected at the start of Phase C and the final sample was collected at the 
beginning of Phase D. Breath samples were not collected during Phase B due 
to the impracticality of using the adaptive breath sampler on the ergometer.  A 
volume of 2.0 dm3 of exhaled breath was collected at each sampling point. 
In addition to the breath samples a 2.0 dm3 air samples was acquired of the 
filtered air used to supply the masks. All samples were stored at 4oC for up to 
14 days until analysis by TD-GC-MS was undertaken. The analysis conditions 
and quality procedures are outlined in detail in chapter 3. 
  
Participant ID Weight /Kg Height / cm Calculated BMI 
CZ01 69.64 176.9 22.3 
CZ02 73.46 173.5 24.4 
CZ03 82.92 189.3 23.1 
CZ04 83.52 196.0 21.7 
CZ05 72.20 174.2 23.8 
CZ06 74.02 181.8 22.4 
CZ07 92.08 191.5 25.1 
CZ08 88.12 177.9 27.8 
CZ09 100.04 176.5 32.1 
CZ10 88.66 168.0 31.4 
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Table 7 Summary of recorded heart rate for the ten participants 
throughout each phase of the experiment. 
 
 
 
 
5.4 Results  
5.4.1 HEART RATE RESULTS 
The lowest resting heart rate recorded in phase A was 52 beats per min 
(BPM) and the highest recorded heart rate in phase A was 90 BPM. As the 
exercise portion of the experiment began a rise in heart rate was observed 
with a maximum heart rate of 218 BPM being recorded from a single 
participant during Phase B. The maximum change observed between resting 
and exercise was 144 BPM and plot of the percentage (%) change in heart 
rate above the initial resting value is presented in Figure 30. Using the 
exercise protocol described previously in this chapter the trend shown 
indicates that a significant increase in heart rate was observed for all 
Phase t.min-1 
Participant Heart Rate (BPM)  
 
CZ01 CZ02 CZ03 CZ04 CZ05 CZ06 CZ07 CZ08 CZ09 CZ10 
A 0 52 63 72 60 76 56 78 76 90 57 
A 10 59 61 72 58 75 64 76 55 86 62 
A 20 52 59 80 63 60 66 73 75 81 57 
A 30 67 71 80 59 70 57 74 71 79 55 
B 35 101 92 69 74 96 109 109 102 74 131 
B 40 120 126 130 131 123 103 133 139 126 147 
B 45 129 148 138 141 149 108 149 156 197 154 
B 50 137 157 151 149 162 111 160 165 210 141 
B 55 144 167 152 153 169 111 167 173 218 148 
B 60 149 168 157 165 173 114 164 175 209 149 
B 65 152 173 159 165 183 113 168 176 215 149 
C 70 90 171 N/R 169 188 114 182 122 213 85 
C 80 73 102 93 90 135 76 101 114 120 67 
C 90 80 82 85 73 105 69 97 97 110 73 
D 100 78 78 67 73 91 65 93 98 111 71 
D 110 66 68 75 70 83 67 94 89 96 63 
D 120 69 76 72 73 80 67 87 82 89 66 
D 130 62 61 67 64 78 67 84 77 88 61 
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participants over the course of Phase B. In the post exercise portion of the 
study (Phase C) a rapid decline in heart rate was observed over 30 mins and 
by the end of the second recovery phase (Phase D) the heart rate had 
returned to a rate that was not significantly different from the initial heart rate 
readings. 
 
Figure 30 Plot of the mean % heart rate change above the initial recorded heart 
rate reading verses the experimental time in min. Error bar shown 
are 95% confidence intervals.  
5.4.2 ACETONE AND ISOPRENE RESULTS 
The assessment of the TD-GC-MS data generated from this study was 
performed initially using the acetone and isoprene responses obtained from 
phases A C and D. The chromatographic responses for each VOC were 
integrated and the peak areas interrogated. These data have been graphically 
summarized as box and whisker plots in Figure 31 and Figure 32. This 
approach was adopted to qualitatively assess and contrast how the observed 
data compares to those presented in current literature. In addition the heart 
rate data from phases A, C and D have also been summarized in box whisker 
plots (Figure 33) to aid comparison with the acetone and isoprene data.  
The observed responses for isoprene exhibit similar interquartile ranges for 
each phase of the experimental study with phase C showing the greatest 
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variability overall. The interquartile ranges of phase A and C show similar 
variation and show similar distribution of responses above and below the 
median line on each plot. In contrast phase D shows a similar interquartile 
variation as A and C, however the majority of responses in the lower 50% of 
the interquartile range exhibit more variation that the upper 50% above the 
median which is the opposite of the distributions observed in phases A and C.   
 
 
Figure 31 Boxplot of observed isoprene responses in Phases A, C and D. 
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Figure 32 Boxplot of observed acetone responses in Phases A, C and D. 
 
Study of the acetone responses reveals differences from the isoprene. The 
box whisker plots show similar interquartile variability between the three 
experimental phases and with the greatest range of intensities being observed 
in phase C. The median trend also differs from that of isoprene showing a 
higher median in phase C, which then decreases in the second rest phase 
(phase D). Again with Phase D the lower 50% of responses exhibit a higher 
degree of variation.  
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Figure 33 Boxplot of observed heart rate responses in Phases A, C and D 
The results of the heart rates, graphically represented in the box whisker plots 
(Figure 32) for the 3 phases; indicates how the participants’ heart rates varied 
in each phase. Phase A illustrates the heart rate of the participants at rest with 
a little variation and an interquartile range that is evenly distributed around the 
median with a variation of less than 25 BPM. This has significantly changed 
directly after exercise with minimal overlap of the phase A and C plots. The 
Phase C plots as with the Acetone and isoprene shows the largest variation 
overall. Phase C plot exhibits partial overlap of with phase D with phase D 
showing a trend that mostly aligns with Phase A, with the exception of the 
upper 50% exhibiting an increased variation above the median when 
compared to the data observed for Phase A. 
5.4.3. CORRELATION OF HEART RATE WITH ACETONE AND isoprene 
responses.  
The mean peak area responses for both acetone and isoprene were plotted 
against the average heart rate observed in each phase. The resultant graphs 
are given in Figure 34.  The data yielded three points for each graph, the 
graph produced for isoprene responses and heart rate exhibited no significant 
correlation. The resultant graph for acetone shows the general trend between 
the mean acetone response and the mean heart rate.  
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Figure 34 Correlation between average HR and average observed intensity of 
isoprene (top) and acetone (bottom) signals. 
 
5.4.3. MULTIVARIATE ANALYSIS OF TD-GC-MS 
A total of 346 individual VOCs were observed in the 40 samples collected and 
subsequently analysed by TD-GC-MS. The sample data was processed using 
the methodology described in chapter 3. The resultant heat map of the 
integrated chromatographic peak areas for each of the 10 participants in 
Phases A, C and D and 10 filter air blanks (BLK) is given in Figure 35. The 
heat map or matrix was then transferred to SIMCA-P+ software, (Umetrics, 
UK, version 12.0) where multivariate analysis was performed.  
The matrix was checked for variables that had responses in less than 25% of 
observations. This value was chosen as there were four classes of 
observation (Phase A, Phase C, Phase D and Filtered Air Blank) in the data 
set. This approach ensured that any VOC components of the breath samples 
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that appear in only one class of observations; effectively presence / absence 
based approach, would not be excluded. The result of this test was that no 
variables were excluded from the matrix. Further to this the data set was 
scaled using Pareto scaling. The model type selected was PCA-X this was an 
unsupervised principle component analysis (PCA).     
The model produced initially investigated the responses yielded in the matrix 
from the observations of the pre-exercise phase (phase A) and post exercise 
phase (phase C) of the study. The model generated two principle components 
that were classed as significant by the SIMCA-P+ software. The first principle 
component [t1] explained 12.7% of the variance of the total variance of X (R2) 
and the second principle component [t2] explained 18.9 % of the total 
variance.  The model yielded Q2 values of 0.832 and 0.202 for [t1] and [t2] 
respectively. The score plot produced from this model is given in Figure 36.    
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Figure 35. Heat maps of the breath data-matrices for air blanks, and sample 
collected in experimental phases A, C and D. 
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Figure 36 PCA score plot of Phase A and C, Phase A observations indicated by 
grey circles and Phase C observations illustrated by the blue 
diamonds. The two principle components generated by the PCA 
model explain a total of 31.5 % of the variation observed. 
A cluster analysis performed on the model showed there were two distinct 
clusters between the responses for observations in phase A and phase C. 
The model exhibited a sensitivity and specificity of 100.0% and 90.0% 
respectively. The false positive observation from this data set was generated 
from participant CZ03. 
There were a total of 11 variables that were found to be responsible for the 
separation observed in the PCA, a list of these variables are given in Table 8.  
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Figure 37 PCA Score plot of phases A, C and D. Phase A observations 
indicated by grey circles, Phase C observations illustrated by the 
blue diamonds and D observations are shown by the green 
squares. Notice only two clusters of observations are still present 
compared with Figure 36 as the Phase D observations are spread 
over the previous two experimental phase observations. 
The PCA analysis was shown including phase D observations. The resultant 
score plot is given in Figure 37. The results of this analysis and the 
subsequent cluster analysis show that the three classes of observations yield 
two clusters. However, with this data set the score plot shows that the 
recovery phase samples (Phase D) exhibit a 60/40 split between the pre-
exercise phase and the post exercise phase. The variables that were found to 
be responsible for the separations observed in the score plots are listed in 
Table 8. To elucidate these variables, the de-convoluted spectrum of each 
compound was compared with NIST 11 mass spectral database. The reverse 
fit matches for each compound are listed in Table 8. In addition to the spectral 
matching the retention index values obtained experimentally from the 
construction of a primary and secondary retention index ladders were also 
compared to the NIST library matches. Where a tentative identification was 
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made using both the retention index and spectral matching these components 
have been named. When the spectral matching returned reverse fit results 
below 700 and / or there was no substantial correlation to the experimental 
retention index values obtained when compared to those in the NIST 
database then the assignment has been given Unknown VOC.        
Table 8.  Candidate exercise response markers. 
Ref 
 
Library Index 
 
NIST 
REV 
match 
NIST 
RIU 
 
Putative annotation 
 
1 VOC 617.8_59_43_0_0_0 950 481 Acetone 
2 VOC 622.6_67_68_53_42_0 890 502 Isoprene 
3 VOC 622.7_95_97_49_93_77 - - Unknown VOC # 1 
4 VOC 631.2_81_67_53_93_95 - - Unknown VOC # 2 
5 VOC 636.9_95_94_97_92_45 936 514 Dimethyl selenide 
6 VOC 637_94_97_45_93_91 - - Unknown VOC #3 
7 VOC 685.1_43_86_41_71_58 811 673 3-Methyl-2-butanone 
8 VOC 702.7_61_90_48_41_47 762 707 Propane, 1-(methylthio)- 
9 VOC 717.8_88_73_45_71_47 839 726 1-Propene, 1-(methylthio)-, (E)- 
10 VOC 726.7_94_95_45_79_97 933 724 Disulfide, dimethyl 
11 VOC 756.3_97_98_69_45_53 903 779 Thiophene, 3-methyl- 
 
5.4.4 TRENDS IN VOC RESPONSES IN BREATH POST EXERCISE. 
The responses for each of the VOC components in breath responsible for the 
separation observed in the PCA for phase A and C are summarised in Figures 
37 to 39. The trends observed for (3) VOC 622.7_95_97_49_93_77 show a 
reduced inter-subject variability in phase C compared to phase A or D. In 
addition Phase C also exhibited a down regulated response with respect to 
the component peak area response that reduced from a maximum of 31 x 104 
cps in Phase A to 13 x 104 cps in Phase C. After the 30 minute resting period 
the inter-subject variability observed increased. The peak response observed 
in Phase D also showed an up-regulated response with respect to Phase C 
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with maximum of 232 x 104 cps being recorded for one participant. The 
general trend of the responses of VOC 622.7_95_97_49_93_77 are contrary 
to those observed for acetone and heart rate.  This trend of down regulated 
responses in the VOCs listed in Table 8, occurs for four additional 
compounds, (6) VOCs 637_94_97_45_93_91, (8) VOC 
702.7_61_90_48_41_47, (10) VOC 726.7_94_95_45_79_97 and (11) VOC 
756_97_98_69_45_53.  The tentative assignment of compounds 8, 10 and 11 
reveals that they are sulfur-containing compounds and include dimethyl 
disulphide. Dimethyl disulphide and dimethyl selenide (compound 5) have 
been reported previously as markers of reduced liver function in exhaled 
breath145. A potential source of sulfur-containing compounds is the incomplete 
metabolism of sulfur-containing amino-acids through the transamination 
pathway145. A second potential source of sulfur containing compounds in the 
body is the GI tract as our diet contains a number of foods such as onions, 
garlic and eggs146. The reduction in the observed responses of these VOCs 
directly after exercise may potentially indicate their metabolic origins lie in the 
organs that receive reduced blood flow as the metabolic demands on them 
are low during the physiological stressful conditions associated with exercise.  
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Figure 38 Box whisker plots of the peak areas observed for VOC breath 
components responsible for the separation in the score plots 
(Figure 36) between phases A and C.  
VOC compounds (5) VOC 636.9_95_94_97_92_45 and (7) VOC 
685.1_43_86_41_71_58 exhibit the same overall trend as that of acetone. 
These compounds tentatively identified as dimethyl selenide and 3-methyl-2-
butanone are compound that have been reported in breath and have been 
used to classify reduced liver function145 while 3-methyl-2-butanone has been 
reported in breath and urine147,52 and as a ketone it is a reasonable 
assumption that it follows the same elimination pathways as acetone, which 
would potentially explain why is shows the same general trend in response  
following exercise.  Dimethyl selenide also appears to follow this trend, 
selenium is an essential mineral and finds its major elimination routes from 
the human body via breath and urine like that of ketones. 
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Figure 39 Box whisker plots of the peak areas observed for VOC breath 
components responsible for the separation in the score plots 
(Figure 36) between phase A and C 
 
 
 
 
Figure 40 Box whisker plot of the peak areas observed for VOC breath 
component responsible for the separation in the score plots 
(Figure 36) between phases A and C 
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5.5 Study summary 
The protocol was successful in causing a physiological response to exercise 
this is indicated by the elevated heart rate (Figure 30). 
Due to the hardware limitations of the adaptive sampler breath samples for 
TD-GC-MS were only able to be collected for experimental phases A, C and 
D.   
The samples from the experimental phases A and C were able to successfully 
distinguish between breath collected pre and directly post exercise with a 
sensitivity and specificity of 100.0% and 90.0% respectively.  
A total of 11 VOCs were found to be responsible for the separation observed 
in the PCA Score plots. These included acetone and isoprene, which agrees 
with previously published observations in the literature. These 11 components 
also showed that when phase D sample observations were incorporated into 
the statistical model they were distributed between the pre and post sets of 
samples indicating that there are differing rates at which the participants 
recovered from the exercise protocol. Within the suite of VOC markers found 
to discriminate physiological stress there were four sulphur-containing VOCs 
that are suggestive that the liver metabolism is sensitive to exercise. One 
selenide compound was also identified which have been reported to 
discriminate healthy and liver disease patients.  
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 The role of the lower intestinal tract in Chapter 6
breath variability  
6.1 Introduction 
There are numerous VOCs that are present in samples of human faeces and 
faecal VOC profiles in breath contain putative biomarkers of bowel 
disease40,13,52,148,149  . Many of the VOCs isolated from faecal samples have 
also been found in breath and this may be explained, in part, by the venous 
system around the anus and the colon has veins that are connected to both to 
the hepatic system and the inferior vena cava (Figure 42) and how they 
integrate with the rest of the cardiovascular system (Figure 41). The inferior 
vena cava is the large portal vein that returns the de-oxygenated blood from 
the lower body to the heart. The returning blood enters the left ventricle of the 
heart and is pumped to the lungs where it then undergoes gas exchange, 
before being transported back to the heart and re-circulated around the body. 
There is therefore the potential for VOCs that are present in the 
gastrointestinal system to be transported directly to the lungs and excreted as 
part of normal gas exchange without encountering first-pass metabolism in 
the liver. 
6.2 Study objectives 
 Observe the effect of defecation on breath VOC profiles  
 Establish if defecation is a factor that needs controlling in breath bio-
marker prospecting studies.  
6.3 Overview of study 
The study panel consisted of 10 participants (6 male and 4 female) aged 
between 23 and 33. All participants were healthy non-smokers and gave 
informed consent prior to taking part. Participants undertaking the study were 
asked to school their bowel movements so they could undergo a normal 
evacuation in the morning between 09:00 and 11:00 hours. The participants 
were required give two breath samples collected in the manner described in 
chapter 3. The first of the two samples was collected at the point at which the 
participant started to feel the need to defecate. The second breath sample 
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was collected 10 minutes after defecation. In both instances the sample 
collection volume was 2.0 dm3. In addition to the breath samples two 
additional air samples were acquired; (i) a 2.0 dm3 of the filtered air used to 
supply the mask and (ii) a passive VOC sample; which the participant was 
required to wear at the start of the sampling procedure. The average passive 
sampling time was 30 minutes and this measurement was used as an 
environmental control to account for exposure to any immoderate sources of 
VOCs from the building or toilet facilities. The acquired samples were stored 
at 4°C for up to 72 hours until analysis by TD-GC-MS was undertaken. The 
analysis conditions and quality procedures are outline in detail in Chapter 3. 
 
Figure 41 Schematic diagram of the human cardiovascular system 
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Figure 42 Anatomical drawing showing the veins associated with lower 
intestine and rectum150  
 
6.4 Results 
6.4.1 STATISTICAL EVALUATION OF VOC BREATH PROFILES 
OBSERVED IMMEDIATELY BEFORE AND AFTER DEFECATION 
The TD–GC–MS data sets were processed following the work-flow described 
in chapter 3 and employed in the studies covered in chapters 4 and 5. 
Samples were aligned by retention index, spectra were deconvoluted and the 
resultant component peak areas calculated and entered into a breath data-
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matrix with a total of 263 variables (spectral and time resolved distinct 
components) and 20 observations (10 x pre and 10 x post defecation breath 
samples).  They were modelled with multivariate analysis using SIMCA-P+ 
(version 12, Umetrics, UK). The model was examined for any observation or 
variables that had less than 50 % of the total responses and none of the 
observational responses were found to have less than 50% of the total 
responses in the entire dataset. The dataset was then scaled with Pareto 
scaling and each observation was assigned as either Pre or Post. An 
OPLSDA model was then applied to the data and in order to classify possible 
discriminator VOCs within that provided a separation between the two classes 
of observations. 
The resultant model provided a separation of the two classes of observations, 
however no significant principle components were isolated. The RX2 and Q2 
results generated are given Table . The S-plot generated from the model 
identified a total of 6 variables that were responsible for the separation 
observed in the OPLSDA model.       
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Figure 43 OPLS-DA Score plot of 10 pre bowel evacuation (grey circles) breath 
samples and 10 post bowel evacuation (black square) breath 
samples 
 
Table  Results of the OPLS-DA model generated by Umetrics SIMCA-P 
statistical package 
 R2X R2X 
(cum) 
Eigenvalue R2Y R2Y 
(cum) 
Q2 Q2(cum) significance 
Model         
1 0.0456 0.631 0.684 0.885 0.885 -0.527 -0.527 NS 
Orthogonal  0.585   0    
 1  0.233  0.233  3.49  0  0      NS 
 2  0.223  0.456  3.34  0  0      NS 
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Figure 44 PCA Score plot of 10 pre bowel evacuation (grey circles) breath 
samples and 10 post bowel evacuation (black square) breath 
samples using unsupervised model generated from the variables 
identified from the OPLSDA analysis 
 
The responses for these variables were isolated and a principle component 
analysis (PCA) was performed to establish whether discrimination of the two 
sets of observations could be retained using an unsupervised model. The 
PCA model generated three principle components. The principle components 
generated in the unsupervised PCA were all significant according to either 
rule 1 (R1) or rule 2 (R2) of the cross validation rules130, however their 
predictive ability (Q2) was poor. The resultant score plot of components t1 
and t2 from the model is given in Figure 44.  
Evaluation of the score plot revealed the there was insufficient separation 
between the two sets of observations to discriminate with any certainty 
between samples taken before and after a bowel evacuation. Further scrutiny 
of the score plot revealed that while there was no common discrimination 
between the pre and post samples, the individual sample sets from each 
participant were all separated to various degrees on the score plot.  
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6.4.2 OBSERVATIONS OF VOC BREATH PROFILES BEFORE AND 
AFTER DEFECATION 
In the absence of a meaningful statistical model to identify potential VOCs that 
change after bowel evacuation a further examination of the individual 
participant samples identified differences in the responses of a number of 
components in the total ion current chromatograms (Table 11). The extracted 
ion chromatograms presented in Figure 44, 45 and 46 have been normalised 
to the response of the pre bowel movement samples for each VOC 
component.  The VOC components presented in these figures show 
reductions in response between 30 to 100% in breath after defecation had 
occurred.  A summary of the VOCs observed to change and their tentative 
identifications based on spectral searching with NIST 11 spectral database 
are given in Table 9.   
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Table 9 VOCs observed to reduce post bowel evacuation 
NIST database assignment  BRI Reference Match  
(Rev) 
5-hepta-2-one-(6-methyl) BRI_978-93-108-43-41-67  783 
unknown Alcohol BRI_871-41-56-55-69-70  - 
unknown aldehyde BRI_998-41-56-82-81-67  - 
2 propylpentanol BRI_1026-57-41-70-83-56  799 
Nonanal BRI_1112-81-67-41-70-69 779 
Decanal BRI_1223-81-67-83-41-82 804 
Unknown VOC #4 BRI_1198-81-95-67-41-71  - 
methylsalicylate BRI_1213-81-95-67-41-71  802 
Benzene-1-methyl-2-(1methylethyl)  BRI_1023-119-91-117-115-77 891 
Anethole  BRI_1311-148-147-117-105-133  889 
Indole BRI-1286-117-90-89-63-73 902 
Unknown Terpene  BRI_1028-93-79-67-94-68 - 
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Figure 45 Example of extracted ion response plotted against calculated 
retention index of detected analytes in pre (dashed line) and post 
(solid line) defecation breath samples observed to reduce in 
intensity after a bowel evacuation. Responses have been 
normalized to pre sample analyte intensities (i) BRI_978-93-108-
43-41-67, (ii) BRI_998-41-56-82-81-67, (iii) BRI_871-41-56-55-69-70 
and (iv) BRI_871-41-56-55-69-70    
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Figure 46 Example of extracted ion response plotted against calculated 
retention index of detected analytes in pre (dashed line) and post 
(solid line) defecation breath samples observed to reduce in 
intensity after a bowel evacuation. Responses have been 
normalized to pre sample analyte intensities (i) BRI_1112-81-67-
41-70-69, (ii) BRI_1223-81-67-83-41-82 (iii) BRI_1198-81-95-67-41-
71and (iv)BRI_1213-81-95-67-41-71.  
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Figure 47 Example of extracted ion response plotted against calculated 
retention index of detected analytes in pre (dashed line) and post 
(solid line) defecation breath samples observed to reduce in 
intensity after a bowel evacuation. Responses have been 
normalized to pre sample analyte intensities. (i) BRI_1023-119-91-
117-115-77, (iii) BRI_1311-148-147-117-105-133, (ii) BRI-1286-117-
90-89-63-73 and (iv) BRI_1028-93-79-67-94-68 
 
6.5 Study summary 
The multivariate analysis of these data generated from pre- and post- 
defecation breath samples yielded statistical models that generated significant 
principle components but had poor predictive ability. As a result there was no 
discernible discrimination possible between the two observation sets in this 
study. There was however a degree of separation within the participants’ 
individual sample sets, which could be seen from both the score plots 
generated from the statistical analysis and the visual observation made on the 
chromatographic data obtained. A total of 12 VOCs were observed to reduce 
over the entire data set after defecation. 
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The observed inter-subject variability suggests that there is a faecal 
component in breath. It is important to note that the reduction of the VOCs 
concentration in breath was in all but one case not completely depleted which 
would indicate that faeces in the rectum was not the only source of these 
VOCs in the breath samples. 
The VOCs identified in this study have been observed previously in faecal 
samples and while present in faecal samples their origins have yet to be fully 
elucidated. Potential origins of the VOCs could be: 
• The intake of different foodstuffs (diet), and their subsequent 
metabolism, catabolism, conversion, oxidation/reduction and 
hydrolysis. 
• The microbiological metabolism within the gastrointestinal tract  
One or both of these sources could account for the contribution of the VOCs 
excreted in breath and this study frames the complexity of seeking to account 
for gastrointestinal factors in designing breath samples.  
At this stage it appears reasonable to propose that the defecation cycle has a 
significant effect on the VOCs present, or absent, in an individual’s breath. It 
is also apparent that microbiological, lifestyle, diet, phenotypic and 
environmental factors combine to create individualised profiles and that 
significantly higher powered experimental design will be needed to establish if 
there are generic faecal discriminator markers.  
The study presented here was undertaken as a pilot study with a small 
population. The wealth of variation observed between the profiles in this 
study, where no controlled stimulus was applied, highlights two main factors 
that should be taken into consideration when attempting to follow up on this 
study.  
 No common VOC artefact in breath was found across all participants; 
with a lack of any commonality among the VOCs associated with 
defecation a significantly larger, single-gender participant cohort will be 
needed in follow up studies.  
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 The participants were not subject to dietary controls, and this study 
indicates that this might be helpful in participant preparation protocols 
for biomarker discovery.  
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 Discussion, conclusions and future Chapter 7
work. 
7.1 Overview of thesis 
This research utilises optimized conditions for the chromatographic, 
instrumentation and data processing methods for the detection of VOCs in 
exhaled breath. The thesis describes new putatively annotated biomarkers 
associated with psychological and physiological stress. It further investigates 
how the everyday occurrences of stress and defecation can impact and 
confound the prospecting of breath biomarkers when using an untargeted 
approach. With the premise that small everyday tasks and situations impact 
on VOCs breath profiles established, it highlights the need for pre-sampling 
participant protocols when embarking on breath analysis studies.   
7.1.1 CHAPTERS 1 AND 2 
The first two chapters set the proposition of this thesis and established the 
research objectives. A Gedankan experiment is used to explore the 
complexity of the VOC profiles obtained from exhaled breath. The 
fundamental theory of gas exchange in the lungs is discussed along with an 
introduction to thermal desorption, GC-MS and the multivariate statistical 
methods commonly used in breath analysis. Finally the different techniques of 
breath capture and analysis that have been reported in the literature are 
reviewed and the applications of breath analysis are reviewed.  
7.1.2 CHAPTER 3 
This chapter outlines the methodology used in this research and describes in 
detail how breath was collected and the analytical methods employed with an 
outline of the instrumentation used. The development of the methodology and 
the final optimized conditions are given. The untargeted global metabolomic 
approach adopted for the data handling and discovery are discussed in detail.  
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7.2 Overview of the studies  
7.2.1 BREATH VOCS AND THE PACED AUDITORY SERIAL ADDITION 
TASK  
The administration of the PASAT caused an elevated amount of anxiety and 
frustration in the study participants. This was confirmed by the increased heart 
rate and blood pressure data obtained before, during and after the task. 
The study reported the first example of breath VOCs being affected by a 
PASAT and indicated the existence of psychological stress-related response 
in the VOC profiles of healthy humans. 
There were six candidate VOC markers that were shown to be responsible for 
the separation observed in the multi-variate analysis. The analysis of the data 
also indicated that gender has a role in the extent of the stress response 
observed for these marker compounds. The resultant score plots yielded 100 
% sensitivity and 90% specificity for the male participants and 83.3% 
sensitivity and specificity of 91.6% for female participants. 
Indole and 2-methylpentadecane; two of the candidate markers were found to 
increase in intensity (up regulated) in samples collected after the PASAT was 
administered. The remaining four showed a decrease in intensity (down 
regulated).  
Consequently this highlights the fact that non-physical stimuli can have a 
bearing of the VOCs observed in breath. These findings illustrate that physical 
disease may not be the only contributing factor in breath profiling of people 
undergoing traumatic and emotionally challenging diagnoses associated with 
serious diseases: The participants’ stress and anxiety levels may need to be 
considered as a confounding factor in the biomarker discovery process.  
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7.2.2 CHANGES TO BREATH VOCS FROM INDUCED PHYSIOLOGICAL 
STRESS. 
The breath samples collected show that the acetone intensities reflect the 
profiles obtained from the heart rate data observed. These results are 
consistent with the published literature. 
The metabolomics approach to the VOC profiles illustrated that pre and post 
exercise breath samples differed significantly when interrogated using the 
data processing protocol previously described in chapter 3.    
There was 100% sensitivity and 90% specificity shown in the separation 
observed from the breath samples collected pre (Phase A) and post (Phase 
C) exercise. 
When the recovery phase samples were incorporated in to the model they 
showed that 60 % were classified as pre exercise samples and 40 % were 
classified as post exercise samples.  This potentially indicates differences in 
the fitness levels and therefore the recovery rates for each participant. This 
finding suggesting that 30 minutes was insufficient for 40 % of participants to 
recovery from the exercise protocol to a metabolic state resembling that prior 
to exercise. 
There were 11 VOCs that were found to be responsible for the separation 
observed in the score plots.  In these VOC compounds there were four that 
were found to be sulfur-containing compounds, which have previously been 
associated with liver function. 
The results of this study highlighted new candidate markers that have not 
been previously reported and are possibly associated with physical stress 
through exercise. These VOC markers are also potentially indicative of 
physical recovery after exercise. This finding supports the fact that human 
breath is not constant and external stimulus can cause a deviation in 
homeostasis. Furthermore after the removal of the external stimulus the 
human body attempts to recover homeostatic environment of breath. 
These findings if investigated further could help in the personalised training 
regimes of athletes or patients recovering from physical trauma through 
physiotherapy. 
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The study also highlights potential confounding factors in the markers 
associated with liver function tests though breath VOC analysis.  
7.2.3 INFLUENCE OF THE LOWER INTESTINAL TRACT ON BREATH 
VOC PROFILES 
The breath VOC profiles pre and post bowel evacuation have shown that 
inter-individual variability was not consistent in the cohort of this study. As a 
result no common markers that correspond to bowel evacuation were 
identified. 
The intra-individual variability of breath VOCs found pre and post sample 
were shown to be random, but significant changes in VOCs were found in 
breath. While multivariate analysis did not establish any common VOCs that 
were able to separate the pre and post samples, the score plots showed that 
there was separation between the individual participants’ profiles. This 
highlights three important conclusions: 
Significant contributions of a number of VOCs in breath find their origins in the 
bowel. 
The time of when a participant’s last bowel movement occurred can influence 
presence and or concentration of VOCs found in breath. 
Potentially the effects of diet not only provide an immediate effect on breath 
profiles directly after consumption such as coffee, but also can be much 
longer lived providing a source of VOCs in the bowel long after their initial 
consumption. The ramifications of this is that diet and the bowel are 
potentially a large contributor to the VOCs found in breath and that there is a 
need to identify what VOCs are generated in the bowel to remove potential 
confounding factors when considering metabolomics workflows. Also anxiety 
and general fitness levels of participants need to be considered when building 
study panels and planning clinical studies. At the very least this data should 
be collected and used when considering controls and test groups that are 
being scrutinised by statistical methods. A list of the VOCs identified in the 
studies described in this thesis are listed in Table 11. 
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Table 10 List of VOCs highlighted in the studies presented in this thesis. 
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Breath Library Ref NIST assignment  Match (Rev) Potentially associated with  RIU 
BRI_617-59-43-0-0-0 Acetone 950 Physiological stress 617 
BRI_622-67-68-53-42-0 Isoprene 890 Physiological stress 622 
BRI_623-95-97-49-93-77 Unknown VOC # 1 - Physiological stress 623 
BRI_631-81-67-53-93-95 Unknown VOC # 2 - Physiological stress 631 
BRI_637-95-94-97-92-45 Dimethyl selenide 936 Physiological stress 637 
BRI_638-94-97-45-93-91 Unknown VOC #3 - Physiological stress 638 
BRI_685-43-86-41-71-58 3-Methyl-2-butanone 811 Physiological stress 685 
BRI_703-61-90-48-41-47 Propane,1(methylthio)- 762 Physiological stress 703 
BRI_718-88-73-45-71-47 1-Propene,1(methylthio) 839 Physiological stress 718 
BRI_727-94-95-45-79-97 Disulfide, dimethyl 933 Physiological stress 727 
BRI_756-97-98-69-45-53 Thiophene, 3-methyl- 903 Physiological stress 756 
BRI_871-41-56-55-69-70  Unknown Alcohol - Bowel  871 
BRI_951-93-91-92-79-121 Unknown terpene compound   Psychological stress 951 
BRI_976-105-77-52-106-95 Benzaldehyde 813 Psychological stress 976 
Breath Library Ref NIST assignment  Match (Rev) Potentially associated with  RIU 
BRI_978-93-108-43-41-67  5-hepta-2-one- (6-methyl) 783 Bowel  978 
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BRI_998-41-56-82-81-67  Unknown aldehyde - Bowel  998 
BRI_1019-41-57-70-85-55 2-ethylhexan-1-ol 830 Psychological stress 1019 
BRI_1023-119-91-117-115-77 Benzene-1-methyl-2- (1methylethyl)  891 Bowel  1023 
BRI_1026-57-41-70-83-56  2-propylpentanol 799 Bowel  1026 
BRI_1028-93-79-67-94-68 Unknown terpene  - Bowel  1028 
BRI_1063-105-77-52-106-51 2-hydroxy-1-phenylethanone 885 Psychological stress 1063 
BRI_1112-81-67-41-70-69 Nonanal 779 Bowel  1112 
BRI_1198-81-95-67-41-71  Unknown VOC  #4 - Bowel  1198 
BRI_1213-81-95-67-41-71  Methyl salicylate 802 Bowel  1213 
BRI_1223-81-67-83-41-82 Decanal 804 Bowel  1223 
BRI_1286-117-90-89-63-73 Indole 889 Psychological stress 1286 
BRI_1286-117-90-89-63-73 Indole 902 Bowel  1286 
BRI_1311-148-147-117-105-133 Anethole  889 Bowel  1311 
BRI_1527-41-57-43-85 2-methylpentadecane 658 Psychological stress 1527 
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7.3 Future work 
7.3.1 VALIDATION OF POTENTIAL CANDIDATE MARKERS FOR 
PSYCHOLOGICAL AND PHYSIOLOGICAL STRESS. 
The studies in this thesis have been of a pilot study size with the cohorts of 
participants being a relatively small number when compared to more 
conventional large-scale metabolic studies. The approach of this research 
was not undertake large scale participant studies but rather to investigate 
potential causes of changes in breath profiles from a baseline using healthy 
control participants. As a result the potential candidate markers highlighted in 
the physical and psychological stress studies have yet to be validated in 
large-scale targeted studies.  
 
In addition there also remain a number of unconfirmed VOCs that would 
benefit from confirmation using commercially available standards as this 
would potentially help to elucidate their biological origins. In some instances 
where there is not a commercial standard available, further elucidation could 
potentially be achieved using MSn and or chemical ionization modes using 
instrumentation described in chapter 3. This could also be accomplished 
using high-resolution mass analysers to provide higher mass accuracy and 
elemental compositions. 
The study described in chapter 6 would also benefit from a larger scale 
investigation with stricter dietary control of the cohort to attempt to elucidate 
common VOCs, which may allow for separation when scrutinized using 
multivariate statistics.  
In addition to the larger scale studies it is proposed that quantification of the 
candidate markers should also be undertaken using matrix matched 
standards and potentially the incorporation of an internal standard into the 
breath sampling procedure. The latter being a difficult challenge as there are 
hundreds of VOCs in breath with a variety of functional groups, polarities and 
molecular weights, so multiple internal standards may be required. Ideally 
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such compounds would be introduced as early as possible in the sampling 
procedure or even administered to the participant prior to sample collection.  
 
7.3.2 DEVELOPING FUTURE STUDIES BASED ON THE CURRENT 
FINDINGS 
The following sections provide an outline of potential future studies that are 
based on and further the research presented in this thesis. 
The application of stress has only been evaluated using healthy participants 
that have undergone a single acute stressful episode. A valuable study would 
include participants that undergo chronic stress. These cohorts could be 
made up of participants from stressful professions such as air traffic 
controllers, soldiers or fire fighters.  
A diurnal study targeting the potential candidate markers for physical and 
psychological stress identified in this research would allow for the monitoring 
of the inherent variability of these breath components. The study would aim to 
collect samples over the course of hours, days and weeks and could be 
aimed at competing athletes as they train and prepare for competitions. This 
approach would aim to establish potential links between physical and mental 
fitness in athletes. 
7.4  Concluding remarks 
How we think, how we move and what we eat, the very environment we find 
ourselves in defines who we are.  Breath VOC analysis has a long history, but 
our understanding of how rich, complex and variable the matrix of breath can 
be, has only started to be realized in the last 15 years. The factors examined 
in this research effect our body’s biochemistry and this is in turn reflected in 
our breath. The studies here however, were not concerned with infections or 
diseases but sort to explore how day to day activities such as exercise and 
toileting, as well as psychological stress impacts on VOC profiles. In the 
course of this research new putative VOC markers have been presented that 
can successfully discriminated participants that had been exposed to 
psychological stressful situation from those who were in a relaxed state. In 
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addition to this group of markers a second panel of putative annotated VOCs 
were elucidated that were associated with the physical stress of exercise. 
These two studies highlight potential confounding factors that could impact on 
future breath VOC studies. They show that if a panel participants or part of 
that panel are exposed to physical stress or acute psychological stress prior 
to the collection of breath samples then it would be conceivable when using 
MVA methods that potential false positive could be identified. The 
investigation into the how defecation changes the composition of breath 
highlighted how a bowel movement can cause major changes in the 
concentrations and occurrence of VOCs observed in the breath of individuals.   
From these findings we ideally need to consider and be aware of the 
management of care and hospital facilities in terms of toileting. We should 
also be assessing people’s state of physical activity as it has an effect on 
breath. This is yet to be fully quantified but is observed in this research. 
Finally, that a participant’s emotional state may need to be noted and 
assessed prior to sample collection. However attempting to control all of these 
aspects is highly impractical and may well never be achieved.  In the same 
way though by not considering these factors, which can impact significantly on 
the breath volatalome and instigate a deviation from homeostasis in human 
breath, we may introduce more complexity which could either mask or 
confound small metabolite signals in future studies. One potential compromise 
to this would be the introduction of a detailed participant diaries or the 
development of using wearable personal technology to gather a range of 
meta-data, such as sleeping patterns, heart rate and exercise patterns.  What 
is apparent is that further investigation is needed to fully understand what a 
normal everyday breath VOC profile should look like. The research presented 
here is only a small fraction of the types of everyday activities that could 
potentially cause significant deviations in the baseline of breath. 
Understanding what constitutes normal breath would undoubtedly enable 
more reliable and robust interpretation of breath VOCs as markers in disease 
diagnostics. 
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APPENDICES 
Appendix 1. Generic Breath Sampling Ethics 
A1.1 Generic participant information sheet 
Breath analysis in <Study Title>> 
Part 1 
Invitation to participate 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for 
you. Please take time to read the following information carefully. Talk to others 
about the study if you wish. This part (Part 1) tells you the purpose of this study 
and what will happen to you if you take part. Part 2 gives you more detailed 
information about the conduct of the study.  
Ask us if there is anything that is not clear, or if you would like more information. 
Please take time to decide whether or not you wish to take part.  
What is the purpose of this study? 
We are testing a new way of detecting changes in the human body, through 
measurement of tiny amounts of chemical substances in the breath.  These 
substances arise from all the processes and reactions that occur in the body.  We 
think that analysis of these compounds may be able to give us information about 
health, diet and diseases. This research may lead to a test that can detect serious 
diseases earlier in the future. 
Why have I been invited? 
You will have been invited because you have << specific inclusion criteria goes 
here>> and this makes you part of the group of people we are particularly 
interested in seeing.  
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Do I have to take part? 
It is up to you to decide.  
We will describe the study and go through this information sheet, which we will 
then give to you. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, and you do not give us a 
reason.  
What will happen to me if I take part? 
If you agree to take part we will arrange for you to visit our <<laboratory>> for a 
single visit lasting about 45 minutes. During this visit we will first ask you a series 
of questions relating to factors that can influence the chemical substances in the 
breath.  These will include questions about food, drink, and medications recently 
consumed, and smoking. We will also ask you some questions about personal 
care including toiletries, perfumes and personal care products. We will also ask 
you for information about diet and digestion, and finally we will ask for some 
information about <Inclusion criteria specified here>.   
For the same reasons, you will be asked to refrain from eating, drinking (other 
than unflavoured water) and smoking for two hours prior to the study visit.   
After we have collected this information, we will collect a breath sample.   This 
involves wearing a face mask that is connected to an air supply.  You will be 
asked to breathe normally throughout the test, whilst sitting comfortably in a 
chair.  A sampling tube is connected to the mask on which we will collect the 
sample. Up to 5 samples will be collected in total and the process will take about 
half an hour.  
What will I have to do? 
We need you to not smoke, eat or drink (although you are permitted to drink 
unflavoured water) for two hours prior to the study visit.   
We also ask you not to use perfumed products (which include not only perfume, 
but also deodorants, after-shaves), or any facial products (such as make-up or 
creams (scented or un-scented)) on the day of the study visit. 
What are the possible disadvantages and risks of taking part? 
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We do not anticipate any risk from taking part in this study.  You may experience 
some initial discomfort wearing the mask. We have tested the mask with 
volunteers with chronic bronchitis and emphysema without any difficulties. Some 
patients experienced slight claustrophobia when first wearing the mask but this 
was in very few cases and was not enough to cause anxiety. We will always be 
with you during this process and we will how to release the mask quickly should 
you wish to take it off. 
What are the possible benefits of taking part? 
There will be no direct benefits to you from taking part in this research. The aim is 
to develop new tests that may be used in future to detect diseases in people or to 
provide information that will help changes in lifestyle to be accurately assessed. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. You may withdraw from the 
study at any time; either before or during the study. The detailed information on 
this is given in Part 2. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2.  
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision.  
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Part 2 
What will happen if I don’t want to carry on with the study? 
You are under no obligation to participate in this study and you may withdraw 
from the whole study, or to contribute only to a part of the study (for example you 
may not wish to give a breath sample, or answer the questionnaire, or vice versa), 
in which case we will use only the sample(s) and answers you agreed to provide. 
We will ensure that you are able to stop the sampling procedure at any time 
quickly and easily should you want to.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions (contact number 
0150 922 2549). You may ask a researcher to clarify anything about the study at 
any time, both before and during sampling. If you remain unhappy and wish to 
complain formally, you can do this through Loughborough University Complaints 
Procedure. Details can be obtained from the University. 
In the event that something does go wrong and you are harmed during the 
research due to someone’s negligence then you may have grounds for a legal 
action for compensation against Loughborough University but you may have to 
pay your legal costs.  
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential, and any information about you which leaves the 
Laboratory will have your name and address removed so that you cannot be 
recognised. 
What will happen to the samples I give? 
The breath samples are collected in small tubes that will be processed at 
Department of Chemistry at Loughborough University.  Your name will be 
removed, and the samples identified only with a code. No genetic testing will be 
performed on any of your samples. 
What will happen to the results of the research study? 
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It is intended to publish the results of this study in a scientific journal. Data 
generated will be kept at the Department of Chemistry at Loughborough 
University. Your name and address will not be kept with the data although a 
record of your participation will be maintained by the principle investigator. The 
measurement data will only be made available to people who are directly involved 
with the study. 
Who is organising and funding the research? 
This study is a collaboration between <<details here>>  
Who has reviewed the study? 
This study has been reviewed and been given a favourable opinion by 
Loughborough University Ethics Committee to protect your safety, rights, wellbeing 
and dignity. 
Who should I contact for further information? 
 
Prof. C. L. Paul Thomas 
Professor of Analytical Science 
Department of Chemistry 
Loughborough University 
LE11 3TU 
Tel: 0150 922 2549 
Thank you for taking time to read this information sheet and considering 
helping us with our research.  Please retain a copy for your reference. 
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A1.2 Generic informed consent form 
CONSENT FORM Breath analysis in <Study Title>> . 
 
Mr/Mrs/Miss/Ms/Dr.............................................  
Name.............................................................. 
Age........................................................................  
Contact details 
 
Trial Supervisor 
Prof. Paul Thomas, Professor Analytical Science, Department of Chemistry, 
Loughborough University, LE11 3TU 
Tel.  No. 0150 922 2549 
Before participating in our study we need you to complete this consent form.   
Please tick the appropriate box.  
I have been given a copy of the information sheet Breath analysis in <Study Title>> Yes No 
I understand that my participation in this study is voluntary and that I am under no 
obligation to take part. Yes No 
I have read and understood the information sheet 
 Yes No 
I have had the opportunity to ask questions and I understand the answers I have been 
give. Yes No 
I understand that I may withdraw from the study at any time 
 Yes No 
I have been shown how to stop the sampling procedure if I want to. 
 Yes No 
I consent to participate in this study Yes No 
PLEASE SIGN HERE 
 
Date 
Many thanks for your help. 
                 
Researcher Use: 
Participant identifier:  
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A.1.3 Example of Generic Participant health screen 
questionnaire.  
Health Screen Questionnaire for Breath analysis in <Study Title>> . 
 
Mr/Mrs/Miss/Ms/Dr.............................................  
Name.............................................................. 
Age........................................................................  
Contact details 
 
Trial Supervisor 
Prof. Paul Thomas, Professor Analytical Science, Department of Chemistry, 
Loughborough University, LE11 3TU 
Tel.  No. 0150 922 2549 
Before participating in our study we need you to complete this health screen 
questionnaire.   
Please tick the appropriate box.  
Do you have any chest or breathing problems? Yes No 
Are you taking or using any medicines, pills, tablets, ointments, injections or any other 
drug, either from your doctor or on your own accord? Yes No 
Do you have or have you ever had any heart or blood pressure Yes No 
Have you experienced nausea, sickness or dizziness in the last week Yes No 
Is there anything else concerning your health, you think we should know about? Yes No 
PLEASE SIGN HERE 
 
Date 
Many thanks for your help. 
                 
 
Researcher use 
Participant identifier:  
 
  
 
160 
 
Appendix 2. Retention Indexing 
Retention Index Method Protocol 
Scope and Introduction 
Incorporation of a retention index ladder into the analysis of complex samples 
allows for data from inter-laboratory analyses to be aligned and compared 
directly, independently of the type of instrument manufacturer, column length 
or column flow.       
Principle 
A primary retention index is generated by using a retention index standard 
and a modified version of Kovat’s retention index equation which allows for 
temperature programming of the gas chromatography system (Equation 1 
shows this modified form).   
 
𝐼𝐼 = 𝑐𝑐𝑅𝑅(𝑈𝑈𝑛𝑛𝑈𝑈𝑛𝑛𝑈𝑈𝑈𝑈𝑛𝑛) − 𝑐𝑐𝑅𝑅𝑅𝑅
𝑐𝑐𝑅𝑅𝑅𝑅 − 𝑐𝑐𝑅𝑅𝑅𝑅
∙ 100 ∙ 𝑧𝑧 ∙ 𝜇𝜇                           (1) 
 
Where:   𝑐𝑐𝑅𝑅(𝑈𝑈𝑛𝑛𝑈𝑈𝑛𝑛𝑈𝑈𝑈𝑈𝑛𝑛)  = Retention time of component of interest (min). 
  𝑐𝑐𝑅𝑅𝑅𝑅  = Retention time of previous lower molecular weight known 
component (min) 
    𝑐𝑐𝑅𝑅𝑅𝑅  = Retention time of next higher molecular weight known component 
(min) 
  𝑧𝑧  = Difference in carbon number between  𝜇𝜇 and 𝑁𝑁   
  
  𝜇𝜇  = Carbon number of the lower molecular weight known component. 
Using the known straight chain hydrocarbons from the retention index 
standard, retention index values are assigned based on the carbon number of 
the component. The values assigned to each of the components are then 
plotted against their respective retention times to produce a linear retention 
ladder. The equation generated from the linear trend line produced is then 
used to assign retention index values to the known components that are 
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present in all sample chromatograms to form a secondary retention index. 
The secondary retention index is then used to align the all sample data 
Safety 
Equipment Nature of 
Hazard 
Precautions to be taken 
GC  Heat When the GC is in use the oven, injectors and detectors 
are all heated. Do not touch these areas. Do not 
operate the GC with any covers or parts removed 
Gas supply pipe lines High pressure  
 
 
 
 
Never apply oil or grease to joints 
Wear safety glasses when working with compressed 
gas 
Close valves when apparatus is not in use 
Mass Spec Transfer 
Line 
Heat 
 
Vacuum 
When the GC oven door is open the transfer line is 
exposed and is heated even when the GC oven is off 
 
 
Chemical Classification First Aid Measures 
Hydrocarbons 
Standards 
Xn, N, R65, R65 
- R67, R20 - 
R36/37/38 - 
R51/53 
General advice 
Consult a physician. Show this safety data sheet to the 
doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not 
breathing give artificial respiration Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a 
physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 
minutes and consult a physician. 
If swallowed 
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Do NOT induce vomiting. Never give anything by mouth 
to an unconscious person. Rinse mouth with water. 
Consult a physician. 
Handling 
Avoid inhalation of vapour or mist. 
Normal measures for preventive fire protection. 
Dichloromethane Xn, Carc.Cat.3, 
R40 
General advice 
Consult a physician. Show this safety data sheet to the 
doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not 
breathing give artificial respiration Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a 
physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 
minutes and consult a physician. 
Aldrich - 239763 www.sigma-aldrich.com Page 2 of 5 
If swallowed 
Never give anything by mouth to an unconscious 
person. Rinse mouth with water. Consult a physician. 
Handling 
Avoid inhalation of vapour or mist. 
Normal measures for preventive fire protection. 
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Chemicals 
1- Chlorodecane CAS: 1002-69-3 Available from Sigma (24205) 
1- Chlorohexane CAS: 544-10-5 Available from Sigma (24771) 
1-Chlorononane CAS: 2473-01-0 Available from Sigma (238457) 
1- Chlorooctane CAS: 111-85-3 Available from Sigma (25660) 
1- Decanol  CAS: 112-30-1 Available from Sigma (30605) 
1-Hexanol  CAS: 111-27-3 Available from Sigma (73117) 
2- Heptanol  CAS: 543-49-7 Available from Sigma (51800) 
2- Octanol  CAS: 126-96-6 Available from Sigma (74858) 
5- Nonanol  CAS: 623-93-8 Available from Sigma (74308) 
Decane  CAS: 124-18-5 Available from Sigma (30540) 
Dichloromethane CAS: 79-05-2 Fisher Scientific (D/1859/17) 
Dodecane  CAS: 112-40-3 Available from Sigma (44010) 
Eicosane  CAS: 112-95-8 Available from Sigma (44818) 
Heptadecane CAS: 629-78-7 Available from Sigma (51578) 
Nonane  CAS: 111-84-2 Available from Sigma(74250) 
Octane  CAS: 111-65-9 Available from Sigma (74821) 
Tetradecane  CAS: 629-59-4 Available from Sigma (87139) 
Undecane  CAS: 1120-21-4 Available from Sigma ( 94000) 
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Apparatus and Glassware 
An analytical balance capable of weighing to 50 + 1 mg 
3 x 10 ml volumetric flasks (grade A) with stoppers 
 Auto pipette capable of dispensing in the range of 20 to 100 ul 
Weighing boat 
Tenax® / Carbotrap Mixed mode thermal desorption tube  
1 μl glass sample syringe 
Reagents and Solutions 
Mixed Stock Retention Index Solution. 
Using a calibrated auto pipette transfer 70 + 5 μl of each of the components 1 
to 16 in Table 4 into a clean 10 ml volumetric flask containing approximately 4 
ml of dichloromethane. 
Make the volumetric flask up to volume using dichloromethane. Stopper the                    
volumetric flask and invert several times to ensure the content is mixed. 
(This solution contains approximately 7 μ / ml of components 1 to 16 listed in 
Table 4.) 
Heptadecane and Eicosane Stock Standard Solution. 
Using a five place analytical balance weigh 50 ± 1 mg of Eicosane in to a 
suitable weighing boat. 
Quantitatively transfer the contents of the weighing boat to a clean, dry 10 ml 
volumetric flask using not more than 8 ml of dichloromethane  
With the aid of a calibrated auto pipette transfer 50 ± 5 μl of Heptadecane to 
the 10 ml volumetric flask  
Make the volumetric flask up to volume with dichloromethane, stopper the 
volumetric flask and invert several times to ensure the content is mixed.   
(This solution contains approximately 5 mg / ml and 5 μl / ml of heptadecane 
and eicosane.) 
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 Retention Index Solution  
Into a clean 10ml volumetric flask containing approximately 8 ml of 
dichloromethane transfer 20 + 2 all of Mixed Stock Retention Index Solution 
using a calibrated auto pipette  
Into the same 10 ml volumetric flask transfer 20 + 2 all of Heptadecane and 
Eicosane Stock Standard Solution using a calibrated auto pipette. 
Make the volumetric flask up to volume with dichloromethane, stopper the 
volumetric flask and invert several times to ensure the content is mixed. 
(This solution contains approximately 50 ng/μl of each of the compounds in 
Table 1 and heptadecane and eicosane). 
Instrumentation 
Markes International Unity Thermal desorber, equipped with a general 
purpose hydrophobic cold trap.   
Gas Chromatograph with an oven capable of heating at a rate of 40oC 
Mass spectrometer capable of scanning 40 to 450 m/z 
Operating conditions 
Table A2.1. Summary of Marks International thermal desorption sampler parameters   
Parameter Setting  
Primary desorption  flow  50 cm3 min-1 
Primary Split 10:1 Ratio 
Primary desorption temperature 300 oC 
Primary desorption time 5 min 
Cold trap volume 0.019  cm3 
Cold trap temperature -10  oC 
Cold trap packing U-T2GPH (General purpose hydrophobic) 
Secondary desorption flow 2  cm3 min-1 
Secondary desorption temperature  300  oC 
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Table A2.2. Summary of Varian 3800 gas chromatograph conditions 
 
Table A2.3. Summary of Varian 4000 ion trap mass spectrometer conditions  
Secondary desorption time 5 min 
Trap heating rate 100  oC  min-1 
Transfer line temperature 140  oC 
Parameter Setting  
Column  60 m x 0.25 mm x 0.25 μm DB 5  
He carrier gas flow 2.0  cm3 min-1 
Initial oven temperature 40 oC 
Initial hold time 0 min 
Oven temperature program 3.3 oC min-1 to 90 oC  
 2.5 oC min-1 to 140 oC  
 10 oC min-1  to 300 oC  hold for 8.85 min  
Total run time 60 min 
Parameter Setting  
 
Scan type  Full 
Mass range 40 to 445 m/z 
Tune type Auto 
Ionization type EI 
Target TIC 20000 counts 
Max ion time 25000 μ Seconds 
Emission current 10 μ A 
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Retention Index Analysis 
A retention Index standard should be run at least once a day when breath 
samples are being analysed. The retention index provides not only a primary 
retention ladder, should it be required, but also quality control to ensure that 
the instrument is responding in an appropriate way day to day.    
Remove the Swagelok fitting from the sampling side of the thermal desorption 
tube. 
With the aid of a 1 μl syringe inject 0.1 μl of Retention Index Solution onto a 
mixed sorbent bed thermal desorption tube into  
Quickly replace the Swagelok fitting to the sampling side of the thermal 
desorption tube. 
Insert the desorption tube into the Unity Thermal desorber. 
Analyse the retention index sample under the conditions described in section 
8. 
Retention Index Assignment 
Retention Index assignment is achieved by designating a retention index 
value (RI) to each of the straight chain hydrocarbon components in the 
retention index standard. The RI for each of the 8 hydrocarbons is based on 
the carbon number of the component. The assignments used in this method 
to align data are given in Table A2.4.    
Total run time 60 min 
Scan time 0.82 Seconds  
Transfer line temperature 300  oC 
Trap temperature 150  oC 
Manifold temperature 50  oC 
Solvent delay time 5.0 min 
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Figure A2.1 Example of a Total Ion Current (TIC) of a Retention Index Standard.  
 
Table A2.4. Component list of identified peaks in the retention index standard. 
 
 
 
Construction of Primary Retention Index Ladder. 
Peak 
Assignment 
Analyte Name Assigned 
RI 
 Peak Assignment Analyte Name Assigned 
RI 
1 Octane 800 10 Undecane 1100 
2 1-Chlorohexane  11 Nonanol  
3 1-Hexanol  12 1-Chlorononane  
4 Nonane 900 13 Dodecane 1200 
5 2-Heptanol  14 Decanol  
6 1-Chloroheptane  15 1-chlorodecane  
7 Decane 1000 16 Tetradecane 1400 
8 2-Octanol  17 Heptadecane 1700 
9 1-Chlorooctane   18 Eicosane 2000 
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Plot a graph of the retention times and the assigned RI values (Table A2.4) for 
the Octane, Nonane, Decane, Undecane, Dodecane, Tetradecane, 
Heptadecane and Eicosane. 
Use the graph to obtain and record the intercept (C) and gradient (M) of the 
trend line produced. 
Secondary Retention Index 
It is not always practical to add numerous retention index compounds to a 
sample at point of collection for the purpose of aligning samples and to aid 
analyte prospecting. In such instances a secondary retention index can be 
employed. Under the specified method conditions in section 8, a number of 
endogenous siloxane components that result from the interactions of moisture 
found in breath and the sorbent beds in the thermal desorption tube have 
been selected. These siloxane components are continually present in all the 
sample chromatograms and have been selected to build such a retention 
index.      
With the aid of a breath sample chromatogram, identify and record the 
retention times for the 5 endogenous siloxane peaks (S1 to S5) indicated in 
Figure A2.2. 
Using the retention times from the identified siloxane components and 
equation (2) calculate the RI value for each of the siloxane compounds. 
 
𝑅𝑅𝐼𝐼 = 𝑐𝑐𝑅𝑅(component)M − C                           (2) 
 
Where:   𝑐𝑐𝑅𝑅(component)    = Retention time of Identified component  
  M  = Gradient of the graph recorded in 10.1.2 
  C  = Intercept of graph recorded in 10.1.2 
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Figure A2.2 Example of breath sample chromatogram with endogenous siloxane peaks (S1 to S5) 
highlighted 
Sample Alignment 
Sample alignment is achieved by assigning a static RI value to the known 
siloxane peaks (S1 to S5) that occur in a particular sample chromatogram. 
The retention times for each of the siloxane and the assigned RI values are 
plotted to produce a calibration curve, from which the remaining analyte peaks 
for that particular sample may be assigned an RI value, therefore enabling the 
direct comparison with other breath sample chromatograms. 
Using the static RI values in Table A2.5 and the retention times for the 
siloxane components in a breath sample construct a linear calibration graph. 
Using the gradient (M) and the intercept (C) obtained from the constructed 
calibration graph (12.1), calculate the RI for the remaining components in the 
breath sample chromatogram using the component’s retention time and 
equation 2. 
For each breath sample chromatogram follow steps 12.1 and 12.2 
The resultant list of retention indices and chromatogram components will now 
be directly comparable to each other.   
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Table A2.5 Static RI values and approximate retention times for siloxane peaks 
used in secondary retention index 
Peak  
Assignment 
Static 
 RI Value 
Approximate Retention Time / 
minutes 
S1 998 7.5 
S2 1142 13.3 
S3 1303 20.6 
S4 1516 28.5 
S5 1664 36.8 
 
 
 
 
 
 
 
Method Transfer Assessment  
For the comparison of different data obtained through analysis on alternative 
equipment or in a different laboratory a method transfer assessment must be 
performed to ensure correct alignment of data. To accomplish this, the results 
of two assessments need to be compared. 
Assessment 1 
A Retention Index standard must be prepared as described in section 6. 
The new and supplied retention index standards must be run under the 
conditions in section 8. A minimum of six repeats for each standard should be 
performed. 
The newly prepared retention index standard is compared directly with that of 
a supplied retention index standard to ensure that all components are present 
when analysing the retention index under the conditions in section 8. 
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Each of the hydrocarbons in each chromatogram should be integrated and the 
peak areas recorded. 
From the peak areas for each set of repeats the mean response and the 
relative standard deviation for each component should be calculated. 
 Assessment 2 
Two duplicate breath samples are required to be analysed by each system / 
laboratory. 
The component peaks are then required to be aligned using the secondary 
retention index (Section 11) and sample alignment (Section 12) procedures.  
The within lab duplicate samples should then be compared to ensure that 
alignment between the samples has been achieved. 
The mean Retention Index values of the five most intense analyte peaks (not 
including siloxane peaks used to construct the secondary retention index) 
should then be obtained for each set of duplicate samples and compared to 
ensure that the samples have been correctly aligned. 
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